erlotinib hydrochloride has been researched along with quinazolines in 2849 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 19,235 | 2,417 | 8,835 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | quinazolines (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.04) | 18.2507 |
| 2000's | 961 (33.73) | 29.6817 |
| 2010's | 1861 (65.32) | 24.3611 |
| 2020's | 26 (0.91) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP | 1 |
| Ciardiello, F; Tortora, G | 1 |
| Fry, DW; Slichenmyer, WJ | 1 |
| Norman, P | 1 |
| Tamura, T | 2 |
| Albanell, J; Baselga, J | 2 |
| Eigenbrot, C; Sliwkowski, MX; Stamos, J | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Couzin, J | 2 |
| Baselga, J; Hammond, LA | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 1 |
| Kim, TE; Murren, JR | 1 |
| Cohen, RB | 1 |
| Lorusso, PM | 1 |
| Muguruma, H; Sone, S; Yano, S | 2 |
| Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS | 1 |
| Vasey, PA | 1 |
| Grünwald, V; Hidalgo, M | 3 |
| Bulgaru, AM; Goel, S; Mani, S; Perez-Soler, R | 1 |
| Akita, RW; Sliwkowski, MX | 1 |
| Bloedow, D; Hidalgo, M | 1 |
| Herbst, RS | 3 |
| Hortobagyi, GN; Sauter, G | 1 |
| Bacus, S; Brattain, MG; deGraffenried, L; Hammond, LA; Hidalgo, M; Kreisberg, JI; Malik, SN; Rizzo, J; Rowinsky, EK; Siu, LL | 1 |
| Garber, K | 4 |
| Bonomi, P | 2 |
| Maneely, D | 1 |
| Baker, SD; He, P; Hidalgo, M; Rudek, MA; Zhao, M | 1 |
| Barbacci, EG; Boscoe, BP; Cox, ED; Emerson, E; Iwata, KK; Jani, JP; Kath, JC; Liu, Z; Miller, PE; Moyer, JD; Provoncha, K; Pustilnik, LR; Rossi, AM | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Figg, WD; Lepper, ER; Sparreboom, A; Swain, SM; Tan, AR | 1 |
| DeGrendele, H | 1 |
| Bloomston, PM; Cojita, D; Durkin, AJ; Giarelli, N; Rosemurgy, AS; Yeatman, TJ; Zervos, EE | 1 |
| Goldman, B | 1 |
| Giaccone, G; Janmaat, ML | 1 |
| Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Gatzemeier, U | 1 |
| Hidalgo, M | 1 |
| Sandler, A | 2 |
| Pérez-Soler, R | 6 |
| Soulières, D | 1 |
| Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE | 1 |
| Averbuch, S; Blackledge, G | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Fayette, J; Le Chevalier, T; Soria, JC | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Mass, RD | 1 |
| Langer, CJ | 2 |
| Thomas, M | 1 |
| A-Borhani, F; Bötefür, IC; Buchfelder, M; Domhof, S; Efferth, T; Gebhart, E; Gehrke, EE; Halatsch, ME; Schmidt, U; Vougioukas, VI | 1 |
| Caponigro, F | 1 |
| Efferth, T; Gebhart, E; Halatsch, ME; Ramirez, T | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Choy, H; Kim, DW | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Kobayashi, K | 1 |
| Baker, M | 1 |
| El-Rayes, BF; LoRusso, PM | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Nishio, K | 1 |
| Bacharach, SL; Berman, A; Brahim, JS; Carrasquillo, JA; Chow, C; Ettenberg, SA; Figg, WD; Hewitt, SM; Lepper, ER; Lipkowitz, S; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Whatley, M; Yang, X | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Price, N; Reddy, GK | 1 |
| Bonomi, P; Chachoua, A; Clark, GM; Hammond, LA; Huberman, M; Karp, D; Pérez-Soler, R; Rigas, J; Rowinsky, EK; Santabárbara, P | 1 |
| Chocholska, S; Krawczyk, P; Milanowski, J | 1 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Vastag, B | 1 |
| Alligood, KJ; Dickerson, SH; Ellis, B; Gilmer, TM; Hassell, A; Horne, E; Lackey, K; McDonald, OB; Pennisi, C; Rusnak, DW; Shewchuk, L; Truesdale, AT; Wood, ER; Yuan, D | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF | 1 |
| Adjei, A; Belani, CP | 1 |
| Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR | 1 |
| Arteaga, CL; Bianco, R; Dugger, T; Forbes, J; King, W; Qu, S; Rinehart, C; Ritter, CA | 1 |
| Arteaga, CL; Caldwell, RL; Caprioli, RM; Dugger, TC; Forbes, JT; Guix, M; Reyzer, ML; Ritter, CA | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Chen, EX; Moore, MJ; Siu, LL; Zhang, W | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Harari, PM | 1 |
| Fuster, LM; Sandler, AB | 1 |
| Patel, JD | 1 |
| Belani, CP | 1 |
| Fenyo, D; Gibson, N; Griffin, G; Haley, JD; Hunt, T; Iwata, K; Petti, F; Settinari, T; Thelemann, A | 1 |
| Akita, H | 1 |
| Dowell, J; Kirkpatrick, P; Minna, JD | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Twombly, R | 2 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Dai, Q; Iwata, KK; Kroog, G; Lia, M; Ling, YH; Perez-Soler, R; Zou, YY | 1 |
| Blumenschein, G; Carbone, DP; Eberhard, DA; Henderson, T; Herbst, RS; Hong, WK; Johnson, DH; Kelley, SK; Kim, ES; Lee, JJ; Liu, DD; Mass, R; Mininberg, E; Ramies, DA; Sandler, A; Seshagiri, S; Tran, H; Truong, MT; Tsao, A; Xie, D | 1 |
| Miller, VA; Pao, W | 1 |
| Faj, D; Kurbel, S | 1 |
| Amador, ML; Bouraoud, N; Hidalgo, M; Jimeno, A; Kulesza, P; Maitra, A; Oppenheimer, D; Rubio-Viqueira, B; Sebastiani, V | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Hampton, T | 3 |
| Albanell, J; Gascón, P | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| Edelman, MJ | 1 |
| Giaccone, G | 2 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Magné, N; Milano, G | 1 |
| Goldstein, D; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Blank, SV; Chang, R; Muggia, F | 1 |
| Byrne, BJ; Garst, J | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Blackhall, FH; Rehman, S; Thatcher, N | 1 |
| Cappuzzo, F | 3 |
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Blackhall, F; Danson, S; Papakotoulas, PI; Thatcher, N | 1 |
| Buter, J; Giaccone, G | 2 |
| Dowell, J; Minna, JD | 1 |
| Haber, DA; Settleman, J | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Lutz, MP | 1 |
| Bezjak, A; Campos, D; Ciuleanu, T; Clark, G; Dediu, M; Findlay, B; Hirsh, V; Johnston, D; Maoleekoonpiroj, S; Martins, R; Rodrigues Pereira, J; Santabárbara, P; Seymour, L; Shepherd, FA; Smylie, M; Tan, EH; Thongprasert, S; Tu, D; van Kooten, M | 1 |
| Cutz, JC; da Cunha Santos, G; Daneshmand, M; Ding, K; Kamel-Reid, S; Lagarde, A; Liu, N; Lorimer, I; Marrano, P; Pater, J; Richardson, F; Sakurada, A; Seymour, L; Shepherd, FA; Squire, J; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Doroshow, JH | 1 |
| Ready, N | 1 |
| Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP | 1 |
| Tuma, RS | 2 |
| Chosidow, O; Dirschka, T; Elsner, J; Layton, A; Mancini, L; Maughan, T; Morere, JF; Santoro, A; Segaert, S; Sobrero, A; Tabernero, J; Van Cutsem, E | 1 |
| Friess, T; Hasmann, M; Scheuer, W | 1 |
| Gandara, DR; Gumerlock, PH | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Peréz-Soler, R; Saltz, L | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Raizer, JJ | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Comis, RL | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Branca, MA | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 1 |
| Agrawal, A; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF | 1 |
| Harper, P; Spicer, J | 1 |
| Ganti, AK; Potti, A | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Burris, HA | 1 |
| Nguyen, D; Simon, RM; Swain, SM; Tan, AR; Yang, SX | 1 |
| Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P | 1 |
| Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J | 2 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Ko, AH; Tempero, MA | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Kurisu, K; Okamura, T | 1 |
| Baughman, C; Edwards, DL; Greco, A; Hainsworth, JD; Sosman, JA; Spigel, DR | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Miller, G | 1 |
| Atwal, J; Chen, DF; Cho, KS; Gore, B; He, Z; Kim, JA; Koprivica, V; Lin, E; Park, JB; Tessier-Lavigne, M; Yiu, G | 1 |
| Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Brown, E; Buck, E; Gibson, N; Griffin, G; Haley, JD; Iwata, KK; Petti, F; Ramnarine, N; Thomson, S | 1 |
| Garfield, DH | 1 |
| Bitran, JD; Nabhan, C | 1 |
| Ladanyi, M; Miller, VA; Pao, W | 1 |
| Ohe, Y; Takano, T | 1 |
| Bates, SE; Fojo, T | 1 |
| D'Amico, TA | 1 |
| Dancey, JE; Schoenfeldt, M | 1 |
| Ciardiello, F; De Vita, F | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Kris, M | 1 |
| Bigner, DD; Friedman, HS | 1 |
| Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Pao, W; Riely, GJ | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Bunn, PA; Hirsch, FR | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Bonner, JA; Clemons, LK; Dobelbower, MC; Posey, J; Raisch, KP; Russo, SM; Seay, LL; Suter, S | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Smith, J | 1 |
| Altundag, K; Altundag, O; Atik, MA; Baptista, MZ; Turen, S | 1 |
| Garey, J; Kim, E; Oishi, K; Rhee, J | 1 |
| Reddy, GK | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Garfield, D; Kashef, G | 1 |
| Moore, MJ | 1 |
| Cardiff, RD | 1 |
| Amler, LC; Cavet, G; Eberhard, DA; Fu, L; Januario, T; Lin, CY; Modrusan, Z; O'Neill, V; Pham, TQ; Seshagiri, S; Soriano, R; Stinson, J; Yauch, RL; Zhu, W | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 2 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Harari, PM; Huang, S | 1 |
| Hamilton, M; Johnson, KA; Ling, J; Lum, BL; Miao, Z; Pantze, MP; Prakash, C; Rakhit, A | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
| Lindsey, H | 1 |
| Nelson, NJ | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| D'Orazio, A; Reddy, K | 1 |
| Moore, MJ; Tang, PA; Tsao, MS | 1 |
| Sun, Y; Wang, Y | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Journagan, S; Obadiah, J | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Abrey, LE; Gilbert, MR; Lassman, AB | 1 |
| Buttitta, F; Felicioni, L; Marchetti, A | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Greten, TF | 1 |
| Polk, B | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| Eppler, S; Frohna, P; Hamilton, M; Kenkare-Mitra, SR; Ling, J; Lu, J; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Sabbatini, P | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| Shepherd, FA; Tsao, MS | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Reck, M | 2 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| de Jager, J; Stebbing, J | 1 |
| Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M | 1 |
| Dowell, JE; Minna, JD | 1 |
| Beard, SE; Cagnoni, PJ; Clark, GM; Hamilton, M; Rusk, J; Witt, K; Wolf, JL | 1 |
| Ballman, KV; Brown, PD; Carlson, BL; Giannini, C; Grogan, P; Guha, A; James, CD; Kitange, GJ; Pandita, A; Sarkaria, JN; Schroeder, MA | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Sipples, R | 1 |
| Garfield, D | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Berger, MS; Keles, GE | 1 |
| Ballman, KV; Brown, PD; Buckner, JC; Fiveash, JB; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Krishnan, S; Nabors, LB; Uhm, JH | 1 |
| Felip, E; Rosell, R | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Fan, H; Grandis, JR; Lui, VW; Mills, GB; Siegfried, JM; Smithgall, TE; Thomas, SM; Xi, S; Zhang, Q | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Armstrong, C; Durkin, AJ; Osborne, DA; Rosemurgy, AS; Yeatman, TJ; Zervos, EE | 1 |
| Bonn, S; Bossemeyer, D; Breitenlechner, CB; Engh, RA; Erlbruch, A; Gassel, M; Herrero, S; Lehmann, W | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Goodin, S | 1 |
| Baselga, J | 1 |
| Pérol, M | 2 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Bozec, A; Fischel, JL; Milano, G | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Mitra, SS; Simcock, R | 1 |
| Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Levitzki, A; Mishani, E | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Arteaga, CL | 1 |
| von Eyben, FE | 1 |
| Sandler, AB | 1 |
| Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Ramalingam, S; Sandler, AB | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Gadgeel, SM | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Clark, GM; Ding, K; Santabarbara, P; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Costa, DB; Huberman, MS | 1 |
| Abrams, DI; Cheng, J; Dhruva, A; Kwong, M; Luce, JA | 1 |
| Glatt, KA; Greulich, H; Ji, H; Lowell, AM; Meyerson, M; Minami, Y; Shah, K; Shapiro, GI; Shimamura, T; Thomas, RK; Wong, KK | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S | 1 |
| Cozzani, E; Parodi, A; Santoro, F | 1 |
| Herbst, R; Sandler, A | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Bach, JP; Faoro, C; Gorg, C; Kiessling, AM; Kleinhans, A; Neubauer, A; Riera-Knorrenschild, J; Schwella, N; Wagner, HJ | 1 |
| Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E | 1 |
| Aguilar, A; Aspiroz, C; Cuétara, MS; del Palacio, A; Martin, L | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Baselga, J; Mendelsohn, J | 1 |
| Belldegrun, A; Figlin, R; Iwata, KK; Jin, Y; Lieberman, R; Pantuck, A; Rao, J; Zhang, ZF | 1 |
| Calarese, P; Morse, L | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Alomar, A; Capdevila, J; García Muret, MP; Marcuello, E; Pallarés, C; Roé, E | 1 |
| Marshall, J | 1 |
| Cavenee, WK; Cloughesy, TF; Dia, EQ; Lu, KV; Mellinghoff, IK; Mischel, PS; Sawyers, CL; Shackleford, GM; Vivanco, I; Wang, MY; Zhu, S | 1 |
| Carey, KD; Garton, AJ; Gibson, N; Haley, JD; Kahler, J; Park, F; Romero, MS; Ross, S; Sliwkowski, MX; Thomson, S | 1 |
| Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M | 1 |
| Morse, L | 1 |
| Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
| Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Baradari, V; Hopfner, M; Huether, A; Scherubl, H; Schuppan, D; Sutter, AP | 1 |
| Ali, MA; Cao, C; Choy, H; Kim, JC; Mukhopadhyay, P; Nandi, A; Saha, D | 1 |
| Nau, JY | 1 |
| Curtiss, FR | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P | 1 |
| Birle, DC; Hedley, DW | 1 |
| Hong, WK; Kim, ES; Lee, HY; Morgillo, F; Woo, JK | 1 |
| Abbruzzese, JL; Baker, AF; Benedetti, JK; Blanke, CD; Dragovich, T; Fenoglio-Preiser, CM; Hackett, CB; McCoy, S; Urba, SG; Wang, J; Zaner, KS | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Ahmed, SM; Salgia, R | 1 |
| Kato, T; Nishio, K | 1 |
| Kahlenberg, MS; Krishnegowda, N; Learn, PA; Talamantez, J | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Bunn, PA | 2 |
| Gallegos Ruiz, M; Giaccone, G; Janne, P; Le Chevalier, T; Oulid-Aissa, D; Rodriguez, JA; Smit, E; Soria, JC; Thatcher, N | 1 |
| Adamoli, L; Catania, C; De Pas, TM; Goldhirsch, A; Manzotti, M; Nolè, F; Pelosi, G | 1 |
| Vansteenkiste, J | 1 |
| Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B | 1 |
| Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O | 1 |
| Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Pao, W | 1 |
| Balko, JM; Black, EP; Haura, EB; Potti, A; Saunders, C; Stromberg, A | 1 |
| Döme, B; Ostoros, G | 1 |
| Jones, DR; Masters, AR; Sweeney, CJ | 1 |
| Gross, GE; Schäd, SG; Zoller, A | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Pujol, JL | 1 |
| Liu, TH | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Beroukhim, R; Cloughesy, T; DeBiasi, RM; Feng, WL; Gabriel, S; Getz, G; Glatt, KA; Greulich, H; Huang, JH; Kawaguchi, T; Khan, H; King, JC; Leahy, DJ; Lee, JC; Levine, RL; Liau, LM; Linhart, DJ; Mellinghoff, IK; Meyerson, M; Mischel, P; Nelson, SF; Nghiemphu, P; O'Neill, K; Onofrio, R; Paez, JG; Peck, TC; Pieper, RO; Rao, PN; Sawyers, CL; Sellers, WR; Thomas, RK; Vivanco, I; Xu, Q; Yoshimoto, K; Yuza, Y; Ziaugra, L | 1 |
| Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ | 1 |
| Kuwano, M; Ono, M | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H | 1 |
| Bee, T; Black, CC; Dmitrovsky, E; Ewings, KE; Freemantle, SJ; Hattab, EM; Kelley, MR; Krizan, KA; Memoli, VA; Spinella, MJ; Vaseva, AV | 1 |
| Borras, AM; Fidias, P; Freidlin, B; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, NI; Lucca, J; Lynch, TJ; Meyerson, M; Ostler, PA; Rabin, MS; Skarin, AT; Temel, J; Yeap, BY | 1 |
| Ramanarayanan, J; Scarpace, SL | 1 |
| Collins, MH; Cripe, TP; Crombleholme, TM; Currier, MA; Hsu, YH; Mahller, YY; Mehrian-Shai, R; Miller, SJ; Ratner, N; Ripberger, MC; Vaikunth, SS | 1 |
| Grenier, J; Soria, JC | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Achille, M; Gallegos-Ruiz, M; Giaccone, G; Soria, JC | 1 |
| Zalcman, G | 1 |
| Bréchot, JM | 1 |
| Quoix, E | 1 |
| Soria, JC | 1 |
| Guitart, J; Lacouture, ME; Lai, SE; Luu, M; Patel, J | 1 |
| Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J | 1 |
| Herzog, M; Hosemann, W; Kaftan, H; Lempas, K; Vogelgesang, S | 1 |
| Akita, RW; Schaefer, G; Shao, L; Totpal, K | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Altiok, S; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Rubio-Viqueira, B; Zhang, X | 1 |
| Barr, S; Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Sennello, R; Thompson, S; Young, D | 1 |
| Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A | 1 |
| Baillargeon, GM; Calvo, E; Chin, SF; Hidalgo, M; Irish, J; Kreisberg, JI; Malik, SN; Rowinsky, EK; Santabarbara, P; Siu, LL | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Personeni, N | 1 |
| Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF | 1 |
| Chandra, NR; Efferth, T; Gebhart, E; Konkimalla, VB; Suhas, VL | 1 |
| Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X | 1 |
| Serke, M | 1 |
| Brenner, PC; Goldstein, D; Hayes, VM; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B | 1 |
| Carlson, BL; Dinca, EB; Galanis, E; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Sarkaria, JN; Schroeder, MA; Wu, W; Yang, L | 1 |
| Dutta, PR; Maity, A | 1 |
| Aglietta, M; Cavalloni, G; Leone, F; Pignochino, Y | 1 |
| Ben-Porat, L; Chapman, PB; Dickler, MN; Panageas, KS; Schrag, D | 1 |
| Auer, D; Daxenbichler, G; Egle, D; Marth, C; Rössler, J; Vergote, I; Zeimet, AG | 1 |
| Costa, LJ; Drabkin, HA; Gemmill, RM | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Clark, GM; Culbertson, JL; Savoie, M; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Carser, JE; Summers, YJ | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Galetta, D; Gridelli, C; Maione, P; Rossi, A | 1 |
| Boeck, S; Heinemann, V; Moosmann, N; Stemmler, HJ | 1 |
| Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS | 1 |
| Kindler, HL | 1 |
| Bhola, NE; Grandis, JR; Gubish, CT; Lui, VW; Mills, GB; Shin, D; Siegfried, JM; Siwak, DR; Thomas, SM; Zhang, Q | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Ho, C; Lara, PN; Lau, DH | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Boige, V; Ducreux, M; Malka, D | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Frolov, A; Frolova, N; Heslin, MJ; Howard, JH; Jhala, NC; Tzeng, CW; Vickers, SM | 2 |
| Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R; Weber, TK; Yuan, Z | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Cannon, EE; Frolov, A; Heslin, MJ; Howard, JH; Ku, BC; Schuller, K; Tzeng, CW; Vickers, SM | 1 |
| Bergot, E; Richard, N; Zalcman, G | 1 |
| Esmaili, A; Vahid, B | 1 |
| Farley, C; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Thompson, DS | 1 |
| Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Chen, TH; Feng, W; Glatt, KA; Greulich, H; Ji, H; Jiang, J; Lee, JC; Meyerson, M; Minami, Y; Shapiro, G; Shimamura, T; Wong, KK; Woo, MS; Yanagisawa, H; Yuza, Y | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Bragg, J; Pomeranz, MK | 1 |
| Hwang, C; Lacouture, ME; Marymont, MH; Patel, J | 1 |
| Dancey, JE | 1 |
| Hopfgartner, G; Richter, WF; Signor, L; Staack, RF; Starke, V; Varesio, E | 1 |
| Burtness, BA; Forastiere, AA | 1 |
| Chen, EX; Chin, SF; Dancey, J; Eisenhauer, EA; Francis, P; Harvey, L; Klein, M; Pond, GR; Siu, LL; Soulieres, D; Winquist, E; Zhang, W | 1 |
| Agulnik, M; Chen, EX; Chen, H; Chen, S; da Cunha Santos, G; Dancey, J; Dos Reis, PP; Hedley, D; Ho, J; Kamel-Reid, S; Marrano, P; Nicklee, T; Pond, GR; Shyr, Y; Siu, LL; Soulieres, D; Squire, JA; Tsao, MS; Winquist, E | 1 |
| Goldman, ID; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Moore, MJ; Welch, SA | 1 |
| Paz-Ares, L; Rosell, R; Sanchez, JJ; Taron, M | 1 |
| Burtness, B | 1 |
| Altomare, DA; Borden, EC; Gandara, DR; Garland, LL; Klein-Szanto, AJ; Nagle, RB; Rankin, C; Rivkin, SE; Scott, KM; Testa, JR | 1 |
| Lupu, R; Menendez, JA | 1 |
| Horowitz, N; Krasner, C; Lee, LM; Olawaiye, A | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Di Todaro, F; Gaudenzi, P; Manfredini, R; Morandi, P; Nielsen, I; Salmi, R | 1 |
| Costa, DB | 1 |
| Aguilar, RJ; Bartholomeusz, C; Felix, E; Hortobagyi, GN; Johansen, MJ; Krishnamurthy, S; Kurisu, K; Mills, GB; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Aftab, DT; Bentzien, F; Cancilla, B; Chen, J; Chu, F; De Costa, A; Engell, K; Gendreau, SB; Jackman, L; Jaeger, CT; Joly, AH; Keast, P; Laird, AD; Lutman, J; Martini, JF; Meyer, SM; Shi, Y; Ventura, R; Wang, J; Yakes, FM; Yu, P; Zhang, W | 1 |
| Baker, SD; He, P; Hidalgo, M; Li, J; Zhao, M | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Brahmer, J; Juergens, R | 1 |
| Bareschino, MA; Ciardiello, F; Martinelli, E; Morgillo, F; Schettino, C; Troiani, T | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Araujo, N; Armand, JP; de La Motte Rouge, T; Dessen, P; Galluzzi, L; Harel-Belan, A; Harper, F; Kroemer, G; Lazar, V; Olaussen, KA; Pierron, G; Pinna, G; Ripoche, H; Robert, T; Soria, JC; Tasdemir, E; Wong, TW; Zermati, Y | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Abbruzzese, JL; Brown, T; Chadha, R; Dancey, J; Glover, K; Morris, J; Rashid, A; Thomas, MB; Wang, X | 1 |
| Jänne, PA; Liu, W; Makrauer, FL; Odze, RD; Qamar, AA | 1 |
| Edelman, MJ; Hohl, RJ; Hollis, DR; Kindler, HL; Lewis, LD; Lichtman, SM; Marshall, JL; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Chan, G; Pilichowska, M | 1 |
| Gyergyay, F | 1 |
| Agus, DB; Castellanos, O; Green, E; Gross, M; Higano, C; Nguyen, K; Pantuck, A | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Kurisu, K; Sudo, T; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Hermanns, JF; Piérard, GE; Quatresooz, P | 1 |
| Bareschino, MA; Ciardiello, F; Gridelli, C; Maione, P; Rossi, A; Schettino, C | 1 |
| Balikó, Z; Sárosi, V | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Davies, AM; Lara, PN | 1 |
| Davies, A; Gandara, D; Ho, C; Mack, P | 1 |
| Carrión, RP; Gracián, AC; Hernandez, PS | 1 |
| Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A | 1 |
| Thatcher, N | 1 |
| Fernández-Guarino, M; Garrido López, P; González-García, C; Jaén, P | 1 |
| Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Baumgart, ED; Bernier, T; Cohen, MS; Jacobs, MA; Libertino, JA; Neto, BS; Rieger-Christ, KM; Summerhayes, IC; Wotkowicz, C | 1 |
| Cuozzo, JW; Green, N; Guler, S; Hall, JP; Hotchandani, R; Hsu, S; Hu, Y; Huang, A; Janz, K; Joseph-McCarthy, D; Kaila, N; Leung, L; Li, HQ; Lin, LL; Marusic, S; Pelker, J; Tam, SY; Telliez, JB; Thomason, J; Wang, Q; Wu, J | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Boeck, S; Heinemann, V; Wollenberg, A | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Huang, MY; Huang, YJ; Liu, SF; Wang, CJ | 1 |
| Cheng, CK; Fan, QW; Hackett, CS; Knight, ZA; Nicolaides, TP; Shokat, KM; Weiss, WA | 1 |
| Long, J; Thotathil, Z | 1 |
| Bradner, JE; Brennan, C; Chin, L; DePinho, RA; Kimmelman, AC; Ligon, KL; Nabioullin, R; Ponugoti, AH; Stegh, AH; Stommel, JM; Wiedemeyer, R; Ying, H | 1 |
| Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF | 1 |
| Cusack, JC; Lee, SW; Sloss, C; Wang, F; Zhang, X | 1 |
| Bukowski, RM; Drabkin, HA; Dutcher, J; Figlin, RA; Flaherty, K; Kabbinavar, FF; McDermott, D; Ryba, S; Scappaticci, FA; Srinivas, S; Vaishampayan, U; Xia, Q | 1 |
| de Gunst, MM; Gallegos-Ruiz, MI; Giaccone, G; Rodriguez, JA | 1 |
| Andersson, M; Nielsen, DL | 1 |
| Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Ferretti, G; Labianca, R; Mandalà, M; Moro, C | 1 |
| Hirsch, FR | 1 |
| Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Goldstein, M; Miksad, RA; Schnipper, L | 1 |
| Buchanan, FG; DuBois, RN; Holla, V; Katkuri, S; Matta, P | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Moldvay, J | 1 |
| Adès, L; Boehrer, S; Braun, T; de Botton, S; Fabre, C; Fenaux, P; Galluzzi, L; Gardin, C; Grosjean, J; Kroemer, G; Le Roux, G; Martin, A | 1 |
| Balak, M; Chmielecki, J; Gong, Y; Jiang, X; Pao, W; Politi, K; Somwar, R | 1 |
| Arteaga, CL; Park, K; Turkson, J; Yang, S | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Balis, FM; Fox, E; McCully, C; Meany, HJ; Tucker, C | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Brown, KA; Emlet, DR; Kociban, DL; Ong, BB; Pollice, AA; Shackney, SE; Smith, CA | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Jordis, U; Knesl, P; Röseling, D | 1 |
| Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Kardaun, SH; van Duinen, KF | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Charoin, JE; Fettner, S; Hamilton, M; Jones, HM; Lum, BL; Pantze, MP; Rakhit, A; Riek, M | 1 |
| Ng, K; Zhu, AX | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Bang, YJ; Han, SW; Kim, TY | 1 |
| Loffeld, A; Orpin, SD; Talsania, N | 1 |
| Schalock, PC; Zug, KA | 1 |
| Conklin, E; Dwyer-Nield, LD; Eckhardt, SG; Fritz, JM; Gustafson, DL; Iwata, KK; Kane, S; Malkinson, AM; Redente, EF; Shroyer, RJ; Tucker, C; Zerbe, LK | 1 |
| Allal, BC; Benlyazid, A; Chatelut, E; Courbon, F; Delord, JP; Lefebvre, JL; Rives, M; Rochaix, P; Sarini, J; Thomas, F | 1 |
| Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A | 1 |
| Miller, JD | 1 |
| Amoroso, D; Baldari, M; Bearz, A; Bettoli, V; Cammilluzzi, E; Crinò, L; De Marinis, F; Di Pietro, FA; Gridelli, C; Grossi, F; Innocenzi, D; Maione, P; Micali, G; Piantedosi, FV; Scartozzi, M | 1 |
| Cai, D; Carlson, NE; Deng, J; Letai, A; Perera, S; Shapiro, GI; Shimamura, T; Wong, KK | 1 |
| De Luca, A; Normanno, N | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E | 1 |
| Knabl, A | 1 |
| Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S | 1 |
| O'Neil, BH; Venook, AP | 1 |
| Fettner, S; Ling, J; Lum, BL; Rakhit, A; Riek, M | 1 |
| Philip, PA | 1 |
| Adkins, TB; Arteaga, CL; Calvo, B; Frierson, KE; Granja, Nde M; Grau, AM; Guix, M; Kelley, MC; Krontiras, H; Krop, IE; Mayer, IA; Meszoely, I; Muthuswamy, S; Pestano, G; Sanchez, V; Sanders, ME; Shyr, Y; Wieman, BM | 1 |
| Dietrich, PY; Lübbe, J; Masouyé, I | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B | 1 |
| Danesi, R; Giaccone, G; Giovannetti, E; Lemos, C; Nannizzi, S; Peters, GJ; Ricciardi, S; Rodriguez, JA; Smid, K; Tekle, C | 1 |
| Alvarez-Hernandez, D; Arcidiacono, MV; Cannata-Andia, J; Dusso, AS; Gonzalez-Suarez, I; Lu, Y; Sato, T; Slatopolsky, E; Tokumoto, M; Tominaga, Y; Yang, J | 1 |
| Miller, VA | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Belluco, C; Deng, J; Espina, V; Esserman, LJ; Laird, J; Liotta, LA; Mammano, E; Nitti, D; Petricoin, EF; Pierobon, M; Speer, R; Swain, SM; Wulfkuhle, JD; Yang, SX | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Belani, C; Ramalingam, S | 1 |
| de Marinis, F; Grossi, F | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Curiel, DT; Dent, P; Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J | 1 |
| Burris, HA; Cucullu, H; Farley, C; Greco, FA; Hainsworth, JD; Hart, LL; Sosman, JA; Spigel, DR; Sylvester, L; Waterhouse, DM; Yost, K | 1 |
| Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M | 1 |
| Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M | 1 |
| Haddad, TC; Yee, D | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Gipps, M; Goldberg, A; Grenader, T | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Atkinson, DM; Carlson, BL; Clarke, MJ; Jacobson, MS; Kemp, BJ; Lowe, VJ; Mladek, AC; Sarkaria, JN; Trump, DP | 1 |
| Giordano, S; Petrelli, A | 1 |
| Dohadwala, M; Dubinett, SM; Elashoff, D; Figlin, RA; Gardner, BK; Inge, L; Krysan, K; Mao, J; Rajasekaran, A; Reckamp, KL; Sharma, S | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Grütter, C; Klüter, S; Michalczyk, A; Rabiller, M; Rauh, D; Rode, HB; Simard, JR | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Brueckl, WM; Hahn, EG; Murray, S; Schoeberl, A; Wiest, GH; Wirtz, RM | 1 |
| Duell, T; Poellinger, B; von Pawel, J; Wagner, H | 1 |
| Boehm, AL; Freilino, M; Gooding, WE; Grandis, JR; Johnson, DE; Seethala, R; Sen, M; Wang, S; Wong, SM | 1 |
| Matuszczak, J; Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
| Stewart, DJ | 1 |
| Gerber, PA; Homey, B | 1 |
| Arango, D; Augenlicht, LH; Byun, DS; Goel, S; Jhawer, M; Klampfer, L; Ling, YH; Mariadason, JM; Montagna, C; Nasser, S; Perez-Soler, R; Shin, J; Soler, RP; Wilson, AJ | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Heymann, WR | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
| Kim, YT | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Cholongitas, E; Ioannidou, D; Kokolakis, GP | 1 |
| Fojo, T | 1 |
| Burris, H; Rocha-Lima, C | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Dorfman, JD; Fuchs, BC; Fujii, T; Goodwin, JM; Lanuti, M; Tanabe, KK; Zhu, AX | 1 |
| Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM | 1 |
| Chalfe, N; Plestina, S; Samarzija, M; Zuljević, E | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Van Laethem, JL | 1 |
| Culkin, A; Eaby, B; Lacouture, ME | 1 |
| Saif, MW | 4 |
| Krishnan, GS; Ramanarayanan, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| McDermott, U; Settleman, J; Sharma, SV | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Coffa, J; Diosdado, B; Hidalgo, M; Hirsch, FR; Iacobuzio-Donahue, C; Jimeno, A; Kulesza, P; Maitra, A; Meijer, GA; Messersmith, WA; Rajeshkumar, NV; Rubio-Viqueira, B; Tan, AC; Varella-Garcia, M; Wheelhouse, J | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Rocha-Lima, CM | 1 |
| Glisson, BS; Johnson, FM; Saigal, B | 1 |
| Guo, RP; Li, JQ; Shi, M; Wei, W; Xu, L; Zhang, YQ | 1 |
| Chen, LK; Huang, H; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Faoro, L; Fleming, GF; Friberg, G; Kasza, K; Morgan, RJ; Nimeiri, HS; Oza, AM; Salgia, R; Stadler, WM; Vokes, EE | 1 |
| Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT | 1 |
| Davidson, C; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Leikauf, GD; Prestridge, A; Whitsett, JA | 1 |
| Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR | 1 |
| Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Bagattini, S; Bladou, F; Brunelle, S; Esterni, B; Gonçalves, A; Gravis, G; Marcy, M; Salem, N; Viens, P; Walz, J | 1 |
| Clark, GM; Ding, K; Seymour, L; Shepherd, FA; Wheatley-Price, P | 1 |
| Merikas, I; Saif, MW; Syrigos, K; Tsimboukis, S | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Baker, SD; Figg, WD; Gonzalez, FJ; Harris, JW; Smith, NF; Sparreboom, A | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Collins, MH; Cripe, TP; Johansson, G; Kim, MO; Kozma, SC; Lane, HA; Mahller, YY; Nobukuni, T; Perentesis, J; Ratner, N; Thomas, G | 1 |
| Black, CC; Dmitrovsky, E; Gribble, GW; Honda, T; Lamph, WW; Liby, K; Liu, X; Risingsong, R; Royce, DB; Sporn, MB; Sporn, TA; Williams, CR; Yore, MM | 1 |
| Buhl, R; Fischer, B | 1 |
| Buchler, T; Joseph, T; Lai, C; Lee, SM | 1 |
| Akita, H; Kinoshita, I | 1 |
| Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP | 1 |
| Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C | 1 |
| Saijo, N | 2 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Gettinger, S | 1 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Enderlein, E; Gerber, PA; Homey, B | 1 |
| Riely, GJ | 2 |
| Yang, CH | 1 |
| Jänne, PA | 1 |
| Dunsford, J | 1 |
| Ding, K; Florescu, M; Hasan, B; Seymour, L; Shepherd, FA | 1 |
| Li, T; Ling, YH; Perez-Soler, R | 1 |
| Balleyguier, C; Besse, B; Soria, JC; Wagner, M | 1 |
| Lin, R; Ling, YH; Perez-Soler, R | 1 |
| Laurent-Puig, P; Taieb, J | 1 |
| Rocha-Lima, C; Vulfovich, M | 1 |
| Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D | 1 |
| Dahse, R; Kosmehl, H | 1 |
| Fidias, P; Jackman, DM; Jänne, PA; Johnson, BE; Kindler, HL; Lucca, J; Morse, LK; Ostler, PA; Salgia, R; Yeap, BY | 1 |
| Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS | 1 |
| Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C | 1 |
| Halpin, C; Harris, GJ; McClatchey, AI; O'Donnell, CC; Plotkin, SR; Singh, MA | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
| Bozec, A; Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Milano, G; Sudaka, A | 1 |
| Crinò, L; Reck, M | 1 |
| Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK | 1 |
| Avizienyte, E; Garner, AP; Ward, RA | 1 |
| Besse, B; Osio, A; Rajpar, S | 1 |
| Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Evans, TR; Kalofonos, HP; Koutras, AK; Makatsoris, T; Mastronikolis, NS; Papadeas, ES | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Cutz, JC; da Cunha Santos, G; Ding, K; Kamel-Reid, S; Liu, N; Marrano, P; Sakurada, A; Seymour, L; Shepherd, FA; Squire, JA; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Brugarolas, A; Eugenieva, E; Farré, J; Fernández Morejón, FJ; González Manzano, R; Martínez Navarro, E | 1 |
| Clark, JJ; Diggelmann, HR; Hansen, MR; Hansen, SS; Provenzano, M; Xu, N | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Chirinos, RE; Falo, LD; Geskin, LJ; Pomerantz, RG | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Holtkamp, N; Malzer, E; Mautner, VF; Mawrin, C; Mucha, J; Okuducu, AF; Schildhaus, HU; von Deimling, A; Zietsch, J | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Arrieta, O; Castillo-Gonzalez, P; de la Cruz Vargas, J; De la Garza, J; Flores-Estrada, D; Gonzalez, C; Gonzalez-De la Rosa, CH; Guzman, E; Hernandez-Pedro, N; Martinez-Barrera, L; Morales-Barrera, R; Rios-Trejo, MA; Téllez, E; Treviño, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Alessio, M; Balsamo, M; Di Modugno, F; Gertler, FB; McConkey, DJ; Melucci, E; Milella, M; Mottolese, M; Natali, PG; Nisticò, P; Philippar, U; Pino, MS | 1 |
| Agulnik, M; Wang, LX | 1 |
| Agulnik, M; Brockstein, B; Lacouture, M | 1 |
| Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Bachariou, A; Chasapi, V; Papadopoulos, R | 1 |
| Beijnen, JH; Bolijn, MJ; Buckle, T; de Vries, NA; Marchetti, S; Mazzanti, R; Schellens, JH; van Eijndhoven, MA; van Tellingen, O | 1 |
| Burgers, JA; Haas, RL; Kappers, I; Klomp, HM; van Pel, R; Van Zandwijk, N | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Hesketh, PJ; Hirsch, FR; Mack, PC; Marchello, BT; Moon, J; Spreafico, A; Wozniak, AJ | 1 |
| Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Barlési, F | 2 |
| Chen, J; Kim, IM; Rockman, HA; Salazar, NC; Tilley, DG; Violin, JD; Whalen, EJ | 1 |
| Astoul, P; Barlési, F; Breen, D; Fina, F; Martin, PM; Nanni-Metellus, I | 1 |
| Giaccone, G; Gutierrez, M; Rajan, A | 1 |
| Dolman, ME; Fretz, MM; Goldschmeding, R; Hennink, WE; Kok, RJ; Lacombe, M; Nguyen, TQ; Pato, J; Prakash, J; Storm, G | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Calvo, E; Chen, H; Dancey, JE; Lin, CC; Mays, T; Mita, AC; Mita, MM; O'Rourke, P; Papadopoulos, KP; Patnaik, A; Preston, GG; Rodon, J; Sarantopoulos, J; Takimoto, CH; Tolcher, AW; Yeh, IT | 1 |
| Tamura, K | 1 |
| Jing, DD; Lu, YY; Wang, XP; Wu, K; Xu, M | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Goggins, MG; Harsha, HC; Hidalgo, M; Hruban, RH; Jimeno, A; Kamath, U; Maitra, A; Mihalas, AB; Molina, H; Pandey, A; Schulick, RD | 1 |
| Dias-Santagata, DC; Lynch, TJ; Nanda, A; O'Hara, CJ; Stubbs, H; Willers, H; Zaner, KS | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Camisão, C; do Carmo, CC; Erlich, F; Ferreira, CG; Fontão, K; Herchenhorn, D; Lima, R; Martins, RG; Moralez, GM; Nogueira-Rodrigues, A; Small, IA; Viegas, C | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Bianchi, F; Neri, I; Patrizi, A | 1 |
| Barr, S; Brown, E; Buck, E; Epstein, D; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Ji, QS; Miglarese, M; Mulvihill, M; O'Connor, M; Pachter, J; Rosenfeld-Franklin, M; Thomson, S; Yao, Y | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Amoroso, D; Ardizzoni, A; Bearz, A; Belvedere, O; Brandes, AA; Cascinu, S; Crinò, L; Gridelli, C; Grossi, F; Labianca, R; Piantedosi, FV; Siena, S; Tiseo, M; Valentino, B; Venturino, P | 1 |
| Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Camidge, DR; Erickson, TM; Koeppe, JR; Miller, YE; Stuart, RW | 1 |
| Buhl, R; Fischer, B; Makowski, J; Meier, S; Post, F; Schad, A; Schadmand-Fischer, S; Sebastian, M; Springer, E; Taube, C; Wiewrodt, R | 1 |
| Chin, TM; Haber, DA; Lynch, TJ; Quinlan, MP; Sequist, LV; Settleman, J; Sharma, SV; Singh, A | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Fu, H; Hawk, N; Kauh, J; Khuri, FR; Ramalingam, SS; Sun, SY; Wang, X; Yue, P | 1 |
| Copeman, M | 1 |
| Cholongitas, E; Ioannidou, D; Kokolakis, G | 1 |
| Jatoi, A; Nguyen, PL | 1 |
| Herbst, RS; Sandler, A | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Arteaga, CL; Li, L; Wang, H; Xia, F; Yang, ES | 1 |
| Boggon, TJ; Chan, PS; Christensen, JG; Dietrich, S; Du, R; El-Telbany, A; Halmos, B; Hirashima, T; Iwasaki, T; Jiang, S; Kawahara, K; Kawase, I; Kern, JA; Kijima, T; Kobayashi, M; Ma, PC; Matsui, K; Nakagawa, K; Okamoto, N; Petri, ET; Salgia, R; Sasada, S; Suzuki, H; Tang, Z | 1 |
| Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Balko, JM; Black, EP | 1 |
| Höhler, T; Oettle, H; Staib, L | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 1 |
| Boyd, J; Brogi, E; Bromberg, JF; Caravelli, JF; D'Andrea, GM; Dancey, J; Dang, CT; Dickler, MN; Eberle, CA; Gilewski, TA; Hudis, CA; Lake, DE; Melisko, M; Moasser, MM; Norton, L; Panageas, KS; Park, JW; Rugo, HS; Seidman, AD; Yeh, B | 1 |
| Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L | 1 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Heinemann, V | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Descourt, R; Misery, L; Roguedas, AM; Rouxel, AM | 1 |
| Pavlidis, N; Pentheroudakis, G; Vassou, A; Voulgaris, E | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Backes, H; Borgman, CL; Jacobs, AH; Koker, M; Li, H; Neumaier, B; Shapiro, GI; Shimamura, T; Sos, ML; Tawadros, S; Thomas, RK; Ullrich, RT; Waerzeggers, Y; Winkeler, A; Wolf, J; Zander, T | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Carlis, L; De Pas, T; Locatelli, M; Lorizzo, K; Pelosi, G; Spitaleri, G; Toffalorio, F | 1 |
| Cardona, AF; Reguart, N; Reveiz, L | 1 |
| Acharya, J; Bottomley, DM; Lyon, C | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Chouaid, C; Coudray-Omnès, C; Moser, A; Vergnenègre, A | 1 |
| Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Boysen, M; Longson, C; Stevens, A | 1 |
| Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M | 1 |
| Mehić, B; Smoljanović, V; Stanetić, M; Tinjić, L | 1 |
| Galvany, L; Herrera-Acosta, E; Iglesias, M; Márquez, G; Umbert, P; Vidal, I | 1 |
| Sakurada, A; Tsao, MS | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Bangerter, M; Brudler, O; Heinrich, B; Reimer, G | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Brown, CW; Campbell, TM | 1 |
| Abbruzzese, J; Chadha, R; Davila, M; Glover, K; Iwasaki, M; Kaseb, A; Kaur, H; Lin, E; Morris, JS; Thomas, MB | 1 |
| Nott, L; Price, TJ | 1 |
| Bajetto, A; Barbieri, F; Capra, MC; Corte, G; Daga, A; Favoni, RE; Florio, T; Gatti, M; Griffero, F; Lo Casto, M; Marubbi, D; Melotti, A; Pattarozzi, A; Porcile, C; Spaziante, R; Zona, G | 1 |
| Choi, W; Haddad, Y; McConkey, DJ | 1 |
| Baker, SJ; Broniscer, A; Ellison, DW; Endersby, R; Gajjar, A; Kocak, M; Laningham, FH; Merchant, TE; Morris, EB; Schaiquevich, P; Stewart, CF | 1 |
| Bates, SE; Chen, YM; Chen, ZS; Fu, LW; Parmar, S; Peng, XX; Robey, RW; Shao, Y; Shen, T; Shi, Z; Zang, F | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Dagnaes-Hansen, F; Jakobsen, S; Keiding, S; Memon, AA; Nexo, E; Sorensen, BS | 1 |
| Denzlinger, C; Hass, HG | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Boinpally, R; Chick, JB; Dunlop, D; Hughes, AN; Nicolson, M; O'Brien, ME; Petty, WJ; Price, A; Rankin, E; Wolf, J; Woll, PJ | 1 |
| Andrew, AS; Duell, EJ; Mason, RA; Memoli, V | 1 |
| Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K | 1 |
| Duchnowska, R; Grala, B; Siemiatkowska, A; Smoter, M | 1 |
| Xing, LN; Zhang, F | 1 |
| Bradley, J; Feins, RH; Gewanter, RM; Gopal, RS; Komaki, RU; Kong, FM; Langer, CJ; Lee, HK; Movsas, B; Rosenzweig, KE | 1 |
| Aritakula, A; Ramasamy, A | 1 |
| Frenkel, EP; Gazdar, AF; Minna, JD; Peyton, M; Soh, J; Xie, Y; Zhang, W | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Brahmer, JR; Ettinger, DS; Finckenstein, FG; Guarino, MJ; Hosford, MA; Lu, H; Philip-Norton, RE; Rudin, CM; Schneider, CJ; Weber, MR | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Blair, E; Clark, JI; Cohen, EE; Dancey, JE; Davis, DW; Dekker, A; Karrison, TG; Kozloff, MF; Liu, W; Nattam, S; Pierce, C; Seiwert, TY; Stenson, K; Vokes, EE; Wong, SJ; Yan, DH | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Jones, D | 1 |
| Gajjar, A; Wright, KD | 1 |
| Barletta, E; Cusano, F; Ferrara, G; Ingordo, V | 1 |
| Andreu, J; Baselga, J; Cedrés, S; del Campo, JM; Felip, E; Martínez, P; Pallisa, E; Prat, A; Quispe, I; Sala, G | 1 |
| Barkauskas, DS; Dowlati, A; Du, R; Flask, C; Gerson, S; Halmos, B; Jiang, S; Kern, JA; Lam, M; Lee, Z; Liu, L; Ma, PC; Molter, J; Richey, J; Tang, Z; Wang, Y; Wu, C | 1 |
| Davidson, CR; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Schmidt, SM; Whitsett, JA | 1 |
| Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ | 1 |
| Atsou, K; Chouaid, C; Hejblum, G; Vergnenegre, A | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Alkemade, JA; Bovenschen, HJ | 1 |
| Brizel, DM | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Altaha, R; Hogan, T; Williams, HJ | 1 |
| Calhau, C; Giovannetti, E; Jansen, G; Kathmann, I; Lemos, C; Peters, GJ | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Bosserman, LD; Britten, CD; Finn, RS; Lum, BL; Malik, M; Press, MF; Slamon, DJ; Wong, SG | 1 |
| Feuerhake, F; Halatsch, ME; Hielscher, T; Löw, S; Mursch, K; Schmidt, U; Unterberg, A; Vougioukas, VI | 1 |
| Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A | 1 |
| Lin, CC; Yang, CH | 1 |
| Aracil, M; Jimeno, J; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Fischer, F; Frommolt, P; Garraway, LA; Gazdar, AF; Girard, L; Heynck, S; Kashkar, H; Koker, M; Mermel, C; Meyerson, M; Michel, K; Minna, JD; Pao, W; Peifer, M; Peyton, M; Rabinovsky, R; Seeger, JM; Sos, ML; Thomas, RK; Weir, BA; Weiss, J; Zander, T | 1 |
| Pakkala, S; Ramalingam, SS | 2 |
| Karapanagiotou, EM; Merikas, I; Saif, MW; Syrigos, KN; Tsimboukis, S | 1 |
| Finn, RS; Zhu, AX | 1 |
| Alexandrescu, DT; Dasanu, CA; Kauffman, CL | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Clark, GM | 1 |
| Hart, JR; Vogt, PK | 1 |
| Cheung, YK | 1 |
| Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ | 1 |
| Hawkins, N; Scott, DA; Thatcher, N; Woods, BS | 1 |
| Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A | 1 |
| Bousamra, M; Fan, TW; Higashi, RM; Kloecker, G; Lane, AN; Miller, DM | 1 |
| Manegold, C | 1 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Aubry, MC; Rickman, OB; Sanyal, B; Thomas, CF; Vohra, PK; Vrana, JA; Wigle, DA | 1 |
| Hoeller, C; Kunstfeld, R; Loewe, R; Paulitschke, V; Pehamberger, H; Pilarski, P; Schicher, N; Swoboda, A | 1 |
| Arellano, J; Leteneux, C | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Li, T; Perez-Soler, R | 1 |
| Chang, BW; Saif, MW | 1 |
| Kaley, K; Li, J; Peccerillo, J; Saif, MW | 1 |
| Amin, AR; Chen, ZG; Khuri, FR; Shin, DM | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Kaji, A; Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Beckett, L; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, D; Perkins, N; Scudder, SA | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Becker, M; Fichtner, I; Leschber, G; Merk, J; Rolff, J | 1 |
| Carlson, RH | 1 |
| Mekhail, T; Pennell, NA | 1 |
| Berger, W; Brandstetter, A; Filipits, M; Gruenberger, T; Herberger, B; Novak, S; Pirker, C; Puhalla, H; Schmid, K | 1 |
| Chu, DS; Johnson, KS; Levin, F | 1 |
| Boronina, T; Cole, PA; Cole, RN; Kavran, JM; Leahy, DJ; Longo, PA; Qiu, C; Tarrant, MK | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Demierre, MF; Goldberg, LJ; Pongpudpunth, M | 1 |
| Benlyazid, A; Chatelut, E; Delord, JP; Hennebelle, I; Lefebvre, JL; Malard, L; Rochaix, P; Sarini, J; Thomas, F; White-Koning, M | 1 |
| Brower, SL; Bush, JE; Rice, SD | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Clément-Duchêne, C; Merritt, R; Wakelee, HA | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| España, A; López-Picazo, JM; López-Zabalza, MJ; Marquina, M; Pelacho, B; Pretel, M | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Broniscer, A; Christiansen, SR; Panetta, JC; Stewart, CF | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Norden, AD; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Biordi, L; D'Ascenzo, S; Dolo, V; Festuccia, C; Ficorella, C; Gravina, GL; Ricevuto, E; Tombolini, V | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Green, J; Hockenhull, J; Macbeth, F; McLeod, C; Proudlove, C; Stevenson, J; Walley, T | 1 |
| de Castro, J; García-Campelo, R; Isla, D; Provencio, M | 1 |
| Lee, YC; Mannel, R; Schilder, RJ; Sill, MW | 1 |
| Li, J; Saif, MW | 1 |
| Cornet, K; Foss, CA; Goodwin, CR; Kim, J; Lal, B; Laterra, J; Muzamil, S; Pomper, MG; Sang, Y | 1 |
| Dorans, K | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Bitran, JD; Galvez, A; Kelby, SK; Lestingi, TM; Nabhan, C; Newman, S; Tolzien, K; Tsarwhas, D | 1 |
| Balius, TE; Rizzo, RC | 1 |
| Huh, K; Kim, MJ; Kim, SW; Oh, J | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Arrieta, O; Michel, RM; Rios Trejo, MA | 1 |
| Aparicio, A; Arap, W; Araujo, JC; Corn, PG; Jonasch, E; Matin, SF; Millikan, RE; Pagliaro, LC; Tamboli, P; Tannir, N; Tu, SM; Wang, X; Wood, CG | 1 |
| Bigelow, RL; Burke, P; Cardelli, JA; Carroll, JL; Coleman, DT; Milligan, SA; Steffan, JJ; Williams, BJ | 1 |
| Anderton, J; Davies, BR; Mark Hickinson, D; Marshall, G; Rukazenkov, Y; Speake, G; Swaisland, A; Wilkinson, RW | 1 |
| Cerniglia, GJ; Choe, R; Durduran, T; Evans, SM; Hahn, SM; Koch, CJ; Lee, WM; Maity, A; Mick, R; Pore, N; Quon, H; Schultz, S; Sehgal, CM; Tsai, JH; Xing, X; Yodh, AG | 1 |
| Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Atkinson, JJ; Borchers, MT; Deshmukh, HS; Di, PY; Dietsch, M; Hardie, WD; Korfhagen, TR; Leikauf, GD; Liu, Y; McLachlan, A; Wesselkamper, SC | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Chang, CC; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Su, YJ | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Ding, J; Hu, G; Li, J; Qian, X; Wang, Z; Zhang, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Dunlop, J; Eaby, B; Groves, RW; McPhelim, J; Nicolson, M; Nijjar, R; Steele, J; Thatcher, N; Ukachukwu, I | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Ahsan, A; Beer, DG; Hasan, MR; Kausar, T; Lin, L; Ralhan, R | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Kang, JH; Kim, HT; Kim, SW; Lee, J; Lee, JS; Park, BB; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS; Uhm, JE | 1 |
| Bastus, R; Bertran-Alamillo, J; Bover, I; Camps, C; Cardenal, F; Catot, S; Garcia-Campelo, R; Gonzalez-Larriba, JL; Insa, A; Isla, D; Lopez-Vivanco, G; Majem, M; Massuti, B; Mayo, C; Molina, MA; Moran, T; Moreno, MA; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Chen, X; Chen, ZS; Fu, LW; Hopper-Borge, E; Kuang, YH; Lee, JW; Shen, T; Sodani, K; Tiwari, AK | 1 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| Kotasek, D; Parnis, FX; Singhal, N | 1 |
| Mendoza, L | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Batra, RK; Dubinett, SM; Limsukon, A; Soo Hoo, GW; Susanto, I | 1 |
| Al-Sarraj, S; Bax, DA; Ellison, DW; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Regairaz, M; Reis, RM; Reis-Filho, JS; Sharp, SY; Stávale, JN; Vassal, G; Viana-Pereira, M; Vuononvirta, R; Workman, P | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| An, SJ; Chen, ZH; Huang, YS; Wu, YL | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| de Stanchina, E; Goel, A; Gong, Y; Koutcher, JA; Mellinghoff, IK; Ouerfelli, O; Pao, W; Politi, KA; Regales, L; Shen, R; Spassova, M; Vivanco, I; Zakowski, MF | 1 |
| Miller, AA; Petty, WJ; Waller, LL | 1 |
| Cai, Q; Freilino, ML; Grandis, JR; Hahm, ER; Johnson, DE; Joyce, SC; Leeman-Neill, RJ; Li, C; Neill, DB; Panahandeh, MC; Seethala, RR; Sen, M; Singh, SV; Thomas, SM; Wheeler, SE | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Da Silva, S; Decaestecker, C; Demetter, P; Mathieu, A; Salmon, I; Verbeken, E; Weynand, B | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Carlson, JJ | 1 |
| Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hung, MC; Krishnamurthy, S; LaFortune, TA; Liu, P; Lucci, A; Singh, B; Ueno, NT; Zhang, D | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Gandara, DR; Lara, PN; Li, T; Mack, PC; Perez-Soler, R | 1 |
| House, L; Liu, Y; Ramírez, J; Ratain, MJ | 2 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Chahbouni, A; den Burger, JC; Sinjewel, A; Vos, RM; Wilhelm, AJ | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Carbone, DP; Chen, X; Dang, TP; Konishi, J; Vo, H; Yi, F | 1 |
| Clark, JI; Crawford, D; Dutcher, J; Gordon, MS; Hussey, M; Lara, PN; Mack, PC; Nagle, RB; Pan, CX; Quinn, DI; Samlowski, W | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Bijnsdorp, IV; Fukushima, M; Gokoel, S; Kruyt, FA; Peters, GJ; Smid, K | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Blakely, J; Houts, AC; Reyes, CM; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Beganovic, S | 1 |
| Dauendorffer, JN; Dupuy, A | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Gnanaraj, J; Saif, MW | 1 |
| Dean, E; Hamilton, M; Judson, I; McCarthy, S; Ranson, M; Reid, A; Shaw, H; Wolf, J | 1 |
| Kawana, S; Mitsuishi, T; Motoki, T | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Chen, HY; Lee, CN; Liu, HE | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Lyseng-Williamson, KA | 2 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Eck, MJ; Yun, CH | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Gutteridge, E; Robertson, JF | 1 |
| Besse, B; Bidart, JM; Bosq, J; Lacroix, L | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Krishnan, H; Ravikumar, K; Singh, AN; Sridhar, B | 1 |
| Qiu, JH; Wang, J | 1 |
| Desai, RU; Rachakonda, LP; Saffra, NA | 1 |
| Cohen, MH; Keegan, P; Pazdur, R; Summers, J | 1 |
| Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK | 1 |
| Geissler, M; Steins, M; Thomas, M | 2 |
| Ganti, AK | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Ma, PC; Manson, GV | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 2 |
| Bharthuar, A; Iyer, R | 1 |
| Fielding, J; Godley, P; Grigson, G; Heathcote, S; Kim, W; Nielsen, M; Pruthi, RS; Rathmell, WK; Schultz, H; Smith, A; Wallen, EM; Whang, Y | 1 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Lai, JI; Lin, PC; Tzeng, CH; Wang, WS | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Abbruzzese, JL; El-Rayes, BF; Ferris, AM; Hess, K; Javle, MM; Kaseb, AO; Philip, PA; Sarkar, FH; Shields, AF; Varadhachary, GR; Wolff, RA | 1 |
| Carney, D; Forde, P; Murphy, C; O'Sullivan, C | 1 |
| Akimov, M; Au, JS; Baselga, J; Damyanov, D; Delmar, P; Essioux, L; Felip, E; Hillenbach, C; Klughammer, B; Kuo, HP; McLoughlin, P; Milanowski, J; Orlov, S; Pluzanska, A; Ramlau, R; Reck, M; Tan, EH; Yang, PC | 1 |
| Hare, KJ; Hartmann, B; Holst, JJ; Poulsen, SS; Rasmussen, AR; Thim, L; Viby, NE | 1 |
| Neal, JW; Sequist, LV | 2 |
| Li, SS; Qiu, Y; Shu, X; Tian, Y; Xie, L; Xu, J; Zhang, X | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Clarke, JL; Lassman, AB; Miller, VA; Pao, W; Wu, N | 1 |
| Hao, GK; Lan, W; Lan, WJ; Sun, R; Wang, J; Wang, RM; Wang, TF; Zhang, RH | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Ramsey, SD | 1 |
| Bradbury, PA; Evans, WK; Isogai, PK; Leighl, NB; Mittmann, N; Ng, R; Seymour, L; Shepherd, FA; Tsao, MS; Tu, D; Zhu, L | 1 |
| Hatsuse, M; Morihara, K; Murakami, S; Nagata, K; Okano, A; Shimazaki, C; Shiotsu, S; Yuba, T | 1 |
| Herzog, M; Hosemann, W; Kaftan, H; Miehe, B; Reuther, L | 1 |
| Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA | 1 |
| Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ | 1 |
| Franklin, G; Kalaichelvan, VK; Manavalan, R; Marslin, G; Reddy, PN; Sheeba, CJ | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
| Ahsan, A; Bhojani, MS; Hegde, A; Helman, A; Hiniker, SM; Lawrence, TS; Menawat, R; Nyati, MK; Nyati, S; Ramanand, SG | 1 |
| Deng, WG; Ekmekcioglu, S; Grimm, EA; Kwon, J; Poindexter, NJ | 1 |
| Agulnik, M; Guitart, J; Lacouture, ME; Reid, DC | 1 |
| Bulj, TK; Cetner, AS; Krunic, AL; Villano, JL | 1 |
| Domínguez-Fernández, I; Eguren, C; García-Díez, A; Santiago-Sánchez-Mateos, DI | 1 |
| Barabasz, A; Fadden, P; Foley, B; Hall, S; Huang, K; Rice, JW; Scott, A; Steed, P; Veal, JM | 1 |
| Burtness, B; Chen, C; Cohen, R; Feigenberg, SJ; Jimeno, A; Kane, M; Lango, M; Mehra, R; Nicolaou, N; Raben, D; Ridge, J; Rusthoven, KE; Song, JI; Swing, R | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK | 1 |
| Fuse, E; Kodaira, H; Kusuhara, H; Sugiyama, Y; Ushiki, J | 1 |
| Cignarelli, M; Fabiano, A; La Macchia, O; Landriscina, M; Maddalena, F; Piscazzi, A | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Hansen, O; Schytte, T | 1 |
| Borrill, J; Edwards, SJ | 1 |
| Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X | 1 |
| Lind, JS; Postmus, PE; Smit, EF | 1 |
| Mehta, SP | 1 |
| Travers, J; Workman, P | 1 |
| Cameron, MD; Kamenecka, TM; Li, X | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Buie, L; Chiu, WK; Davies, JM; Dees, EC; Irvin, W; Ivanova, A; Keller, K; O'Neil, BH; Sanoff, HK; Stinchcombe, TE; Walko, C | 1 |
| Belani, CP; Owonikoko, TK; Ramalingam, SS | 1 |
| Arbiser, JL; Bhola, NE; Cai, Q; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Neill, DB; Thomas, SM | 1 |
| Athanasiou, A; Bardi, G; Chandrinou, H; Stathopoulos, GP; Trafalis, D | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Glimelius, B | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM | 1 |
| De Pas, TM; Delmonte, A; Gregorc, V; Spitaleri, G; Toffalorio, F | 1 |
| Fietkau, R; Heinemann, V; Knoefel, WT; Oettle, H; Tannapfel, A | 1 |
| Chefrour, M; Ciccolini, J; Ferri-Dessens, RM; Fischel, JL; Formento, P; Francoual, M; Giacometti, S; Marouani, H; Mercier, C; Milano, G; Renée, N | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Li, LY; Wang, MZ; Xu, LY; Zhang, L; Zhang, XT; Zhang, XY; Zhong, W | 1 |
| Drillenburg, P; Hoekzema, R | 1 |
| Calles, A; Custodio, A; Pérez-Segura, P | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Camps, C; Carcereny, E; Gasco, A; Massuti, B; Moran, T; Quiroga, V; Rosell, R; Viteri, S; Wei, J | 1 |
| Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| Brugger, W; Cappuzzo, F; Cicenas, S; Ciuleanu, T; Esteban, E; Giaccone, G; Juhász, E; Klingelschmitt, G; Klughammer, B; Melezínek, I; Molinier, O; Stelmakh, L; Szczésna, A | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Besse, B; Buisine, MP; Copin, MC; Dansin, E; Ferté, C; Parent, F; Penel, N; Soria, JC | 1 |
| Fukudo, M; Inui, K; Masago, K; Mishima, M; Togashi, Y | 1 |
| Ueno, NT; Yamauchi, H | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM | 1 |
| Kaelin, W; LoRusso, P; Malik, G; Nadler, P; Rogers, LR; Shields, A | 1 |
| Erlichman, CE; Holen, KD; Horvath, L; Kim, GP; Kolesar, JL; Loconte, NK; Lubner, SJ; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Van Hazel, G; Yong, WP | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 1 |
| Ahmed, IS; Craven, RJ; Rohe, HJ; Twist, KE | 1 |
| Dunn, EF; Harari, PM; Wheeler, DL | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Wörmann, B | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ji, H | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Hughes, DP; Richards, KN; Speleman, F; Trevino, J; Van Roy, N; Zage, PE; Zweidler-McKay, PA | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Kim, YH; Masago, K; Mishima, M | 1 |
| Babineaux, S; Klein, R; Lawson, A; Liepa, AM; Muehlenbein, C; Schwartzberg, L; Wielage, R | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Ackerman, J; Albain, KS; Barlesi, F; Berkowitz, L; Besse, B; Gabrail, N; Hart, LL; Herbst, RS; Leighl, NB; Massarelli, E; Melnyk, O; Miller, VA; Raez, LE; Rosen, PJ; Shepherd, FA; Shun, Z; Sternas, L | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Alexander, TR; Bindels, RJ; Dimke, H; Hoenderop, JG; Meijer, IM; Mulder, GM; Tejpar, S; van der Wijst, J; van Goor, H | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| He, C; Li, P; Ma, J; Ma, Z; Wang, H; Wang, Q; Wei, B; Zhu, H | 1 |
| Dahm-Daphi, J; Dikomey, E; Holst, K; Kasten-Pisula, U; Kriegs, M; Rieckmann, T; Saker, J | 1 |
| Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Abbruzzese, JL; Davis, D; Fogelman, D; Javle, MM; Reddy, SA; Shroff, RT; Varadhachary, GA; Wolff, RA; Xiong, H; Zhang, Y | 1 |
| Antoniou, C; Chasapi, V; Dilana, KD; Karapanagiotou, EM; Matekovits, AE; Stratigos, AJ; Syrigos, KN; Tsimboukis, S; Vergou, T | 1 |
| Kenner-Bell, BM; Lacouture, ME; Paller, AS | 1 |
| Buchanan, SG; Dekoning, T; Eagleson, B; Essenburg, C; Kang, L; Kaufman, D; Staal, B; Su, Y; Vande Woude, GF; West, R; Zhang, YW | 1 |
| Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Arnoletti, JP; Frolov, A; Heslin, MJ; Howard, JH; Kossenkov, AV; Kulesza, P; Liles, JS; Tzeng, CW | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 1 |
| Allal, BC; Brillouet, S; Canal, P; Caselles, O; Courbon, F; Delord, JP; Filleron, T; Rochaix, P; Thomas, F; Vergez, S | 1 |
| Costa, DB; Hamada, A; Kobayashi, S; Yeo, WL | 1 |
| Chen, L; Li, C; Liu, X; Tian, Q; Wang, P; Xu, Y; Yang, Z; Zhao, W | 1 |
| Landgraf, R | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Eaton, KD; Martins, RG | 1 |
| Blum, RA; Cheng, CP; Hanifudin, A; Lim, LT | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J | 1 |
| Adachi, K; Chiba, S; Deki, T; Kawarada, S; Miyoshi, A; Mizoguchi, K; Suzuki, M | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Kink, JA; Raines, RT; Rutkoski, TJ; Schilling, CI; Strong, LE | 1 |
| Bertran-Alamillo, J; Cardenal, F; Cobo, M; Garrido, P; Isla, D; Lianes, P; Manegold, C; Massuti, B; Molina, MA; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Stahel, R; Taron, M; Trigo, JM | 1 |
| Amitay-Laish, I; David, M; Stemmer, SM | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Duong, S; Leung, M | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Lam, KC; Mok, TS | 2 |
| Ghosh, G; Kron, SJ; Lee, AG; Palecek, SP; Yan, X | 1 |
| Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Beyene, RT; Bleau, AM; Boockvar, JA; Gursel, DB; Holland, EC; Howard, BM | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Dakhil, SR; Flynn, PJ; Jatoi, A; Loprinzi, CL; Mattar, BI; Nikcevich, DA; Novotny, P; Sekulic, A; Sloan, JA; Thrower, A; Wentworth-Hartung, NL | 1 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Fabian, P; Lakomý, R; Nemecek, R; Slabý, O; Stanková, M; Svoboda, M; Vyzula, R | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Abu-Khalaf, M; Gunturu, KS; Saif, MW | 1 |
| Chiu, CW; Hanahan, D; Nozawa, H | 1 |
| Siu, LL | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Chin, K; da Cunha Santos, G; Dhani, N; Kamel-Reid, S; Ludkovski, O; Moore, MJ; Parulekar, W; Squire, J; Tsao, MS; Tu, D | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T | 1 |
| Fu, XY; Huang, Q; Li, DJ; Lu, MQ; Su, J; Xu, XH; Xue, F | 1 |
| Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME | 1 |
| Chiu, YF; Kuo, YH; Lin, YW; Su, YC; Tsai, MS | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Bai, CM; Cheng, YJ; Zhang, ZJ | 1 |
| Eberhardt, W | 1 |
| Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F | 1 |
| Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Shirane, M | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Carreau, JH; Foster, JM; Gatalica, Z; Govindarajan, V; Loggie, BW; Nath, SK; Radhakrishna, U; Sharma, P | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Levêque, D | 1 |
| Frank, RC; Lincer, R; Mody, K; Strauss, E | 1 |
| Beijnen, JH; Buckle, T; de Vries, NA; Schellens, JH; van Tellingen, O; Zhao, J | 1 |
| Bardou-Jacquet, E; Guyader, D; Lorho, R | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Aerts, I; Andreiuolo, F; Chatelut, E; Frappaz, D; Gentet, JC; Geoerger, B; Hargrave, D; Jaspan, T; Le Deley, MC; Leblond, P; Méresse, V; Morland, B; Ndiaye, A; Paoletti, X; Riccardi, R; Saint-Rose, C; Thomas, F; Varlet, P; Vassal, G | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Burtness, B; Psyrri, A | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM | 1 |
| Akar, U; Arun, BK; Hortobagyi, GN; LaFortune, TA; Nieves-Alicea, R; Tari, AM; Ueno, NT; Zhang, D | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Minna, JD; Murudkar, C; Shay, JW; Shultz, JC; Wijesinghe, DS | 1 |
| Grygárková, Y; Havel, L; Hrnciarik, M; Kolek, V; Koubková, L; Krejcí, J; Pesek, M; Salajka, F; Skalová, B; Skricková, J; Stícha, M; Tomísková, M; Zatloukal, P | 1 |
| Katayama, T; Maehara, Y; Mitsudomi, T; Murakami, I; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Abd Elmageed, ZY; Amin, AH; Matrougui, K; Partyka, M | 1 |
| Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM | 1 |
| Duchnowska, R | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Le Maître, A; Seymour, L; Shepherd, FA; Tsao, MS; Zhao, H | 1 |
| Bendell, JC; Blobe, GC; Broadwater, G; Bullock, KE; Gockerman, JP; Howard, LA; Hurwitz, HI; Lager, JJ; Meadows, KL; Morse, MA; O'Neill, MM; Petros, WP; Truax, R; Uronis, HE; Younis, I; Zafar, SY | 1 |
| Altiok, S; Bai, Y; Eschrich, S; Fang, B; Haura, EB; Kinose, F; Koomen, J; Li, J; Lin, H; Liu, RZ; Oguz, U; Remily-Wood, ER; Zhang, G | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Bai, F; Carcaboso, AM; Elmeliegy, MA; Stewart, CF; Tagen, M | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Horger, M; Schulze, M; Spengler, W | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Abbott, DW; Asara, JM; Tigno-Aranjuez, JT | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A | 1 |
| Azzoli, CG; Brevet, M; Johnson, ML; Ladanyi, M | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Holzman, DC | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J | 1 |
| Cheon, GJ; Choi, CM; Choi, SJ; Choi, YJ; Jeon, BS; Kim, CH; Kim, HR; Lee, JC; Rho, JK; Woo, SK | 1 |
| Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M | 1 |
| Childs, BH; Pal, SK; Pegram, M | 1 |
| Ren, GJ; Wang, MZ; Xia, Y; Zeng, X; Zhang, L; Zhu, YJ | 1 |
| Bednash, JS; Freilino, ML; Gooding, WE; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Lingen, MW; Neill, DB; Panahandeh, MC; Seethala, RR; Singh, SV; Thomas, SM | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Ardizzoni, A; Bartolotti, M; Boggiani, D; Bortesi, B; Bozzetti, C; Gelsomino, F; Sammarelli, G; Thai, E; Tiseo, M | 1 |
| Lin, CC; Yang, JC | 1 |
| Beijnen, JH; Fanggiday, JC; Lankheet, NA; Malingré, MM; Staaks, GH; Ter Heine, R; Van Der Westerlaken, MM | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Heigener, DF; Reck, M | 1 |
| Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Gong, F; Gu, L; Gu, Y; Luo, Q; Sun, Y; Wu, X; Xu, Q; Zheng, W | 1 |
| Berardi, F; Colabufo, NA; Contino, M; Leopoldo, M; Niso, M; Perrone, R | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Grazioso Russi, E; Numico, G; Silvestris, N | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Chang, FT; Kung, YC; Liaw, SF; Lin, CC; Lin, MW | 1 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Ariza, A; Benlloch, S; Bertran-Alamillo, J; Bivona, TG; Carcereny, E; Cardenal, F; Cobo, M; Costa, C; de Aguirre, I; Garcia-Campelo, R; Gimenez-Capitan, A; Insa, A; Isla, D; Majem, M; Massuti, B; Mate, JL; Mayo, C; Mendez, P; Molina, MA; Moran, T; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Sawyers, CL; Simonetti, S; Taron, M; Viteri, S | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Chen, CT; Genden, EM; Gupta, V; Gurudutt, V; Kao, J; Misiukiewicz, K; Packer, SH; Rivera, M; Teng, M; Tong, CC | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H | 1 |
| Duyster, J; Kancha, RK; Peschel, C | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Blanchet, B; Goldwasser, F; Mir, O | 2 |
| Buhren, BA; Gerber, PA; Homey, B | 1 |
| Camidge, DR; Cappuzzo, F; Varella-Garcia, M | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Hureaux, J; Jeanfaivre, T; Le Maignan, L; Mirebeau-Prunier, D; Urban, T; Vervueren, L | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Beinert, T; Binder, D; Buckendahl, AC; Hübner, RH; Schlattmann, P; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Christensen, IJ; Ladekarl, M; Lassen, U; Olesen, RK; Pappot, H; Pfeiffer, P; Rohrberg, KS; Skov, BG; Sørensen, M; Westman, M | 1 |
| Mountzios, G; Syrigos, KN | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Buhren, BA; Gerber, PA; Homey, B; Kukova, G | 1 |
| Friedrich, MJ | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Hibino, M; Kudo, S; Minamiya, Y; Nakamura, M; Ogawa, J; Okuyama, M; Sasaki, Y; Tenma, K | 1 |
| Dong, PP; Fang, ZZ; Ge, GB; Li, W; Liu, CX; Mao, YX; Qu, YQ; Wang, LM; Yang, L; Zhang, YY; Zhu, LL | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Choudhary, A; Diep, CH; Han, H; Munoz, RM; Von Hoff, DD | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Gu, FY; Hu, XY; Li, MD; Shen, H; Yuan, Y; Zhong, X | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Burga, LN; Hofstatter, EW; Hu, H; Juvekar, A; Troyan, SL; Tung, NM; Wulf, GM | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Masago, K; Mishima, M; Miura, M; Togashi, Y; Toyama, Y | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Boyd, J; Capanu, M; Ilson, DH; Kelsen, D; Klimstra, D; Levine, DA; Miron, B; Schwartz, G; Shah, M | 1 |
| Akhavanfard, S; Bergethon, K; Christensen, JG; Cosper, AK; Dias-Santagata, D; Digumarthy, S; Engelman, JA; Fidias, P; Gettinger, S; Heist, RS; Iafrate, AJ; Lanuti, M; Lynch, TJ; Mark, EJ; Mino-Kenudson, M; Sequist, LV; Shaw, AT; Temel, J; Turke, AB; Vernovsky, K; Wain, JC; Waltman, BA | 1 |
| Bivona, TG; Chang, K; Costa, C; Dahlman, K; Hannon, G; Hieronymus, H; Miller, VA; Moonsamy, P; Parker, J; Rosell, R; Sawyers, CL; Taron, M | 1 |
| Murphy, M; Stordal, B | 1 |
| Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J | 1 |
| Bigg, M; Della Zanna, G; Garcia, A; Gonzalez, R; Hewitt, SM; Imagawa, D; Lee, J; Lipkin, S; Meyskens, F; Richmond, E; Rodriguez, LM; Schnoll-Sussmans, F; Tucker, C; Wong, V; Zell, JA | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Goswami, P; Kalen, AL; Miller, FJ; Orcutt, KP; Parsons, AD; Scarbrough, PM; Sibenaller, ZA; Simons, AL; Sobhakumari, A; Spitz, DR; Wilke, WW; Zhu, Y | 1 |
| Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
| Tuder, RM; Winn, RA | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, H; Kim, MJ; Kim, SH; Kim, SJ; Park, SJ | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chung, WC; Gold, KA; Hittelman, WN; Kang, SM; Ki Hong, W; Kim, ES; Koo, JS; Lee, J; Ryu, SH | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Airiau, K; Belaud-Rotureau, MA; Belloc, F; Eimer, S; Jeanneteau, M; Laharanne, E; Loiseau, H; Merlio, JP; Véron, N; Vital, A | 1 |
| Dhillon, S; Muir, VJ | 1 |
| Baumert, TF; Brino, L; Cosset, FL; Davis, C; Doffoël, M; Fischer, B; Fofana, I; Fresquet, J; Gorke, S; Lavillette, D; Lupberger, J; McKeating, JA; Mee, CJ; Patel, AH; Pessaux, P; Pietschmann, T; Poch, O; Raffelsberger, W; Rothenberg, SM; Royer, C; Thumann, C; Turek, M; Xiao, F; Zahid, MN; Zeisel, MB; Zona, L | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA | 1 |
| Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Ardizzoia, A; Bertolini, A; Cortesi, E; Fagnani, D; Farina, G; Farris, A; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Mancuso, A; Martelli, O; Moscetti, L; Pavese, I; Rulli, E; Scanni, A; Tomirotti, M; Valmadre, G | 1 |
| Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J | 1 |
| Crinò, L; Metro, G | 1 |
| Dragnev, KH; Graham, RM; Memoli, VA; Petty, WJ; Swift, CB; Urbanic, JJ; Varela, VA; Voelzke, WR; Waller, LL | 1 |
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Hazama, M; Kim, YH; Niimi, M; Sakamori, Y; Tanaka, S; Yanagihara, K | 1 |
| Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| Banz, K; Bischoff, H; Brunner, M; Chouaid, C; de Castro Carpeño, J; de Marinis, F; Grossi, F; Vergnenègre, A; Walzer, S | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Geoerger, B; Leblond, P | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Honma, M; Suzuki, H; Yamamoto, N | 1 |
| Brugger, W; Cappuzzo, F; Ciuleanu, T; Coudert, B; Giaccone, G; Gopalakrishna, P; Park, K; Wu, YL | 1 |
| Halatsch, ME; Karpel-Massler, G; Wirtz, CR | 1 |
| Gunn, JR; Korc, M; Sempere, LF | 1 |
| Bolgar, MS; Lloyd, DK; Lo, L; Lu, X; Xiao, B | 1 |
| Berghmans, T; Meert, AP; Sculier, JP | 1 |
| Ansari, R; Bustin, F; Flynn, P; Hainsworth, J; Hart, L; Herbst, RS; O'Connor, P; Otterson, GA; Soh, CH; Vlahovic, G | 1 |
| Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Massiello, A; Mayton, EK; Mukerjee, P; Murudkar, CS; Park, MA; Pinkerman, RL; Shultz, JC; Wijesinghe, DS | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C | 1 |
| Cheon, YH; Jeon, DH; Kang, MG; Kim, CY; Kim, HJ; Kim, MJ; Kim, YE; Lee, GW; Lee, SS | 1 |
| Date, H; Mishima, M; Nagai, H; Niimi, M; Sasaki, T; Seo, N; Tanaka, S; Yanagihara, K; Yasuda, H | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Bhatnagar, PK; Dastidar, SG; Kapoor, S; Nithya, D; Ray, A; Senthil, V; Sharma, A; Talwadkar, A; Tandon, R; Vali, S; Venkataramanan, R | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Gu, A; Han, B; Shen, J; Shi, C; Xiong, L | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Baselga, J; Felip, E; Hermes, A; Klughammer, B; Reck, M; Tan, EH | 1 |
| Borget, I; Cadranel, J; Chouaid, C; Coudert, B; Daniel, C; Dansin, E; Friard, S; Madelaine, J; Madroszyk, A; Morin, F; Pignon, JP; Quoix, E; Westeel, V | 1 |
| Baumann, M; Bütof, R; Deuse, Y; Eicheler, W; Grenman, R; Gurtner, K; Krause, M; Oertel, R; Schaal, K; Thames, H; Yaromina, A | 1 |
| Agustoni, F; Buzzoni, R; Ducceschi, M; Formisano, B; Gelsomino, F; Pietrantonio, F; Platania, M; Pusceddu, S; Vitali, M; Zilembo, N | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Okamoto, I; Takeda, M | 1 |
| Cranmer, L; Curiel-Lewandrowski, C; Engelhardt, C; Warneke, J | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| Fujimoto-Ohuchi, K; Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Yanagisawa, M; Yorozu, K | 1 |
| Balagula, Y; Boone, SL; Lacouture, ME; Luu, M; Patel, J; Rademaker, AW; Sullivan, P | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE; Westhoff, MA; Wirtz, CR | 1 |
| Belani, CP; Blumenschein, G; Goss, G | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Correa, PD; Rizwanullah, M; Shrimali, RK | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Boons, CC; Boven, E; Hugtenburg, JG; Mangnus, D; Moes, JE; Smit, EF; Swart, EL; Timmers, L | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Brand, TM; Dunn, EF; Iida, M; Kostopoulos, KT; Li, C; Myers, RA; Peet, CR; Wheeler, DL | 1 |
| Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS | 1 |
| Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH | 1 |
| Jafarirad, S; Namazi, H | 1 |
| Amato, KR; Arcila, M; Chmielecki, J; de Stanchina, E; Foo, J; Ginsberg, MS; Hutchinson, K; Inoue, A; Kris, MG; Ladanyi, M; Michor, F; Miller, VA; Ohashi, K; Oxnard, GR; Pao, W; Socci, ND; Somwar, R; Sos, ML; Thomas, RK; Viale, A; Wang, L | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J | 1 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Arias de la Vega, F; Arrazubi, V; Calvo, FA; Contreras, J; de la Torre, A; de Las Heras, M; García-Saenz, JA; Herruzo, I; Prieto, I; Romero, J | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Mitsudomi, T | 2 |
| Becker, A; Crombag, L; Heideman, DA; Postmus, PE; Smit, EF; Thunnissen, FB; van Wijk, AW | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Arnoletti, JP; Frolov, A; Frost, AR; Heslin, MJ; Kossenkov, AV; Kulesza, P; Liles, JS; Mikhaylina, A | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Kim, C; Lee, KB; Shah, BP; Subramaniam, P | 1 |
| Hotta, K; Kiura, K | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Aziz, F; Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
| Dao, KM; DiCarlo, B; Elashoff, R; Hecht, JR; Lin, LS; Park, DJ; Patel, R; Ryba, N; Wainberg, ZA; Wang, HJ | 1 |
| Bazzoli, A; Du, H; Hu, Z; Zhang, Y | 1 |
| Belousov, R; Colombo, C; Ghadimi, MP; Hornick, JL; Lazar, AJ; Lev, D; Liu, J; Lopez, G; Peng, T; Reynoso, D; Xie, X; Young, ED; Zhu, QS | 1 |
| Cunningham, D; Yim, KL | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Erasmus, JJ; Stewart, DJ | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Baumann, M; Benes, C; Dahm-Daphi, J; Dikomey, E; Gheorghiu, L; Krause, M; Kriegs, M; Morsbach, F; Nanda, A; Sander, D; Settleman, J; Wang, M; Willers, H | 1 |
| Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS | 1 |
| Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W | 1 |
| Gong, Y; Pao, W | 1 |
| Bade, LK; Dehut, HA; Goldberg, JE; Hall, MK; Schwertfeger, KL | 1 |
| Cortes, J; Roché, H | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Glimelius, B; Häggblad Sahlberg, S; Lennartsson, J; Nygren, P; Spiegelberg, D; Stenerlöw, B | 1 |
| Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R | 1 |
| Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
| Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S | 1 |
| Brdar, I; Deng, X; Faessler, R; Mani, NS; Roessler, A; Sales, ZS; Wu, J | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Baumeister, P; Harréus, U; Heinrich, K; Märte, M; Reiter, M; Schwenk-Zieger, S | 1 |
| Loo, BW; Ma, L; Meng, X; Murphy, JD; Sun, X; Yu, J | 1 |
| Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q | 1 |
| Custodio, A; de Castro, J | 1 |
| Li, T; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
| Arakawa, H; Hataji, O; Johkoh, T; Kusumoto, M; Sakai, F; Taguchi, O | 1 |
| Clark, P; George, E; Rinaldi, F | 1 |
| Chen, ZW; Lu, S; Song, ZB; Yu, YF | 1 |
| Fujita, T; Fuse, E; Kodaira, H; Kusuhara, H; Sugiyama, Y; Ushiki, J | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Belani, C; Boinpally, R; Evans, J; Franke, A; Gail Eckhardt, S; Haluska, P; Leong, S; O'Bryant, CL; Ramalingam, S; Ramanathan, RK; Rosen, L; Venugopal, B; Witt, K | 1 |
| Chen, ZG; Huang, D; Shin, DM; Su, L; Wang, D; Zhang, H | 1 |
| Bacha, OM; Lalancette, M; Levesque, E; Renaud, MC | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, MJ; Kim, SH; Kim, SJ; Oh, SO | 1 |
| Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B | 1 |
| Erlichman, C; Flynn, PJ; Holen, KD; Mahoney, MR; Northfelt, DW; Philip, PA; Picus, J; Pitot, HC | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Choi, CM; Choi, DR; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Hockenhull, J; Martin Saborido, C; Oyee, J; Ramani, VS | 1 |
| Blasinska-Morawiec, M; Brugger, W; Cappuzzo, F; Curescu, S; Manikhas, GM; Mayne, K; Mazieres, J; Sakalauskas, R; Triller, N; Trunzer, K; Ward, C; Whittom, R | 1 |
| Shepherd, FA | 1 |
| Bertucci, F; Chetaille, B; Guiramand, J; Launay, SG; Medina, F; Moureau-Zabotto, L; Nazarian, S; Perrot, D | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 2 |
| Bendapudi, PK; Chen, J; Choi, P; Felsher, DW; Horng, G; Hughes, NP; Kawashima, T; Kitamura, T; Koh, S; Lin, HJ; Miller, VA; Paik, D; Schwartz, LH; Tran, PT | 1 |
| Dhanesh, SB; James, J; Mundayoor, S; Shobana, S; Sivakumar, KC | 1 |
| Diefendorf, LP; Jette, DF; Mohammed, A; Mondal, S; Moses, MA; Searleman, SA; Stevens, DA; Wilton, KM; Woodworth, CD | 1 |
| Barboriak, DP; Brizel, DM; Carroll, MD; Cleland, E; Craciunescu, OI; MacFall, JR; Muradyan, N; Yoo, DS | 1 |
| Chen, CH; Hsu, WM; Hu, RH; Huang, HC; Huang, J; Huang, MC; Huang, MJ; Lai, HS; Lee, JJ; Lee, PH; Liu, CH; Wu, YM | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Agus, DB; Choi, NC; Foo, J; Leder, K; Mallick, P; Michor, F; Mumenthaler, SM; Pao, W | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Doheny, S; Hughes, D | 1 |
| Chao, YS; Cherniack, AD; Chiang, D; Cho, J; Dutt, A; Johnson, W; Kesari, S; Kwon, J; Meyerson, M; Onofrio, RC; Pastorino, S; Vandenberg, S; Verhaak, R; Watanabe, H; Xu, X; Yuza, Y; Zeng, Q | 1 |
| Chen, C; Fujioka, N; Gupta, K; Gupta, V; Johnson, KN; Kratzke, RA; Li, Y; Nguyen, J; Niehans, G; Pasrija, T | 1 |
| Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Dainton, M; Lim, E; Min, T; Nicholson, AG; O'Brien, ME; Popat, S; Swansbury, J; Vieira de Araújo, A; Wotherspoon, A | 1 |
| Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Buysschaert, I; Carmeliet, P; Christensen, IJ; Høyer-Hansen, G; Ladekarl, M; Lassen, U; Olesen, RK; Pappot, H; Pfeiffer, P; Rohrberg, KS; Skov, BG; Sørensen, M | 1 |
| Brownstein, CM; Chen, D; Crino, L; Eberhardt, WE; Engelman, JA; Habben, K; Jänne, PA; Liu, L; Novello, S; Ramalingam, SS; Reck, M; Schneider, CP; Spigel, DR; Steins, MB | 1 |
| Hanbali, AS; Munoz, J | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Balko, JM; Black, EP; Britson, J; Bryant, JL; Frolov, A; Timmons, R; Willian, M | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Benz, G; Brutsche, M; Früh, M; Putora, PM; Rodriguez, R | 1 |
| Cromwell, I; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Ebi, N; Fukusho, R; Sugimoto, Y; Takahashi, Y; Tsuruno, K; Yamaguchi, O | 1 |
| Hatashita, E; Kita, A; Kuwata, K; Nakagawa, K; Okamoto, I; Okamoto, K; Ono, M; Yamaguchi, H; Yamanaka, K | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Groen, HJ; Hiltermann, TJ; Schuuring, E; Timens, W | 1 |
| Garden, BC; Lacouture, ME; Wu, S | 1 |
| Chan, AB; Lam, KC; Lee, KW; Lo, AW | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Suzuki, Y; Yamamoto, T | 1 |
| Daub, H; Schreiber, TB; Weber, C | 1 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Forsyth, M; Nadler, E; Reyes, C; Satram-Hoang, S | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Conradt, L; Diersch, S; Eser, S; Godl, K; Kleeff, J; Michalski, CW; Saur, D; Schaab, C; Schmid, RM; Schneider, G; Schnieke, A; Tebbe, A | 1 |
| Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C | 1 |
| Conroy, T; Mitry, E | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Akar, U; Bartholomeusz, C; Esteva, FJ; Kazansky, A; Kigawa, J; Kondo, K; Krishnamurthy, S; Lee, J; Liu, P; Oishi, T; Saso, H; Ueno, NT | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Bischoff, H; Chouaid, C; de Castro Carpeño, J; Grossi, F; Heigener, D; Nuijten, MJ; Vergnenègre, A; Walzer, S | 1 |
| Bar, J; Onn, A | 1 |
| Aleknavičius, E; Cicėnienė, A; Drobnienė, M; Grigienė, R; Lachej, N; Steponavičienė, L; Zelvienė, TP | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC | 1 |
| Chhatwani, L; Colevas, AD; Decker, R; Fisher, GA; Krupitskaya, Y; Latz, JE; Padda, SK; San Pedro-Salcedo, M; Wakelee, HA | 1 |
| Buck, E; Desai, V; Epstein, DM; Miglarese, M; Wang, J; Zhao, H | 1 |
| Ren, SX; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT | 1 |
| Hong, D; Kurzrock, R; Munoz, J | 1 |
| Appleyard, CB; Coppola, D; Cruz, ML; Isidro, AA; Pagán, B; Ren, Y; Wu, J | 1 |
| Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Jensen, LH | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Koshiishi, H; Takahashi, E; Takahashi, M | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Fan, R; Geng, F; Guo, D; Heath, JR; Hood, L; Mischel, PS; Qin, L; Shi, Q; Shin, YS; Wei, W | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M | 1 |
| Arola, M; Kähkönen, M; Lohi, O; Parto, K; Vettenranta, K; Vornanen, M | 1 |
| Burns, SS; Bush, ML; Chang, LS; Davletova, S; Jacob, A; Oblinger, J; Welling, DB | 1 |
| Cromwell, I; Malfair Taylor, SC; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Lee, SH | 1 |
| Chen, ZG; Fan, S; Khuri, FR; Koo, J; Li, Y; Owonikoko, TK; Ramalingam, SS; Sun, SY; Yue, P | 1 |
| Chen, Z; Cheng, D; Ding, K; Le Maitre, A; Liu, G; Liu, N; Patel, D; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Adjei, A; Brown, A; Camidge, DR; Doebele, R; Dy, G; Fetterly, G; Franklin, W; Hirsch, FR; Jackson, MK; Lettieri, J; Lu, X; Maxson, D; Oton, A; Reynolds, M; Varella-Garcia, M; Weickhardt, A; Wynes, MW; Youssoufian, H | 1 |
| Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM | 1 |
| Agulnik, M | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Brizel, DM; Broadwater, G; Carroll, MD; Clough, R; Craciunescu, O; Dunphy, FR; Esclamado, RM; Hoang, J; Kirkpatrick, JP; MacFall, JR; Peterson, BL; Ready, NE; Scher, RL; Yoo, DS | 1 |
| Bienvenu, S; Chaudhry, MA; Forastiere, A; Gilbert, J; Gillison, M; Higgins, MJ; Rudek, MA; Tsottles, N; Wahl, R; Zhao, M | 1 |
| Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G | 1 |
| Paz-Ares, L | 1 |
| Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Govindan, R; Subramanian, J | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Argast, GM; Davies, A; Epstein, DM; Mercado, P; Richardson, F; Sennello, R; Wacker, B; Wolf, J; Young, GD | 1 |
| Abe, T; Aoki, T; Furuya, N; Hayama, N; Hisata, J; Igawa, S; Katagiri, M; Masuda, N; Mineshita, M; Miyazawa, T; Tajiri, S; Urano, T | 1 |
| Cha, YJ; Go, S; Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kwon, HC; Lee, GW; Lee, S; Oh, SY | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Faris, JE; Zhu, AX | 1 |
| Abbruzzese, JL; Deaton, FL; Garrett-Mayer, E; Hassabo, HM; Hassan, MM; Iwasaki, M; Kaseb, AO; Lin, E; Morris, JS; Onicescu, G; Thomas, MB; Xiao, L | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Akazawa, Y; Imamura, F; Kumagai, T; Nishino, K; Okyuama, T; Uchida, J | 1 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H | 1 |
| Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Li, Y; Song, L | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Pick, A; Wiese, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Lin, TC; Wu, PY | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Anderes, K; Bliesath, J; Bunag, D; Drygin, D; Ho, C; Huser, N; Lim, JK; O'Brien, SE; Omori, M; Proffitt, C; Rice, WG; Ryckman, DM; Siddiqui-Jain, A; Streiner, N | 1 |
| Bai, H; Han, B | 1 |
| Akama-Garren, EH; Edalati, A; Lindstrom, TM; Petralia, JD; Robinson, WH; Ruiz, PJ; Stein, EA; Swanson, CD | 1 |
| Chang, JW; Chang, NJ; Chen, CH; Cheng, HY; Chung, FT; Hou, MM; Hsieh, JJ; Hsu, T; Huang, SF; Kuo, HP; Lin, HC; Lin, YC; Ou, LY; Tsai, YH; Wang, CL; Wang, HM; Yang, CT; Yu, CT | 1 |
| Chan, P; Cheung, TT; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Jeong, SH; Kim, J; Kim, S; Ku, B; Lee, DW | 1 |
| Azad, A; Chong, G; Dobrovic, A; Fluck, K; Gebski, V; Johns, TG; Mariadason, JM; Pavlakis, N; Price, TJ; Salemi, R; Scott, AM; Skrinos, E; Tebbutt, NC; Weickhardt, AJ | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Craven, RJ; Jin, L; Mir, SU | 1 |
| Chen, J; Chen, JK; Harris, RC | 1 |
| Chang, GC; Chen, HY; Chen, KC; Hsu, KH; Tseng, JS; Yang, TY | 1 |
| Egawa, K; Matsushita, H; Miura, H; Osawa, T; Takahashi, T; Tsubouchi, Y; Yuyama, K | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B | 1 |
| Ghosh, G; Kron, SJ; Lian, X; Palecek, SP | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 1 |
| Hirsh, V; Novello, S; Sandler, AB; Scagliotti, GV; Schiller, JH; Schwartz, B; Sequist, LV; Soria, JC; von Pawel, J; Von Roemeling, R | 1 |
| de Marinis, F; del Signore, E; Fulvi, A; Gori, B; Ricciardi, S | 1 |
| Aparna, U; Chandregowda, V; Karunakara, C; Reddy, CG | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Capasso, A; Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Fujii, S; Hamada, A; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, J; Semba, H; Tsubata, Y; Urata, M; Ushijima, S | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Plotkin, SR; Terry, AR | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Abali, H; Kara, S; Koc, Z; Onal, C | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
| Kim, JH; Klingelschmitt, G; Ng, C; Park, K; Wu, YL; Zaatar, A | 1 |
| Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
| Chien, CR; Hsia, TC; Lin, CC | 1 |
| Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Arango, N; Bonilla, C; Cuello, J; Llinás, N; Rivas, G; Rubiano, J | 1 |
| Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P | 1 |
| Li, Y; Ren, YY; Zhang, LY | 1 |
| Burger, JA; Saintigny, P | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Bellail, AC; Gao, S; Hao, C; Li, B; Liu, T; Wei, F | 1 |
| Kita, K; Mano, H; Matsumoto, K; Nakade, J; Nakagawa, T; Nakamura, T; Nanjo, S; Soda, M; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Lo, RS | 1 |
| Abemayor, E; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, DA; Lin, Y; Luo, J; Sharma, S; St John, MA; Wang, G | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ | 1 |
| Kaneko, F; Oyama, N; Togashi, A; Yamamoto, T | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Fallet, V; Lacave, R; Lavolé, A; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Bahlo, M; Klapdor, R; Klapdor, S | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Chauhan, S; Gupta, M; Gupta, MK; Kesari, AA; Madabhavi, I; Rastogi, M; Revannasiddaiah, S; Seam, RK | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Brewster, M; Cedrés, S; Dean, E; Felip, E; Galdermans, D; Martínez, P; McNally, V; Ranson, M; Ross, G | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Au, JS; Cheng, CK; Merimsky, O; Reck, M; von Pawel, J | 1 |
| Mason, DP | 1 |
| Eastman, BM; Gonias, SL; Jo, M; Takimoto, S; Webb, DL | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| Nakamura-Wakatsuki, T; Yamamoto, T | 1 |
| Asrani, K; Bremner, R; Cheng, E; Hostetter, G; Inge, L; Jameson, NM; Kingsley, CB; Loftus, JC; Tran, NL; Weiss, GJ; Whitsett, TG; Winkles, JA | 1 |
| Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W | 1 |
| Govindarajan, R; Makhoul, I; Siegel, E; Williamson, S | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Le Caer, H; Locher, C; Monnet, I; Vergnenegre, A | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Berezov, A; Greene, MI; Huang, JM; Karlan, B; Kumagai, T; Mizuno, T; Nagatomo, I; Suzuki, E; Wang, Q; Zhang, H | 1 |
| Ashizawa, J; Deguchi, Y; Hashimoto, R; Hitani, K; Hori, Y; Maeno, T; Shiba, T; Ubuka, M | 1 |
| Ali, K; Kumar, I; Usman Saeed, M; Usman-Saeed, M | 1 |
| Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S | 1 |
| Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN | 1 |
| Keshtgarpour, M; Ma, PC; Pennell, NA; Yin, L | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Califano, R; D'arcangelo, M; Mok, TS | 1 |
| Perez-Soler, R; Piperdi, B | 1 |
| Benoit, JP; Hureaux, J; Saulnier, P; Vrignaud, S; Wack, S | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF | 1 |
| Argiris, A; Ferris, RL; Freilino, ML; Gooding, WE; Grandis, JR; Gross, N; Moskowitz, HS; Thomas, SM | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Borger, DR; Brard, L; Dizon, DS; Growdon, WB; Horowitz, NS; Krasner, CN; Lee, J; Liu, JF; Matulonis, UA; Olawaiye, AB | 1 |
| Abdel-Rahman, M; Arcila, M; Au, V; Bivona, TG; Boggon, TJ; Choi, CM; Choi, YJ; Costa, C; Halmos, B; Jang, SJ; Kim, SW; Kim, WS; Ladanyi, M; LaFramboise, T; Lee, DH; Lee, JC; Lee, JS; Levine, AD; Lin, L; Ma, PC; Miller, VA; Moonsamy, P; Olivas, V; Park, YS; Rho, JK; Rosell, R; Sawyers, C; Taron, M; Wang, X; Zhang, Z | 1 |
| Burgers, JA; Codrington, HE; Kappers, I; Klomp, HM; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Barrios, CH; Blackhall, F; Bover, I; Boyer, M; Campbell, AK; Frank, R; Krzakowski, M; Letrent, SP; Liang, JQ; O'Connell, J; Park, K; Ramalingam, SS; Rosell, R; Ruiz-Garcia, A; Seog Heo, D; Talbot, DC; Taylor, I | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Grandis, JR; Quesnelle, KM; Ratay, MK; Wheeler, SE | 1 |
| Benlyazid, A; Delmar, P; Delord, JP; Hennebelle, I; McLoughlin, P; Rochaix, P; Sarini, J; Thomas, F; Vergez, S | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Dong, XR; Huang, J; Liu, L; Lu, HD | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Abe, H; Arao, T; Azuma, K; Hayashi, K; Kage, M; Kanda, R; Kawahara, A; Kubo, T; Kuwano, M; Murakami, Y; Nishio, K; Ono, M; Rosell, R; Sonoda, K; Tabara, K; Tahira, T; Yoshinaga, A | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Gui, T; Shen, K | 1 |
| Li, H; Ren, XB; Wang, CL; Wang, M; Yu, JP; Zhang, LM; Zhao, J | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L | 1 |
| Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Nagpal, S; Riess, J; Wakelee, H | 1 |
| Bezler, M; Hengstler, JG; Ullrich, A | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Chen, RC; Halle, J; Higginson, DS; Marks, LB; Morris, DE; Pham, E; Rosenman, JG; Socinski, MA; Stefanescu, M; Tracton, G | 1 |
| Al Saleh, S; Khajah, MA; Luqmani, YA; Mathew, PM | 1 |
| Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S | 1 |
| Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY | 1 |
| Jänne, PA; Oxnard, GR | 1 |
| Balabathula, P; Bhattacharjee, H; Mandal, B; Mittal, N; Wood, GC | 1 |
| Shi, YK | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Brown, HA; Bruntz, RC; Bryson, BL; Cipriano, R; Graham, J; Jackson, MW; Miskimen, KL; Scott, SA; Stark, GR | 1 |
| O'Reilly, EM | 1 |
| Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z | 1 |
| Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H | 1 |
| Ali, K; Kumar, I; Saeed, MU; Usman-Saeed, M | 1 |
| Galvani, E; Giovannetti, E; Peters, GJ | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Meluch, A; Peyton, J; Rubin, M; Waterhouse, D; Webb, C | 1 |
| Choi, M; Kim, R; Razzaque, S | 1 |
| Kris, MG; Ladanyi, M; Moreira, AL; Paik, PK; Rekhtman, N; Sima, CS; Varghese, AM | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Abell, F; Boyer, M; De Souza, P; Horwood, K; Johnston, M; Millward, M; Pavlakis, N; Rischin, D; Stein, B | 1 |
| Gao, G; Ren, S; Wu, X; Zhou, C | 1 |
| Ahsan, A; Bradford, CR; Chepeha, DB; D'Silva, N; Eisbruch, A; Helman, JI; Lawrence, TS; Nyati, MK; Ramanand, SG; Tsien, CI; Wolf, GT; Worden, FP | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Beculic, H; Dervisevic, S; Imsirovic, B; Mekic-Abazovic, A | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Cei, M; Mumoli, N; Vitale, J | 1 |
| Daw, H; Haddad, A; Petrosyan, F; Spiro, T | 1 |
| Azuma, J; Iekushi, K; Iwabayashi, M; Morishita, R; Rakugi, H; Sanada, F; Shimizu, K; Taniyama, Y | 1 |
| Abou-Alfa, GK; Ang, C; O'Reilly, EM | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Li, WF; Wu, SX; Xie, CY; Zhang, P; Zhang, XB | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| Cai, J; Chen, T; Chen, Y; Deng, J; Du, Z; Li, Q; Lu, J; Shan, B; Song, X; Wery, JP; Yang, M; Zhang, L | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Arcaroli, J; Cusatis, G; Garrett-Mayer, E; Hidalgo, M; Messersmith, WA; Rubio-Viqueira, B; Song, D; Weekes, CD; Wilson, LA; Winn, RA | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Carlson, JJ; Yeung, K | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
| Commandeur, S; de Gruijl, FR; El Ghalbzouri, A; van Drongelen, V | 1 |
| Barbacid, M; Guerra, C; Hernández-Porras, I; Navas, C; Schuhmacher, AJ; Sibilia, M | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Chen, HJ; Chen, KF; Chou, YC; Huang, JW; Kim, I; Liu, CY; Pao, KC; Shiau, CW; Su, JC | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Chmielecki, J; Foo, J; Michor, F; Pao, W | 1 |
| Ackerman, A; Costa, DB; Goldstein, MA; Kobayashi, S | 1 |
| Li, QS; Sun, S; Tang, JF; Wang, XL; Yang, YS; Zhang, F; Zhang, YB; Zhu, HL | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Dziadziuszko, R; Jassem, J | 2 |
| Llombart, B; Requena, C; Sanmartín, O | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Karavasilis, V; Kosmidis, P; Murray, S; Papadopoulos, S; Razis, E | 1 |
| Jiang, SJ; Ma, XB; Zhang, QC; Zhang, S | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Chiang, HC; Du, S; Liang, B; Ma, W; Wang, L; Wu, W; Xie, Z; Yao, X; Zhong, Y | 1 |
| Clark, P; Dillon, B; Knight, H; Naidoo, B | 1 |
| Brierley, R | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
| Chen, YM; Chiang, CL; Chiu, CH; Chou, TY; Lai, SL; Lee, YC; Shih, JF; Tsai, CM | 1 |
| Hallek, M; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Bivona, TG; Blakely, CM | 1 |
| Chen, M; Lin, J; Liu, Y; Luo, Z; Song, L | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Riely, GJ; Yu, HA | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S | 1 |
| Griesinger, F; Overbeck, TR | 1 |
| Guevara, T; Orzáez, M; Pérez-Payá, E; Sancho, M | 1 |
| Brock, K; Evans, TR; Gedrich, R; Hopkins, CA; Macpherson, IR; Poondru, S; Simon, GR; Stephens, A; Stewart, K | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Lemmon, MA; Liu, Y; Park, JH; Radhakrishnan, R | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Baghdadi, TA; Bhatia, S; Hanna, N; Harb, W; Jalal, SI; Johnson, C; McClean, J; Riggs, H; Taber, D; Yu, M | 1 |
| Lou, D; McCormick, F; Young, A | 1 |
| Airiau, K; Avril, T; Belaud-Rotureau, MA; Belloc, F; Dugay, F; Eimer, S; Quillien, V | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Deng, ZL; Dong, YC; Han, QL; Jiang, T; Lv, XH; Ren, H; Xing, WJ; Zou, Y | 1 |
| Ali, A; Candy, PA; Epis, MR; Ganda, C; Giles, KM; Kalinowski, FC; Leedman, PJ; Webster, RJ | 1 |
| Fletcher, EV; Knudson, CM; Love-Homan, L; Martin, SM; Parsons, AD; Simons, AL; Sobhakumari, A; Spitz, DR | 1 |
| Lee, JG; Wu, R | 2 |
| Baty, F; Brutsche, M; Bubendorf, L; Carbone, D; Crowe, S; Dingemans, AM; Gautschi, O; Grigorieva, J; Hsu Schmitz, SF; Na, KJ; Peters, S; Pless, M; Roder, H; Roder, J; Smit, E; Stahel, R; Zappa, F | 1 |
| Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R | 1 |
| Bidkhori, G; Masoudi-Nejad, A; Moeini, A | 1 |
| Adjei, AA; Burris, HA; Dy, GK; Eckhardt, SG; Huff, A; Infante, JR; Jones, SF; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Bahce, I; Heideman, DA; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Schuit, RC; Smit, EF; Thunnissen, E; van der Veldt, AA; Windhorst, AD; Yaqub, M | 1 |
| Chen, SS; Falchook, GS; Fok, JY; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, SA; Stephen, B; Tsimberidou, AM; Wheler, JJ | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Bird, L; Fox, EA; Kopp, N; Lane, AA; Rodig, SJ; Shindoh, N; Sullivan, TJ; Weigert, O; Weinstock, DM; Yoda, A; Yoda, Y | 1 |
| Basti, S; Borkar, DS; Lacouture, ME | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Gemma, A; Saito, Y | 1 |
| Kay, M | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Beijnen, JH; Burgers, JA; Huitema, AD; Lankheet, NA; Rosing, H; Schaake, EE; Schellens, JH | 1 |
| Chambers, CR; Sheikh, N | 1 |
| Chang, YL; Chen, HJ; Chen, KF; Cheng, AL; Liu, CY; Shiau, CW; Yu, HC | 1 |
| Jaster, R; Kossow, C; Lange, F; Rateitschak, K; Wolkenhauer, O | 1 |
| Guirgis, HM | 1 |
| Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Krug, S; Michl, P | 1 |
| Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Grandis, JR; Gubish, CT; He, G; Henry, C; Joyce, S; Lui, VW; Quesnelle, KM; Siegfried, JM; Stabile, LP; Thomas, S | 1 |
| Cioffi, P; Fanizza, C; Giglioni, A; Grappasonni, I; Marotta, V; Natoli, C; Petrelli, F | 1 |
| Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| El-Sawy, T; Esmaeli, B; Glisson, BS; Kies, MS; Lippman, S; Myers, JN; Sabichi, AL; William, WN | 1 |
| Baqir, W; Husband, A; Mahony, M; Todd, A; Williamson, S | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Barocelli, E; Bonelli, M; Carbognani, P; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Graiani, G; La Monica, S; Madeddu, D; Mozzoni, P; Mutti, A; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Bailey, AS; Canepa, HM; Costa, DB; Goldstein, MA; Huberman, MS; Kobayashi, S; Nakayama, S; Yamaguchi, N | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Chen, Z; Han, R; Sun, L; Wang, J; Wang, X; Zhang, J; Zhao, J; Zhong, D | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Anand-Apte, B; Blobel, CP; Chan, RV; Chiang, MF; Farage, E; Glomski, K; Hewing, NJ; Khokha, R; Swendeman, S; Vermaat, J; Weskamp, G | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Matsuo, K; Takada, Y | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Bridge, S; Dharamshi, K; Jäkel, A; Johns, A; Modha, R; Plested, M | 1 |
| Docheva, D; Eibl-Lindner, KH; Kampik, A; Kernt, M; Liegl, R; Mayer, W; Wertheimer, C | 1 |
| Wong, ET; Zhu, JJ | 1 |
| Koh, Y; Serizawa, M; Takahashi, T; Yamamoto, N | 2 |
| Elmquist, WF; Mittapalli, RK; Sane, R | 1 |
| Hendrikse, NH; Poot, AJ; Slobbe, P; van Dongen, GA; Windhorst, AD | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Bou Matar, RN; Klein, JD; Sands, JM | 1 |
| Brooks, MB | 1 |
| Duyster, J; Kancha, RK; Kunst, PW; Reinten, RJ; van der Ven, WH; van Noesel, CJ; van Noesel, J; van Os, TA; Weegenaar, J | 1 |
| Giuliani, J; Marzola, M | 2 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Campos-Martín, Y; García-Claver, A; Lorente, M; Meléndez, B; Mollejo, M; Mur, P; Velasco, G | 1 |
| Kuiper, JL; Smit, EF | 1 |
| Chao, NJ; Chute, JP; Deoliviera, D; Doan, PL; Fixsen, E; Harris, JR; Helms, K; Himburg, HA; Kirsch, DG; Quarmyne, M; Russell, JL; Sullivan, JM | 1 |
| Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K | 1 |
| Pallis, AG; Syrigos, KN | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Hu, Y; Tang, JF; Wang, XL; Yang, W; Yang, YS; Zhang, F; Zhang, YB; Zhong, WQ; Zhu, HL | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Fang, Z; Li, B; Zang, YS | 1 |
| Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR | 1 |
| Khan, I; Sarker, SJ; Whitehead, A | 1 |
| Ather, F; Fejzo, MS; Finn, RS; Hamidi, H; Head, C; Kabbinavar, F; Letrent, S; Wong, SG | 1 |
| Ahsmann, EJ; Eshuis, M; van Egmond, NH | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Gaffney, DC; Simpson, F; Soyer, HP | 1 |
| Díaz-Rubio, E; González-Larriba, JL; Hernández, S; Manzano, A; Pérez, P; Puente, J; Sanz, J; Sotelo, M; Zugazagoitia, J | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Bingman, A; Carothers, S; Kraut, EH; Layman, RM; Lustberg, MB; Lynn, M; Mrozek, E; Ottman, S; Ramaswamy, B; Reinbolt, R; Ruppert, AS; Shapiro, CL; Wesolowski, R | 1 |
| Chen, HJ; Cheng, YP; Chiu, HC | 1 |
| Couraud, S | 1 |
| Bastida, C; Falchook, GS; Fu, S; Hong, DS; Jiang, Y; Kurzrock, R; Morgan-Linnell, SK; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Boeck, S; Egg, R; Goritschan, C; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Laubender, RP; Modest, DP; Neumann, J; Ormanns, S | 1 |
| Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Nanjo, S | 1 |
| Akerley, WL; Cowie, RH; Hornberger, J; Nelson, RE; Spinella, DG | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Hu, CP; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Sterman, DH | 1 |
| Austin, M; Bauman, JE; Chai, X; Eaton, KD; Futran, N; Hayes, DN; Kurland, BF; Liao, JJ; Martins, RG; Mendez, E; Papagikos, MA; Parvathaneni, U; Raez, LE; Schmidt, R; Sharma, AK; Wallace, SG; Wang, DX; Yunus, F | 1 |
| Altavilla, G; De Pas, TM; Rosell, R; Santarpia, M; Spaggiari, L | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S | 1 |
| Cao, YF; Fang, ZZ; Ge, GB; Hu, CM; Song, JH; Zhao, DW; Zhu, LL | 1 |
| Eckert, R; Faehling, M; Griese, U; Kamp, T; Kuom, S; Ott, G; Spengler, W; Sträter, J | 1 |
| Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M | 1 |
| Bayne, M; Cherrett, L; Davis, R; Fenton, P; Laurence, V | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Okamoto, T; Onda, S | 1 |
| Ke, S; Pan, G; Zhao, J | 1 |
| Baumert, TF; Duong, FH; Durand, SC; Fofana, I; Heim, MH; Lupberger, J; Pessaux, P; Thumann, C; Xiao, F; Zeisel, MB; Zona, L | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Dong, Z; Kang, Y; Liu, G; Ma, X; Qian, Q; Zhang, X | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Bode, A; Gill, SC; Grubbs, CJ; Iwata, KK; Juliana, MM; Lubet, RA; Nicastro, HL; Steele, VE; Szabo, E; Tucker, C | 1 |
| Fukudo, M; Ikemi, Y; Inui, K; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Terada, T; Teramukai, S; Togashi, Y | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Biasco, G; Brandi, G; Dika, E; Maibach, H; Patrizi, A; Venturi, M | 1 |
| Megahed, M; Wahl, RU | 1 |
| Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W | 1 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B; Schwartz, EL; Sironi, J; Zou, Y | 1 |
| Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Aragane, N; Harada, T; Ichinose, Y; Kawakami, S; Kishimoto, J; Morinaga, R; Nagata, S; Nakanishi, Y; Saruwatari, K; Takayama, K; Yamada, K | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Hejduk, K; Pochop, L | 1 |
| Cappuzzo, F; D'Arcangelo, M | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Chen, M; Dominguez, SL; Eastham-Anderson, J; Le Pichon, CE; Lewin-Koh, N; Ngu, H; Scearce-Levie, K; Solanoy, H; Watts, R | 1 |
| Bhatnagar, PK; Chaira, T; Cliffe, I; Das, B; Dastidar, SG; Diwan, M; Gupta, P; Kumar, A; Malik, R; Malik, S; Nithya, D; Pamidiboina, V; Ray, A; Senthil, V; Tandon, R; Venkataramanan, R | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Evans, T; Gettinger, S; Hensing, TA; Ireland, B; Socinski, MA; Stinchcombe, TE; VanDam Sequist, L | 1 |
| Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A | 1 |
| Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM | 1 |
| Berg, K; Selbo, PK; Weyergang, A | 1 |
| Cho, YS; Kim, HU; Kim, JI; Nam, KH; Park, J; Yun, SK | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chen, TC; Lee, KM; Lien, CT; Lin, SY; Lu, PL | 1 |
| Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL | 1 |
| Hsu, JH; Li, MF; Shiau, EL; Wu, MT | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Essenburg, C; Kaufman, D; Lewis, S; Staal, B; Vande Woude, GF; Zhang, YW | 1 |
| Carr, LL; Jett, JR | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Bartsch, R; Chrysikos, D; Dimopoulos, MA; Filipits, M; Papadimitriou, CA; Sergentanis, TN; Zagouri, F; Zografos, CG | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Berglund, A; Bergström, D; De Pont Christensen, R; Fernebro, E; Frödin, JE; Garm Spindler, KL; Hagman, H; Jakobsen, A; Johnsson, A; Keldsen, N; Sundberg, J | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Belani, CP; Benner, RJ; Chachoua, A; Cuevas, JD; Eisenberg, PD; Mather, CB; Meech, SJ; Nemunaitis, JJ; Raez, LE | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Bachem, MG; Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR; Zhou, S | 1 |
| Cheng, AL; Chiou, TJ; Hsu, C; Hsu, CH; Jin, K; Kang, YK; Sandoval-Tan, J; Shao, YY; Shun, CT; Su, WC; Yang, TS | 1 |
| Ogbonna, OH; Saif, MW | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G | 1 |
| Aoki, Y; Fujii, T; Ishii, N; Kondoh, O; Mio, T; Ono, N; Sakata, K; Suda, A; Tsukaguchi, T; Tsukuda, T; Yamazaki, T | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Costa, C; Fujita, H; Kage, M; Kanda, R; Kawahara, A; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Sonoda, K; Uramoto, H; Watari, K | 1 |
| Kathagen, A; Kolbe, K; Lamszus, K; Liffers, K; Merlo, A; Riethdorf, S; Schulte, A; Westphal, M; Zapf, S | 1 |
| Augustin, A; Avila, D; Berrera, M; Ebeling, M; Golling, S; Lamerz, J; Langen, H; Tzouros, M | 1 |
| Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Sadiq, AA | 1 |
| Bettini, A; Bianchi, F; Broggini, M; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Giaccone, G; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Scanni, A; Tomirotti, M; Torri, V; Veronese, S | 1 |
| Chalasani, P; Clausen, C; Dhiwakar, M; Kalapurakal, S; Malone, J; Rao, K; Robbins, KT; Robinson, K; Ronen, O; Shevlin, B | 1 |
| Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X | 1 |
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Owonikoko, TK; Ramalingam, SS; Sica, GL; Sun, SY | 1 |
| Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M | 1 |
| Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Havel, L; Hrnciarik, M; Krejci, J; Minarik, M; Pesek, M; Salajka, F | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chikamori, K; Fukuyama, T; Goto, K; Hida, T; Katakami, N; Kozuki, T; Maemondo, M; Nishio, M; Seto, T; Tamura, T; Yamamoto, N; Yoshioka, H | 1 |
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A | 1 |
| Stinchcombe, TE; Weiss, JM | 1 |
| Bai, S; Bothos, J; Damico-Beyer, LA; Davis, JD; Eppler, S; Jin, D; Joshi, A; Kaur, S; Nijem, I; Patel, P; Peterson, A; Xin, Y | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Gao, BL; Hang, JB; Hu, JA; Xu, ZH | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Basu, D; Bewley, AF; Diehl, JA; Facompre, ND; Gimotty, PA; Herlyn, M; Montone, KT; Nakagawa, H; Rasanen, K; Rustgi, AK; Sperry, SM; Weinstein, GS | 1 |
| Izumi, Y; Nomori, H; Yamamoto, J; Yamauchi, Y | 1 |
| Aisner, DL; Berge, EM; Doebele, RC | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Cheng, PS; Lai, FJ | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J | 1 |
| Falchook, GS; Fok, JY; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, RG | 1 |
| Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A | 1 |
| Fenaux, P; Galluzzi, L; Kepp, O; Kroemer, G; Lainey, E; Micol, JB; Sukkurwala, AQ; Wolfromm, A | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y | 1 |
| Alberti, AM; Apolone, G; Cammilluzzi, E; Cesario, A; D'Angelillo, RM; De Quarto, AL; Fiore, M; Greco, C; Ippolito, E; Ramella, S; Ramponi, S; Trodella, L | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Aerts, JG; Biesma, B; Burgers, S; Codrington, H; Dalesio, O; Dingemans, AM; Groen, HJ; Lankheet, NA; Smit, EF; Vincent, AD | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
| Azzariti, A; Brunetti, AE; Gnoni, A; Lorusso, V; Maiello, E; Merchionne, F; Nardulli, P; Reni, M; Santini, D; Silvestris, N; Tonini, G; Vincenti, L | 1 |
| Amoroso, D; Chao, TY; Chung, CY; Ciuleanu, T; Groen, HJ; Heo, DS; Klingelschmitt, G; Klughammer, B; Middleton, G; Milanowski, J; Szczesna, A; Thatcher, N; Tsai, CM; Tsao, CJ; Zeaiter, A | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Koba, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Torres-Garcia, VZ; Vazquez-Martin, A; Visa, J | 1 |
| Stinchcombe, TE | 1 |
| Adak, S; Landgraf, R; Macdonald-Obermann, JL; Pike, LJ; Piwnica-Worms, D | 1 |
| Huang, Q; Li, J; Liu, JY; Xue, JP; Zhang, FL; Zheng, K | 1 |
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Shin, DM; Sica, GL; You, S | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Candy, PA; Epis, MR; Giles, KM; Goodall, GJ; Kalinowski, FC; Leedman, PJ; Redfern, AD; Stuart, LM; Zhang, PM | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Boisdron-Celle, M; Fey, L; Hureaux, J; Morel, A; Rieux, C; Urban, T | 1 |
| Batlle, D; Egido, J; Eguchi, S; Keri, G; Morgado-Pascual, JL; Ortiz, A; Pato, J; Ramos, AM; Rayego-Mateos, S; Ruiz-Ortega, M; Sanz, AB | 1 |
| Chen, Y; Fisher, CJ; Kuta, V; Lai, B; Lilge, LD; Niu, CJ | 1 |
| Baty, F; Betticher, D; Brutsche, M; Bubendorf, L; Cathomas, R; Crowe, S; Dröge, C; Früh, M; Gautschi, O; Pless, M; Rauch, D; Rothschild, S; Zappa, F | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A | 1 |
| Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Köhler, J; Schuler, M | 1 |
| Chen, CH; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Austin, MC; Bauman, JE; Chai, X; Hayes, DN; Kurland, BF; Martins, RG; Mendez, E; Parvathaneni, U; Sampath, S; Schmidt, R; Vaezi, A | 1 |
| Digumarthy, S; Goldberg, SB; Jackman, DM; Lennes, IT; Muzikansky, A; Oxnard, GR; Sequist, LV | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; Donehower, RC; Edil, BH; Fan, KY; Herman, JM; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, CA; Laheru, DA; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD | 1 |
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Deitz, S; Gore, J; Korc, M; Ouyang, H | 1 |
| Deng, CH; Li, HQ; Li, L; Li, MY; Lu, W; Wu, Q; Zhou, TY | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Barlesi, F; Blumenschein, GR; Daniel, DB; Ervin, TJ; Godbert, B; Goldschmidt, JH; Govindan, R; Krzakowski, MJ; Orlov, SV; Patel, PH; Patel, T; Peterson, AC; Phan, SC; Ramlau, RA; Robinet, G; Spigel, DR; Wertheim, MS; Yauch, RL; Yu, W; Zha, J | 1 |
| Bowden, C; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Kressel, B; Lin, CY; Marsland, T; Miller, V; Patel, T; Polikoff, J; Rubin, M; White, L; Yang, JC | 1 |
| Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
| Bourra, H; Hassam, B | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Fukuda, M; Iida, T; Ikeda, T; Ikegami, Y; Kohno, S; Mizoguchi, K; Motoshima, K; Nagashima, S; Nakamura, Y; Sano, K; Takemoto, S; Tsukamoto, K | 1 |
| Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Ding, JF; Zhong, DF | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Cai, HR; Ding, JJ; Liu, L; Miao, LY; Ren, SX; Schmid-Bindert, G; Wang, YS; Zhou, CC | 1 |
| Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N | 1 |
| Fujii, T; Fujiwara, M; Fukuda, S; Hotta, Y; Kanda, M; Kasuya, H; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Nomoto, S; Sahin, TT; Sugimoto, H; Tan, G; Tanaka, C; Tanaka, M; Tsurumaru, N; Yamada, S; Yamamura, K | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Mennecier, B; Quoix, A; Sakhri, L | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
| Fujimoto-Ouchi, K; Furugaki, K; Harada, N; Iwai, T; Moriya, Y | 1 |
| Ema, T; Enomoto, Y; Kawano, R | 1 |
| Gröschel, A; Reck, M; Reinmuth, N | 1 |
| Ahmad, A; Bao, B; Gadgeel, SM; Ginnebaugh, KR; Li, Y; Maitah, MY; Sarkar, FH | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Hiemstra, CN; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Bennouna, J; Dansin, E; Favrel, S; Hiret, S; Kowalski, D; Krzakowski, M; Penel, N; Tourani, JM | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Khurana, M | 1 |
| Brahmer, JR; Guaglianone, PP; Hidalgo, MM; Keppen, MD; Kolesar, JM; Lee, JW; Patel, JD; Schiller, JH; Siegfried, JM; Traynor, AM | 1 |
| Keith, DJ; Stewart, DG | 1 |
| Dobrowsky, RT; Pan, P | 1 |
| Song, Z; Zhang, Y | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Bettegowda, C; Burger, PC; Connis, N; Gallia, GL; Hann, CL; Jiao, Y; Ruzevick, J; Siu, IM; Xia, X; Zhao, Q | 1 |
| Galichet, A; Müller, EJ; Rüegg, S; Sayar, BS; Schmidt, E; Sibilia, M; Siffert, M; Suter, MM | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Furuse, J | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Molina-Pinelo, S; Pastor, MD; Paz-Ares, L | 1 |
| Cavenee, WK; Cloughesy, TF; Eskin, A; Furnari, FB; Gini, B; Gomez, G; Heath, JR; Hwang, K; James, CD; Koga, T; Kornblum, HI; Masui, K; Mischel, PS; Mottahedeh, J; Nathanson, DA; Nelson, SF; Ohashi, M; Paucar, A; Rao, PN; Reed, R; Visnyei, K; Wang, J; Wykosky, J; Yang, H; Zhu, S | 1 |
| Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN | 1 |
| Meng, X; Teng, FF; Yu, JM; Zhang, JD | 1 |
| Besse, B; Bonardel, G; Chargari, C; Farace, F; Gontier, E; Hadoux, J; Helissey, C; Lamand, V; Le Moulec, S; Soria, JC; Tanz, R; Vedrine, L | 1 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Choi, CM; Choi, YJ; Kim, HR; Kim, SY; Lee, JC; Park, GM; Rho, JK; So, GS | 1 |
| Baio, G | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Allen, JN; Berger, DL; Blaszkowsky, LS; Borger, DR; Clark, JW; Cusack, JC; Hong, TS; Kwak, EL; Mamon, HJ; Ryan, DP; Shellito, PC; Szymonifka, J; Vasudev, E; Zhu, AX | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Guan, Y; Jiao, S; Meng, J; Yan, X; Zhao, H | 1 |
| Afonso, J; Amenedo, M; Casal, J; Fírvida, JL; Lázaro, M; Santomé, L; Vázquez, S | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Bannerji, R; Edelman, MJ; Jou, YM; Joy, AA; Martin, JC; Nemunaitis, J; Small, K; Statkevich, P; Stephenson, JJ; Yao, SL; Zhang, D; Zhou, H; Zhu, Y | 1 |
| Hager, H; Khalil, AA; McCulloch, T; Meldgaard, P; Mellemgaard, A; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Chan, AW; Lo, SH; To, KF; Tong, JH | 1 |
| Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Dhanda, R; Mallick, R; Nadler, E; Pan, IW | 1 |
| Bobilev, D; Peleg, R; Priel, E | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Bennett, DC; Charest, J; Contessa, JN; Huang, Y; Morris, ED; Petrulli, JR; Sullivan, JM; Zheng, MQ | 1 |
| Aust, D; Buchholz, M; Gress, T; Griesmann, H; Krug, S; Kühnemuth, B; Lölkes, C; Michl, P; Milosevic, N; Mühlberg, L; Pilarsky, C; Ripka, S | 1 |
| Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M | 1 |
| Chen, X; Du, Y; Kong, L; Sun, H; Sun, M; Wang, F | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB | 1 |
| Fang, MH; Li, RC; Yu, SY; Zheng, LJ | 1 |
| El-Mashtoly, SF; Gerwert, K; Kötting, C; Mosig, A; Petersen, D; Reinacher-Schick, A; Yosef, HK | 1 |
| Yaqub, F | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Wirth, LJ | 1 |
| Abrams, MB; Kjell, J; Olson, L; Pernold, K | 1 |
| Liu, XQ; Qiao, TK | 1 |
| Chen, CY; Chiu, HC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Wo, TY | 1 |
| Blakely, LJ; Schwartzberg, LS; Smiley, LM; Stewart, CF; Tagen, M; Tauer, KW | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Asklund, T; Henriksson, R; Riklund, K; Sandström, M; Shahidi, S | 1 |
| Benhadji, KA; Brail, LH; Bumgardner, W; Cohen, EE; Hollebecque, A; Houédé, N; Italiano, A; Massard, C; Miller, J; Soria, JC; Westwood, P | 1 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Iwasaki, T; Mitsudomi, T; Mizuuchi, H; Sato, K; Suda, K; Takemoto, T | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Cao, X; Hong, Z; Lan, L; Li, N; Luo, L; Pan, X; Shen, L; Yin, Z; Zhang, Y; Zhou, Y | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Drolet, DW; Fettner, SH; Hamilton, M; Lum, BL; Rakhit, AK; Witt, K; Wolf, JL | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Ladanyi, M; Riely, GJ; Yu, HA | 1 |
| Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL | 1 |
| Castañeda, G; Muñoz, L; Navarro, D; Rodríguez, J; Villa, JC | 1 |
| Bertran-Alamillo, J; Bivona, T; Carcereny, E; Costa, C; Drozdowskyj, A; Felip, E; Garcia-Campelo, R; Gervais, R; Giannikopoulos, P; Giménez-Capitán, A; Karachaliou, N; Majem, M; Massuti, B; Molina, MA; Moran, T; Ono, M; Rosell, R; Taron, M; Viteri, S; Wei, J | 1 |
| Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J | 1 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Fan, X; Jiang, L; Li, S; Liu, Z; Wu, X; Zhao, H; Zhu, F | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dong, XL; Dong, Z; Li, G; Li, XL; Mu, XY; Ni, YH; Sun, EL; Sun, J; Yi, Z | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Bader, AG; Kelnar, K; Zhao, J | 1 |
| Chan, TA; Luwor, RB; Mariadason, JM; Ng, I; Putoczki, TL; Stylli, SS; Ung, N; Zhu, HJ | 1 |
| Bohnet, S; Deppermann, KM; Eiff, MV; Fischer, JR; Heigener, DF; Koester, W; Kortsik, C; Pawel, JV; Reck, M; Schnabel, PA; Thomas, M | 1 |
| Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E | 1 |
| Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW | 1 |
| Beltran-Alamillo, J; Benlloch, S; Bordogna, W; Botero, ML; Chen, D; de Aguirre, I; Gimenez-Capitán, A; Klughammer, B; Kovach, B; Lawrence, HJ; Mayo, C; Palma, JF; Queralt, C; Ramirez, JL; Ramón y Cajal, S; Schlegel, M; Shieh, F; Taron, M; Wu, L; Zhang, G | 1 |
| Docheva, D; Eibl-Lindner, KH; Kampik, A; Kernt, M; Liegl, R; Wertheimer, C | 1 |
| Bansal, N; Center, B; Fetrow, JS; Furdui, CM; Kuremsky, JG; Marrs, GS; Mims, J; Olex, AL; Porosnicu, M; Qian, J; Tsang, AW; Wani, R; Yin, L; Zhao, W | 1 |
| Rerknimitr, P; Rungtrakulchai, R | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Alves, FV; Carmo, CC; Erlich, F; Ferreira, CG; Grazziotin, R; Mamede, M; Moralez, G; Nogueira-Rodrigues, A; Small, IA; Triginelli, SA; Viegas, C | 1 |
| Choi, JS; Choi, YL; Jung, K; Kim, YJ; Kundu, J; Kwon, MJ; Lee, SE; Oh, E; Seo, J; Shin, YK; Song, JY | 1 |
| Chen, C; Cretoiu, SM; Shi, L; Wang, B; Wang, L; Wang, Q; Wang, X | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Li, S; Ren, S; Zhou, C; Zhou, F | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C | 1 |
| Baumann, M; Benes, CH; Chowdhury, D; Efstathiou, JA; Greninger, P; Hülskötter, M; Kern, AM; Krause, M; Pan, Y; Settleman, J; Singh, A; Wang, M; Willers, H | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Bardeesy, N; Caravan, P; Chen, X; Crenshaw, A; DePeralta, DK; Fuchs, BC; Fujii, T; Golub, TR; Gupta, S; Hoshida, Y; Kuroda, T; Lanuti, M; Lauwers, GY; McGinn, CM; Onofrio, R; Schmitt, AD; Tanabe, KK; Taylor, B; Wei, L; Winckler, W; Yamada, S | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Dafni, U; Karlis, D; Peters, S; Smit, E | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Amler, L; Desai, R; Do, A; Filvaroff, E; Fu, L; Huang, J; Januario, T; Koeppen, H; Lazarov, M; Lipkind, M; Louie, SG; Mohan, S; Pandita, A; Parab, V; Patel, P; Patel, R; Penuel, E; Peterson, A; Phan, SC; Raja, R; Ramakrishnan, V; Rangell, L; Shames, DS; Wistuba, I; Xia, X; Yauch, RL; Yu, W; Zha, J | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N | 1 |
| Behringer, D; Desaiah, D; Dittrich, C; Hartmann, JT; Kazeem, G; Leschinger, MI; Papai-Szekely, Z; Sederholm, C; Vinolas, N; von Pawel, J | 1 |
| Harris, RC; Paueksakon, P; Wang, Y; Zhang, MZ | 1 |
| Chang, CX; Li, P; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Bajaj, PS; Carlson, JJ; Goertz, HP; Veenstra, DL | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Seto, T; Shiraishi, Y; Taguchi, K; Takenaka, T; Takenoyama, M; Takeo, S; Toyokawa, G; Toyozawa, R; Ushijima, C; Yamaguchi, M; Yoshida, T | 1 |
| Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Cao, Z; Li, H; Li, J; Li, M; Lu, Z; Shu, H; Wang, T; Xu, J; Yang, J; You, L; Zhang, T; Zhao, Y; Zhou, L | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Argiris, A; Bauman, JE; Chiosea, S; Conrads, TP; Denq, W; Ferris, RL; Flint, MS; Gooding, WE; Grandis, JR; Gross, ND; Hood, BL; Johnson, JT; Kim, S; Nikiforova, MN; Siegfried, JM; Sun, M; Thomas, SM; Wang, L; Wirth, L | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Bergbower, E; Dennis, PA; Dogan, I; Ekmekci, A; Gills, JJ; Kawabata, S; Rudin, CM; Wilson, W | 1 |
| Anand, S; Camargo, MF; Cascone, T; Cheresh, DA; Desgrosellier, JS; Diao, L; Elliott, KC; Franovic, A; Heymach, JV; Husain, H; Kato, S; Lesperance, J; Lippman, SM; Lowy, AM; Mielgo, A; Seguin, L; Wang, J; Weis, SM; Wistuba, II; Yebra, M | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Audigier Valette, C; Cadranel, J; Chabaud, S; Moro-Sibilot, D; Perol, D; Perol, M | 1 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Fan, L; Fang, X; Gao, Z; Gu, Y; Hu, L; Li, W; Shen, Y; Shu, Y; Sun, Y; Wu, X; Xu, Q; Yang, B | 1 |
| Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Hager, H; Khalil, A; Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Cho, KH; Choo, J; Ganbold, EO; Joo, SW; Kim, D; Kim, S; Lam, AT; Lee, SY; Singh, DK; Son, SJ; Yoon, J | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| Aimiuwu, J; Blachly, JS; Gao, Y; Hicks, WJ; Li, J; Otterson, GA; Papp, A; Phelps, MA; Poi, M; Schaaf, LJ; Socinski, MA; Starrett, SL; Stinchcombe, TE; Villalona-Calero, MA; Wang, D; Wei, L; Zhao, W | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Chun, KS; Hong, YS; Jang, WJ; Jeong, CH | 1 |
| Yano, S | 1 |
| Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Evangelista, M; Merchant, M; Peng, J; Peterson, D; Raha, D; Settleman, J; Wilson, C; Wilson, TR; Yue, P | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Aichler, M; Buck, A; Eickelberg, O; Fernandez, IE; Hauck, SM; Huber, K; Janssen, KP; Keller, U; Li, Z; Sun, N; Walch, A; Zitzelsberger, H | 1 |
| Deng, ZJ; Dreaden, EC; Hammond, PT; Lee, MJ; Morton, SW; Shah, NJ; Shopsowitz, KE; Siouve, E; Yaffe, MB | 1 |
| Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L | 1 |
| Bridgewater, J; Davidenko, I; Ducreux, M; Fittipaldo, A; Hillenbach, C; Klughammer, B; Kupcinskas, L; Propper, D | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Chang, JY; Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Berger, MF; Kris, MG; Krug, LM; Ladanyi, M; Pietanza, MC; Rekhtman, N; Riely, GJ; Varghese, AM; Wang, L; Won, HH; Yu, HA; Zakowski, MF | 1 |
| Asada, H; Imoto, K; Ommori, R; Park, K | 1 |
| Buclin, T; Decosterd, LA; Gairard-Dory, AC; Gourieux, B; Guidi, M; Petit-Jean, E; Quoix, E; Ubeaud-Séquier, G; Widmer, N | 1 |
| Butts, CA | 1 |
| Aieta, M; Bachi, A; Barni, S; Bearz, A; Bulotta, A; Cattaneo, A; de Marinis, F; De Pas, T; Doglioni, C; Floriani, I; Foti, S; Gregorc, V; Grigorieva, J; Grossi, F; Lazzari, C; Levra, MG; Mencoboni, M; Novello, S; Petrelli, F; Roder, H; Roder, J; Torri, V; Tsypin, M; Viganò, M | 1 |
| Addeo, R; Caraglia, M; Parlato, C; Zappavigna, S | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
| Ando, M; Asami, K; Endo, T; Fukuda, M; Ibata, H; Isa, S; Kamimura, M; Kawaguchi, T; Kozuki, T; Kubo, A; Nakagawa, H; Okano, Y; Saka, H; Sakamoto, K; Soejima, Y; Takada, M; Tamura, A; Tomizawa, Y; Yoshimi, M | 1 |
| Leighl, NB; Zer, A | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Wakelee, HA | 1 |
| Nakanishi, Y | 1 |
| He, C; Hong, W; Lou, G; Shao, L; Song, Z; Xie, F; Zhang, B; Zhang, Y; Zheng, L | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Blumenthal, GM; Boyd, K; He, K; Jiang, X; Justice, R; Keegan, P; Khozin, S; Murgo, A; Pazdur, R | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Aisner, DL; Berge, EM; Damek, D; Doebele, RC; Poonia, S | 1 |
| Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A | 1 |
| Cotreau, MM; Han, M; Hofmeister, CC; Isaacs, R; Jac, J; Papadopoulos, KP; Patnaik, A; Payumo, FC; Ramanathan, RK; Tibes, R; Tolcher, A; Weiss, GJ | 1 |
| Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X | 1 |
| Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J | 1 |
| Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Koh, Y; Kusuhara, M; Serizawa, M; Takahashi, T; Urakami, K; Watanabe, M; Yamaguchi, K; Yamamoto, N; Zangiacomi, V | 1 |
| Gillissen, A; Nieber, K; Oelkrug, C; Schubert, A; Simasi, J | 2 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 2 |
| Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Ma, D; Mathur, G | 1 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Allen, EJ; Garbett, SP; Leander, R; Quaranta, V; Tyson, DR | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Chang, FY; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Bolton, LM; Cree, IA; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Beißbarth, T; Bender, C; Henjes, F; Korf, U; Sonntag, J; von der Heyde, S | 1 |
| Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Fekrat, S; Proia, AD; Rao, V; Schneider, E | 1 |
| Ayoubi, JM; Broutin, S; Couderc, LJ; Friard, S; Gil, S; Goetgheluck, J; Paci, A; Picone, O; Tcherakian, C | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X | 1 |
| Carroll, WR; Chung, TK; Clemons, L; Desmond, R; Nabell, L; Rosenthal, EL | 1 |
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A | 1 |
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Krainhöfer, J; Reissig, A; Steinert, M; Walther, M | 1 |
| Akay, A; Dragomir, A; Erlandsson, BE | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Iwata, T; Kim, YH; Mishima, M; Nagai, H; Nishimura, T; Ozasa, H; Sakamori, Y; Sunadome, H | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M | 1 |
| Calcasola, M; Cane, P; Izatt, L; Michalarea, V; Spicer, J; Tobal, K | 1 |
| Brunetti, A; De Rosa, V; Del Vecchio, S; Fonti, R; Gargiulo, S; Gramanzini, M; Greco, A; Iommelli, F; Monti, M; Ortosecco, G; Panico, M | 1 |
| McCulloch, T; Røe, OD; Szejniuk, WM | 1 |
| Blanchet, B; Cessot, A; Goldwasser, F | 1 |
| Bunn, PA; Herbst, RS; Hirsch, FR | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| De, S; Dermawan, JK; Stark, GR | 1 |
| Koskinen, PK; Palin, N; Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chao, TT; Chen, KF; Chen, YL; Chu, PY; Hung, MH; Liu, CY; Shiau, CW; Wang, CY; Yu, HC | 1 |
| Ma, PC; Medina Mendez, CA; Singh, AD | 1 |
| Auliac, JB; Berard, H; Bizieux, A; Bota, S; Chouaid, C; Corre, R; Descourt, R; Falchero, L; Fournel, P; Greiller, L; Greillier, L; Labrunie, A; Le Caer, H; Marin, B; Monnet, I; Schott, R; Vergnenegre, A | 1 |
| Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM | 1 |
| Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Jänne, PA; Paweletz, CP | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Cheung, TT; Chiu, JW; Fan, ST; Leung, R; Pang, R; Poon, R; Wong, H; Yau, T | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Aldape, K; Berens, ME; Carrera-Silva, EA; Dietrich, JD; Errasti, AE; Ghosh, S; Gibbs, D; Hulme, C; Kusne, Y; Loftus, JC; Lu, Z; Mandell, EK; Perry, AS; Rothlin, CV; Rushing, EJ; Sanai, N; Yang, W | 1 |
| Colburn, D; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Klughammer, B; Kressel, B; Marsland, T; Miller, V; Patel, T; Rubin, M; White, L; Yang, JC | 1 |
| Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T | 1 |
| Amann, JM; Arasada, RR; Carbone, DP; Huppert, SS; Rahman, MA | 1 |
| Ashkenazi, A; Belmont, L; Chan, S; Koeppen, H; Lin, E; McNamara, E; Neve, RM; Pham, T; Settleman, J; Wilson, C; Yauch, RL; Ye, X | 1 |
| Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Fadlalla, K; Gales, DN; Manne, U; Putcha, BD; Samuel, T | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Fuereder, T; Hoeflmayer, D; Kornek, G; Kuehrer, I; Scheithauer, W; Stift, J; Stranzl, N | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Boeck, S; Clemens, MR; Esposito, I; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Laubender, RP; Märten, A; Ormanns, S; Schlitter, AM; Sipos, B; Siveke, JT; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Rosell, R | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Geng, Z; Han, X; Hu, L; Li, Z; Qin, X; Wang, Z; Xiao, X; Zeng, C | 1 |
| Chao, TT; Chen, KF; Chen, PT; Chen, YL; Huang, YC; Lai, CC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI | 1 |
| Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Chen, Z; Chen, ZG; Hu, Z; Jiang, N; Kim, S; Müller, S; Qian, G; Saba, NF; Shin, DM; Wang, D; Xu, J; Zhang, H | 1 |
| Cecconi, M; Lane, K; Thomas, C | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL | 1 |
| Chai, S; Ke, CQ; Lin, G; Tang, C; To, KK; Wang, YZ; Yao, S; Ye, Y; Yin, C | 1 |
| Cai, W; Cheng, K; Li, T; Shao, T; Zhao, B; Zheng, Y | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Clause, AL; Pieters, T; Vanderheyde, K | 1 |
| Bender, C; Fichtner, I; Fröhlich, H; Herwig, R; Hülsmann, HJ; Jarahian, M; Korf, U; Kuner, R; Merk, J; Rolff, J; Sültmann, H; Thomas, M | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
| Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A | 1 |
| Celik, T; Kosker, M | 1 |
| Demura, Y; Fujita, Y; Gemma, A; Harada, M; Ishii, Y; Ishimoto, O; Kobayashi, K; Maemondo, M; Matsumoto, Y; Miura, S; Morikawa, N; Okudera, K; Saijo, Y; Sato, I; Takamura, K; Usui, K | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H | 1 |
| Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L | 1 |
| Bhagathavula, N; Dame, MK; Dawes, SM; Elder, JT; Fu, W; Gudjonsson, JE; Johnston, A; Lambert, S; Varani, J; Ward, NL; Warner, RL | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Adler, KB; Arif, M; Chen, CH; Chiu, CL; Statt, S; Thai, P; Wu, R | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Huang, MD; Huang, Q; Liu, JY; Xue, JP; Zhang, FL | 1 |
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB | 1 |
| Furuyama, K; Gotanda, K; Harada, T; Ieiri, I; Iwama, E; Li, H; Nakanishi, Y; Okamoto, I; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK | 1 |
| Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z | 1 |
| Jabbour, SK | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Alexander, PB; Chen, J; Chen, R; Radiloff, DR; Sun, T; Wang, XF; Wu, H; Xiang, H; Yang, P; Yuan, L | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ | 1 |
| Adema, AD; Avan, A; Hoebe, EK; Huijts, CM; Peters, GJ; Ruijtenbeek, R; Veal, GJ; Wosikowski, K | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Iseri, K; Iyoda, M; Kuno, Y; Matsumoto, K; Saito, T; Shibata, T; Shindo-Hirai, Y; Suzuki, T; Wada, Y; Yamamoto, Y | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Jang, C; Li, J; Wang, J; Wu, F; Xiong, J | 1 |
| Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X | 1 |
| Cho, SJ; Choi, HG; Im, YJ; Jeon, JY; Kim, MG; Kim, Y; Seo, YH; Song, EK | 1 |
| Liu, Z; Mao, JH; Wang, Q; Wang, Y; Wei, G; Wen, M; Yuan, H; Zhang, P | 1 |
| Jenks, S | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Peters, S; Smit, E | 1 |
| Bennouna, J; Boyer, MJ; Docampo, LI; Doherty, JP; Goldberg, Z; Jänne, PA; Liang, JQ; Mather, CB; Mok, T; O'Byrne, K; O'Connell, J; Paz-Ares, L; Pluzanski, A; Ramalingam, SS; Shtivelband, M; Taylor, I; Von Pawel, J; Zhang, H | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Takeuchi, S; Yano, S | 1 |
| Agarwal, VR; Ahmed, T; Bhatia, D; Bose, J; Choudhari, S; Damre, A; Deore, V; Joshi, A; Kumar, S; Lad, VJ; Pandey, PK; Sahu, B; Sangana, R; Sharma, S; Sonawane, V; Srivastava, A; Tannu, P; Venkataraman, M; Venkatesha, VA | 1 |
| Cheng, W; Hu, Y; Peng, P; Qiu, N; Sheng, R; Yuan, Y | 1 |
| Boros, S; Breza, N; Dancsó, A; Greff, Z; Hegymegi-Barakonyi, B; Illyés, E; Kékesi, L; Kéri, G; Nemes, Z; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Assaraf, YG; Azzariti, A; Giovannetti, E; Jansen, G; Kathman, I; Paradiso, A; Peters, GJ; Porcelli, L; Scheffer, GL | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Byers, L; Coombes, KR; Date, H; Diao, L; Girard, L; Giri, U; Heymach, JV; Komaki, R; Lin, SH; Menju, T; Minna, JD; Saintigny, P; Wang, J; Weinstein, JN; Wistuba, II; Wu, CC; Zhang, J | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Haskins, JW; Nguyen, DX; Stern, DF | 1 |
| Amin, C; Cangany, M; Cripe, LD; Czader, M; Konig, H; Sayar, H | 1 |
| Graziani, C; Hegde, S; Saif, MW | 1 |
| Bortlicek, Z; Bruha, F; Fiala, O; Minarik, M; Mukensnabl, P; Pesek, M; Racek, J; Svaton, M | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H | 1 |
| Abe, M; Aoki, M; Fujii, T; Fujimoto-Ouchi, K; Hashimoto, E; Motegi, H; Nagahashi, S; Nakatani, N; Sakata, K; Sano, Y; Sasaki, E; Satoh, Y; Sugimoto, M; Yatabe, Y | 1 |
| Choi, E; Daugherty, A; Eguchi, S; Elliott, KJ; Forrester, SJ; Fukuda, Y; Kawai, T; Kobayashi, T; Obama, T; Rizzo, V; Takayanagi, T; Taro, Y; Tsuji, T | 1 |
| Nakamoto, Y; Nakatsura, T; Ofuji, K; Saito, K; Shimomura, M; Tada, Y; Yoshikawa, T; Yoshimura, M | 1 |
| Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX | 1 |
| Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD | 1 |
| Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R | 1 |
| Asgari, D; Barar, J; Barghi, L; Nakhlband, A; Valizadeh, H | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
| Amadori, D; Burgio, MA; Calistri, D; Capelli, L; Casanova, C; Chiadini, E; Crinò, L; Dazzi, C; Delmonte, A; Dubini, A; Gamboni, A; Mariotti, M; Papi, M; Puccetti, M; Ragazzini, A; Ulivi, P; Verlicchi, A | 1 |
| Pirker, R | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE | 1 |
| Ma, H; Tian, JH; Tian, X; Wang, F; Wang, X; Wang, Y; Zhang, Y; Zhou, JG | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Liu, WL; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V | 1 |
| Anderson, RA; Sun, Y; Tan, X; Thapa, N | 1 |
| Gréen, H; Lundeberg, J; Svedberg, A; Vikingsson, S; Vikström, A | 1 |
| Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H | 1 |
| Cohen, DE; Colozza, S; Okereke, UR | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Barberis, M; Catania, C; Conforti, F; de Marinis, F; De Pas, T; Lazzari, C; Noberasco, C; Spitaleri, G; Stufano, V; Toffalorio, F; Vecchio, F | 1 |
| Balanis, NG; Carlin, CR; Pascuzzi, PE; Schiemann, BJ; Schiemann, WP; Wendt, MK; Williams, WK | 1 |
| Reguart, N; Remon, J | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL | 1 |
| Barouch-Bentov, R; Berkerman, E; Einav, S; Mulholland, J; Neveu, G; Ziv-Av, A | 1 |
| Geng, L; Liu, Y; Wang, G; Wei, F; Zhang, P; Zhang, Y | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Abraham, RR; Girotra, M; Jones, J; Klair, JS | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC | 1 |
| Carcereny, E; de Marinis, F; Drozdowskyj, A; Dubos-Arvis, C; Passaro, A; Perez-Moreno, P; Rosell, R; Vergnenegre, A; Zeaiter, A | 1 |
| Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q | 1 |
| Buyse, M; Ding, K; Parulekar, WR; Péron, J; Roche, L; Roy, P | 1 |
| Bhattacharya, R; Bovonratwet, P; Liu, L; Mathew, MP; Saeui, CT; Tan, E; Yarema, KJ | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
| Espinosa-Cotton, M; Koch, AT; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Abera, MB; Kazanietz, MG | 1 |
| Aerts, JG; Boons, CC; Boven, E; Hugtenburg, JG; Moes-Ten Hove, J; Smit, EF; Swart, EL; Timmers, L; van de Ven, PM | 1 |
| Alves, F; Bellizzi, A; Bruns, P; Cardone, RA; Casavola, V; Greco, MR; Kalthoff, H; Menga, M; Pilarsky, C; Reshkin, SJ; Saccomano, M; Schwab, A; Zaccagnino, A; Zeeberg, K | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Liu, N; Wang, L; Wang, P; Xu, X; Zhao, L | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Baumann, M; Brammer, I; Can, Y; Dikomey, E; Dorniok, F; Gal, A; Grob, TJ; Gurtner, K; Kasten-Pisula, U; Krause, M; Kriegs, M; Laban, S; Oertel, R; Petersen, C; Rieckmann, T; Wysocki, M | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Takahashi, M | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Bekerman, E; Einav, S | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Davisson, RL; Eguchi, S; Elliott, KJ; Forrester, SJ; Fukuda, Y; Kawai, T; Obama, T; Park, JY; Takayanagi, T; Tilley, DG; Tsuji, T | 1 |
| Fujita, S; Hata, A; Hayashi, M; Katakami, N; Kawamura, T; Takeshita, J; Tomii, K | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Aprile, G; Cardellino, GG; Foltran, L; Macerelli, M; Mazzer, M | 1 |
| Del Giudice, P; Delord, JP; Hubiche, T; Roché, H; Sibaud, V; Tournier, E | 1 |
| Delaney, C; Frank, S; Huang, RS | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Chariot, A; Shostak, K | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Fujiwara, Y; Goto, Y; Hamada, A; Horinouchi, H; Kanda, S; Katsuya, Y; Nokihara, H; Ohe, Y; Osawa, S; Sunami, K; Takashima, Y; Tamura, T; Utsumi, H; Yamamoto, N | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Asada, K; Imokawa, S; Inoue, Y; Inui, N; Karayama, M; Kasamatsu, N; Koshimizu, N; Matsuda, H; Shirai, T; Suda, T; Yamada, T; Yokomura, K | 1 |
| Doyle, KP; Flores, EJ; Kamdar, MM; Maytal, G; Mino-Kenudson, M; Rinehart, TJ; Sequist, LV | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Chen, WD; Deng, R; Feng, GK; Ji, J; Jiao, L; Kong, PF; Li, X; Li, YT; Li, ZH; Qian, XJ; Wu, RY; Yu, Y; Zhu, XF | 1 |
| Gao, BL; Hang, JB; Hu, JA; Shun, WW; Xu, ZH | 1 |
| Aydiner, A; Ciftci, R; Sen, F | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Busch, TM; Cengel, KA; Gallagher-Colombo, SM; Miller, J; Putt, ME; Vinogradov, SA | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Guckenberger, M | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Fuchs, BC; Gilpin, SE; Lanuti, M; Ott, HC; Ren, X; Tanabe, KK; Tapias, LF; Wei, L | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Akerley, W; Barlesi, F; Favaretto, A; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Ross, JS; Sandler, A; Santoro, A; Scagliotti, G; Schwartz, B; Sequist, LV; Shepherd, FA; Shuster, D; Spigel, D; von Pawel, J; von Roemeling, R; Wang, Q | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K | 1 |
| Sala González, MÁ | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Croniger, CM; De, S; DeSantis, D; Li, X; Stark, GR; Zhou, H | 1 |
| Asakuma, M; Fukui, T; Hamada, A; Hayashi, N; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katagiri, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Saito, H; Sasaki, J; Takakura, A; Toyooka, I; Wada, M; Yamamoto, M; Yokoba, M | 1 |
| Azzoli, CG | 1 |
| Cai, L; Hu, J; Liu, C; Liu, W; Meng, QW; Ning, JF; Zhao, YB | 1 |
| Cascone, T; Heymach, JV | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Li, E; Li, J; Qiao, H; Ren, K; Shi, H; Zhao, D | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Gu, M; Hong, X; Liang, J; Lu, C; Sun, X; Tang, J; Wang, X; Xu, W; Yao, X; Zhong, T | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Ashida, A; Koizumi, T; Ogawa, E; Okuyama, R; Uhara, H | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Dong, JY; Li, YL; Lin, NM; Mao, SY; Pan, JP; Pan, YN; Sun, J; Wu, WJ; Zhang, C; Zhang, DY; Zhao, YM | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Hagen, T; Hong, SY; Luo, Y; Yu, FX | 1 |
| Ni, J; Zhang, L | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Mehra, R; Zibelman, M | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Planchard, D | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Becker, C; Keul, M; Nguyen, HD; Öcal, S; Phan, T; Rauh, D; Simard, JR | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Abreu, S; Bernardes, N; Carvalho, FA; Fernandes, F; Fialho, AM; Santos, NC | 1 |
| Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ | 1 |
| Ang, MK; Chowbay, B; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Toh, CK; Zhang, Z | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL | 1 |
| Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Manole, S; Meyer, AS; Richards, EJ | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Griffith, N; Kolli, S; Li, Q; Liu, Z; Poi, MJ; Wetz, K | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL | 1 |
| Baty, F; Brutsche, M; Cerny, T; Dutly, A; Ess, S; Früh, M; Hitz, F; Joerger, M; Joos, L; Krähenbühl, S; Neumair, P; Warschkow, R | 1 |
| Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Eigenmann, MJ; Frances, N; Hoffmann, G; Lavé, T; Walz, AC | 1 |
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Kawahara, K; Maeda, T; Watanabe, S; Yamada, D | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 2 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Fujimoto, J; Goshima, N; Higa, A; Hiyama, G; Hoshi, H; Inageda, K; Ishikawa, K; Kawamura, Y; Semba, K; Takagi, M; Takahashi, N; Togashi, T; Wakamatsu, A; Watanabe, S | 1 |
| Bando, H; Fujisawa, F; Hara, H; Homma, M; Kaburagi, T; Kojima, H; Mitsuhashi, S; Naito, K; Ohgami, M; Suzuki, Y; Takei, K; Uchiumi, K; Yamada, M; Yamada, Y | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Chen, L; Gonzalez, FJ; Gu, J; Hu, CL; Hu, L; Li, L; Li, S; Lin, XM; Liu, JF; Tang, J; Wang, HY; Wang, RY; Wu, MC; Yan, XZ; Zhang, BH; Zhou, WP; Zhu, YJ | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Chen, ZY; Dong, ZY; Hou, QY; Li, YS; Liu, SY; Su, J; Wu, YL; Yan, HH; Zhai, HR; Zhong, WZ | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Jiang, T; Qiao, M; Ren, S; Su, C; Zhou, C; Zhou, F | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Fraser, A | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Abahussain, AO; Alzoman, NZ; Maher, HM; Shehata, SM | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Biswas, L; Keechilat, P; Melge, AR; Mohan, CG; Panicker, PS | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Cho, YJ; Chung, JH; Eo, EY; Jung, MH; Kim, CH; Kim, S; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Park, JS; Park, MY; Yoon, HI | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cui, S; Jiang, L | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Dupuis, N; Ehrnrooth, E; Felip, E; Gadgeel, S; Georgoulias, V; Göker, E; Goss, G; Guclu, SZ; Isla, D; Krämer, N; Lee, KH; Lu, S; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Bulitta, JB; Jeong, SW; Joo, SH; Kim, S; Kim, TH; Kwon, DR; Lee, DY; Ma, E; Park, GY; Shin, BS; Shin, S; Weon, KY; Yoo, SD | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Chen, Z; Feng, X; Gao, Y; He, J; Li, X; Liu, T; Lv, Z; Pan, H; Wang, Y; Xie, S; Yang, W; Yang, X; Zhang, J | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Hayashi, T; Kohsaka, S; Mano, H; Nagano, M; Shimada, N; Suehara, Y; Suzuki, K; Takahashi, F; Takahashi, K; Takamochi, K; Ueno, T | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Wu, X | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Girard, N | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Amador, M; Andrade Santiago, JM; Aparisi, F; Arriola, E; Artal, A; Barneto, I; Diz, P; García Gómez, R; Gutierrez, V; Isla, D; Majem, M; Martínez Aguillo, M; Paredes, A; Peralta Muñoz, S; Ponce, S; Provencio, M; Sánchez-Torres, JM; Valdivia, J; Vicente Baz, D | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Hutton, D; Li, Q; Wen, F; Zhang, P; Zheng, H | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Li, L; Liu, W; Meng, L; Wang, Y; Wang, Z; Yan, H; Zhang, H | 1 |
| Gao, MY; Lin, C; Qin, Y; Wang, YF; Zhang, H | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Moriguchi, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H | 1 |
| Jassem, J | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Golabiewska, E; Holownia, A; Niechoda, A; Rybak, A; Zarzecki, M | 1 |
| Cheong, SC; Fadlullah, MZH; Gan, CP; Kelly, GM; Lee, BKB; Lee, HM; Patel, V; Yee, PS; Zainal, NS | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Guo, C; Li, R; Wu, K | 1 |
| Abdel-Aziz, HA; Abdelsalam, EA; Abou Taleb, NA; Amin, KM; Eldehna, WM; Hammad, SF; Mekawey, AAI; Zaghary, WA | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Esmaeili, S; Fassihi, A; Fayyazi, N; Ghasemi, JB; Saghaie, L; Taheri, S | 1 |
| Agnihotri, VK; Ansari, AJ; Joshi, G; Kalra, S; Kumar, R; Maurya, AK; Sawant, DM; Singh, S; Yadav, UP | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Bach, DH; Hu, R; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Li, M; Xiang, J; Zhang, C | 1 |
| Bedir, S; Celik, E; Cikman, DI; Degerli, E; Demirci, NS; Demirelli, FH; Derin, S; Karadag, M; Oruc, K; Oztas, NS; Samanci, NS | 1 |
| Kaul, SC; Kumar, V; Malik, V; Sundar, D; Wadhwa, R | 1 |
| Beijnen, JH; Rood, JJM; Somovilla, VJ; Sparidans, RW; Toraño, JS | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Cui, H; Dong, H; Hu, Z; Jiang, X; Li, J; Tan, K; Xue, C; Yu, Y; Zhang, J; Zhang, X; Zheng, H | 1 |
| Dahal, A; El-Sadek, M; Emam, AM; Enriz, RD; Ibrahim, SM; Jois, SD; Kothayer, H; Singh, SS; Tosso, RD | 1 |
| Akiyama, M; Chiba, S; Hirano, K; Maemondo, M; Nagashima, H; Sato, H; Sugai, T; Utsumi, Y; Yakuwa, K | 1 |
| Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Dezfouli, AA; Dezfuli, MM; Heshmatnia, J; Lotfabadi, AS; Mirtavoos-Mahyari, H; Rismani, E; Sheikhy, K | 1 |
| Imoto, S; Miyano, S; Park, H; Yamaguchi, R | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Asquith, CRM; Bieberich, AA; Crona, DJ; Fatig, RO; Laitinen, T; Maffuid, K; Morris, DC; Torrice, CD | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Amelia, T; Kartasasmita, RE; Ohwada, T; Setiawan, AN; Tjahjono, DH | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Ko, AH | 1 |
509 review(s) available for erlotinib hydrochloride and quinazolines
| Article | Year |
|---|---|
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2001 |
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2001 |
OSI-774 OSI Pharmaceuticals.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Oncogenes; Quinazolines; Structure-Activity Relationship | 2001 |
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Erlotinib OSI/Roche/Genentech.
Topics: Animals; Clinical Trials as Topic; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; Cetuximab; Clinical Trials as Topic; Depression, Chemical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines | 2003 |
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
Development of the epidermal growth factor receptor inhibitor OSI-774.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2003 |
Preclinical studies with Erlotinib (Tarceva).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines | 2003 |
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).
Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines | 2003 |
Erlotinib (Tarceva): an update on the clinical trial program.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2003 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Tumor Cells, Cultured | 2003 |
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines; Signal Transduction | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
New targeted therapies in gastrointestinal cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Panitumumab; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: preclinical investigations.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous | 2003 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Patient Selection; Predictive Value of Tests; Quinazolines | 2003 |
HER1/EGFR targeting: refining the strategy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2004 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Therapeutic implications of epidermal growth factor receptor in lung cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
The HER receptor family: a rich target for therapeutic development.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Neoplasm Proteins; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2004 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines | 2004 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
Review of epidermal growth factor receptor biology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Morpholines; Neoplasm Proteins; Panitumumab; Quinazolines; Radiation Tolerance; Receptor, ErbB-2 | 2004 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Targeting the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Resistance to target-based therapy and its circumvention].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Rituximab; Trastuzumab | 2004 |
Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lung Neoplasms; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4; Trastuzumab | 2003 |
Targeted therapies for cancer 2004.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab | 2004 |
Epidermal growth factor receptor inhibition strategies in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Small molecules with EGFR-TK inhibitor activity.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab | 2004 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in non-small cell lung cancer: a review.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2005 |
Perspectives on novel therapies for bronchial carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib hydrochloride.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2005 |
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Overview of tyrosine kinase inhibitors in clinical breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Recent updates on the role of chemotherapy in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2005 |
Erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Mutation; Quinazolines; Survival Rate | 2005 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Topics: Administration, Topical; Antibodies, Monoclonal; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Steroids | 2005 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
A review of erlotinib and its clinical use.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
[Erlotinib. A new option for non-small cell lung cancer].
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Targeting HER1/EGFR in cancer therapy: experience with erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
Clinical experience with erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neovascularization, Pathologic; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Vascular Endothelial Growth Factor A | 2006 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
Epidermal growth factor receptor targeting in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR-targeted therapy and related skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Models, Biological; Neoplasms; Quinazolines; Signal Transduction | 2006 |
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
The role of the epidermal growth factor receptor in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2 | 2006 |
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Topics: Antineoplastic Agents; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Second-line therapeutic options in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha | 2006 |
Defining clinically relevant molecular subsets of lung cancer.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Erlotinib in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Duplication; Genes, ras; Humans; Models, Biological; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction | 2006 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
Diagnosis and therapy of oral squamous cell carcinoma.
Topics: Age Factors; Alcohol Drinking; Antineoplastic Agents; Aporphines; Azo Compounds; Berberine; Carcinoma, Squamous Cell; Chromosome Aberrations; Crystallography, X-Ray; Databases, Factual; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Mouth Neoplasms; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Stilbenes; Structure-Activity Relationship | 2007 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
[Molecular-based treatment concepts in advanced pancreatic cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Metalloproteases; Molecular Biology; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
[New biological treatments for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biopsy; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Mutation; Patient Selection; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.
Topics: Bronchoscopy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Ultrasonography | 2007 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Erlotinib in cancer treatment.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines | 2007 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Bevacizumab in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Erlotinib in non-small cell lung cancer treatment: current status and future development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines; Treatment Outcome | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2007 |
Targeted therapy in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Erlotinib in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
[Targeting ErbB receptors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
Topics: Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2007 |
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis | 2007 |
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2007 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Considerations for second-line therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
[Pancreatic cancer: ten years of systemic therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2008 |
An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benchmarking; Cetuximab; Decision Trees; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Incidence; Panitumumab; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Review: hepatotoxicity and EGFR inhibition.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.
Topics: Algorithms; Antineoplastic Agents; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Genes, erbB-1; Humans; Incidence; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
Topics: Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2008 |
Novel advances in pancreatic cancer treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Delivery Systems; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Management of targeted molecular therapies toxicities in thoracic cancerology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Delivery Systems; Erlotinib Hydrochloride; France; Humans; Lung Neoplasms; Palliative Care; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2008 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Counseling; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Panitumumab; Quinazolines | 2008 |
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2008 |
[Treatment of advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Platinum; Quinazolines; Terminal Care | 2008 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Predictive biomarkers for EGFR therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Economics of treatments for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bias; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids; Young Adult | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3 | 2009 |
Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Investigational agents in the management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking; Smoking Cessation | 2010 |
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2010 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2010 |
[KRAS status versus EGFR status in lung cancer therapy].
Topics: DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2009 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
[New data on pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Histone Chaperones; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Nuclear Proteins; Quinazolines; RNA, Messenger | 2010 |
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Time Factors | 2010 |
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance chemotherapy in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2010 |
Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.
Topics: Animals; Antacids; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Quinazolines | 2011 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasm Proteins; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2010 |
Triple negative breast cancer: unmet medical needs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, BRCA2; Humans; Phenotype; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2011 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Advances in EGFR-directed therapy in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2011 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2011 |
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2011 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Combinations; Drug Synergism; Erlotinib Hydrochloride; Glioma; Humans; Models, Biological; Neoplasm Grading; Quinazolines | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
Tissue sampling in lung cancer: a review in light of the MERIT experience.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Practice Guidelines as Topic; Precision Medicine; Quinazolines; Tissue and Organ Harvesting; Tissue Array Analysis | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Erlotinib in glioblastoma: lost in translation?
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2011 |
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Quinazolines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2012 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Treatment Outcome | 2011 |
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
[A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature].
Topics: Aged; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vascular; Vasculitis | 2011 |
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors | 2012 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2012 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2012 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Novel agents in early phase clinical studies on refractory pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Ipilimumab; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2012 |
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Targeting EGFR in pancreatic cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Chemotherapy: present and future.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Follow-Up Studies; Forecasting; Humans; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Radiosurgery; Risk Assessment; Treatment Outcome | 2012 |
Recent advances in non-small cell lung cancer biology and clinical management.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2012 |
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeted therapy for lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2012 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Clinical and economic review of erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Treatment Outcome | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Taxoids | 2013 |
Personalized medicine for glioblastoma: current challenges and future opportunities.
Topics: Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Genetic Variation; Glioblastoma; Humans; Isocitrate Dehydrogenase; MicroRNAs; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment | 2013 |
Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.
Topics: Administration, Oral; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; White People | 2013 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2014 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Erlotinib in the first-line treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Targeted therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pyrazoles; Pyridines; Quinazolines | 2013 |
Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Second-Line Therapy for Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Target therapies in pancreatic carcinoma.
Topics: Albumins; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Matrix Metalloproteinases; Molecular Targeted Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2014 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
[Hemolytic anemia under erlotinib treatment].
Topics: Aged, 80 and over; Anemia, Hemolytic; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
[New developments in treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Imaging; Quinazolines | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Infant; Male; Middle Aged; Neoplasms; Quinazolines; Young Adult | 2015 |
Erlotinib: early clinical development in brain cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography Scanners, X-Ray Computed | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Eyelid Diseases; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?
Topics: Antibodies, Anti-Idiotypic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Platinum Compounds; Quinazolines | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autopsy; Critical Care; Diagnosis, Differential; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2015 |
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines | 2015 |
EGFR and NF-κB: partners in cancer.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction | 2015 |
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
544 trial(s) available for erlotinib hydrochloride and quinazolines
| Article | Year |
|---|---|
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2001 |
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines | 2004 |
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib (Tarceva) for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Exanthema; Humans; Quinazolines | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis | 2005 |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Brief communication: a new combination in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Survival Rate | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cross-Over Studies; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Therapeutic Equivalency | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome | 2006 |
Effects of smoking on the pharmacokinetics of erlotinib.
Topics: Adult; Area Under Curve; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Molecular Structure; Quinazolines; Reference Values; Safety; Smoking; Time Factors | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Aged; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis | 2006 |
Phase II study of erlotinib in patients with advanced biliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2006 |
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Topics: Biomarkers, Tumor; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Tablets | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2007 |
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines | 2007 |
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Quinazolines; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines | 2007 |
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Topics: Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Skin | 2007 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diarrhea; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Taxoids | 2007 |
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Quinazolines; Treatment Outcome | 2007 |
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin | 2008 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Topics: Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Erlotinib Hydrochloride; Forecasting; Humans; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Hybridization; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2007 |
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Topics: Administration, Oral; Adult; Aged; Algorithms; Area Under Curve; Creatine Kinase; Cross-Over Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fasting; Food-Drug Interactions; gamma-Glutamyltransferase; Glossitis; Hematuria; Humans; Liver; Male; Middle Aged; Molecular Structure; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
Improving treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Tandem Mass Spectrometry; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Carcinoma, Renal Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2007 |
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemokines, CC; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Matrix Metalloproteinase 9; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1 | 2008 |
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
[Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Selection; Peritoneal Neoplasms; Quinazolines; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan | 2008 |
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis | 2008 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2009 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Ontario; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors | 2008 |
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quinazolines; Survival Rate | 2008 |
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome | 2008 |
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Environmental Exposure; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Particulate Matter; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasms; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Quinazolines; Radiation Oncology; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome | 2008 |
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Middle Aged; Quinazolines; Treatment Outcome | 2008 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.
Topics: Aged; Bosnia and Herzegovina; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy | 2008 |
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Topics: Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2009 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2009 |
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Tissue Distribution; Trastuzumab; Treatment Outcome | 2009 |
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2009 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2009 |
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2010 |
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Tomography, X-Ray Computed | 2010 |
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Prostatic Neoplasms; Quinazolines | 2009 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Proportional Hazards Models; Prospective Studies; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome; Wound Healing | 2009 |
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis | 2010 |
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines | 2010 |
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Topics: Aged; Antineoplastic Agents; Cystectomy; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Isoflavones; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Quinazolines | 2010 |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome | 2011 |
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2010 |
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retreatment; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2010 |
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Phenotype; Quinazolines; Treatment Outcome; Vinblastine | 2011 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients].
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2010 |
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2010 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
[Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2010 |
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Taxoids | 2011 |
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2010 |
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2010 |
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2010 |
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2010 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Medication Adherence; Middle Aged; Neoplasms; Quality of Life; Quinazolines; Sunscreening Agents | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Canada; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sex Characteristics; Survival Rate; Treatment Outcome | 2011 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Topics: Adolescent; Adult; Brain Stem Neoplasms; Child; Child, Preschool; Erlotinib Hydrochloride; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Therapies, Investigational; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A | 2010 |
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2011 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Quinazolines | 2010 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazoles; Quinazolines; Radiation-Sensitizing Agents; Retreatment; Sulfonamides | 2011 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Retreatment | 2011 |
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines | 2011 |
Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Mucin 5AC; Pancreatic Neoplasms; Quinazolines | 2011 |
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome | 2011 |
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting | 2012 |
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mu
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Genes, ras; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Survival Rate; Taxoids; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Research Design; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Platinum Compounds; Prospective Studies; Quinazolines | 2012 |
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2011 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis | 2011 |
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2011 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2011 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids | 2011 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Protein Binding; Quinazolines | 2012 |
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2012 |
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2011 |
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Guidelines as Topic; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; Platinum; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2011 |
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2011 |
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Area Under Curve; Bevacizumab; Chemoradiotherapy; Cisplatin; Contrast Media; Erlotinib Hydrochloride; Gadolinium DTPA; Head and Neck Neoplasms; Humans; Image Enhancement; Lymphatic Metastasis; Magnetic Resonance Imaging; Microcirculation; Molecular Targeted Therapy; North Carolina; Quinazolines | 2012 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Receptor, IGF Type 1 | 2011 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk | 2012 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinazolines | 2012 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cadherins; Carcinoma, Hepatocellular; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2012 |
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Retrospective Studies; Treatment Outcome | 2012 |
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome | 2012 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Docetaxel; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2012 |
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Treatment Outcome | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Research Design; Salvage Therapy; Survival Rate | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2012 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2013 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2013 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Interleukin-6; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sulindac; Transforming Growth Factor alpha | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2012 |
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate | 2013 |
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
[Phase II study of radiotherapy plus erlotinib for elder patients with esophageal carcinoma].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Neoplasm Staging; Quinazolines | 2012 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis | 2012 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thiophenes; Tissue Distribution | 2013 |
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Demography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Quinazolines; Sulfonamides; Treatment Outcome | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2013 |
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis | 2013 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2013 |
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Prognosis; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2013 |
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Nitrogen Mustard Compounds; Quinazolines; Severity of Illness Index | 2013 |
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2013 |
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Pain; Quinazolines; Remission Induction; Treatment Outcome | 2013 |
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Up-Regulation | 2013 |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9 | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Prospective Studies; Quinazolines; Thoracic Duct | 2013 |
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines | 2013 |
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Male; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2013 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pemetrexed; Quinazolines; Recurrence; Taxoids | 2013 |
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines; Retreatment; Risk Factors; Treatment Outcome | 2013 |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Topics: Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prospective Studies; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2013 |
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2013 |
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Vinblastine | 2014 |
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Preoperative Care; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms | 2014 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Treatment Outcome | 2014 |
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cyclic N-Oxides; Cyclin-Dependent Kinases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indolizines; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pyridinium Compounds; Quinazolines | 2014 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2014 |
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Genotype; Humans; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Topotecan | 2014 |
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Everolimus; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Time Factors; Treatment Outcome; Vomiting | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Topics: Adult; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Erlotinib Hydrochloride; Female; Healthy Volunteers; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rifampin; Young Adult | 2014 |
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Treatment Outcome | 2014 |
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases | 2014 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan | 2014 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Uterine Cervical Neoplasms | 2014 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2014 |
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger | 2014 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Treatment Outcome | 2014 |
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sulindac; Tissue Array Analysis | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome | 2014 |
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Biopsy; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2014 |
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2014 |
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Topics: Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Proportional Hazards Models; Quinazolines; Taxoids; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden | 2014 |
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden | 2014 |
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate | 2014 |
Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neutropenia; Pemetrexed; Quinazolines; Thrombocytopenia; Treatment Outcome | 2013 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United States; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
Topics: Adult; Biomarkers, Tumor; eIF-2 Kinase; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Tumor Suppressor Protein p53; Young Adult | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2014 |
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retreatment; Treatment Outcome | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome | 2014 |
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome | 2014 |
Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine | 2015 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.
Topics: Adult; Asian People; Chemistry, Pharmaceutical; Cross-Over Studies; Erlotinib Hydrochloride; Humans; Male; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Therapeutic Equivalency; Young Adult | 2015 |
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Quinazolines; Sorafenib | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Ranitidine; Young Adult | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome | 2015 |
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Treatment Outcome | 2015 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cross-Over Studies; Erlotinib Hydrochloride; Fasting; Female; Food-Drug Interactions; Humans; Lung Neoplasms; Male; Middle Aged; Postprandial Period; Protein Kinase Inhibitors; Quinazolines | 2015 |
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrrolidinones; Quinazolines; Quinolines; Young Adult | 2015 |
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2015 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2016 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Evaluation of the VeriStrat
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Hematologic Tests; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Treatment Outcome | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Massachusetts; Protein Kinase Inhibitors; Quinazolines | 2018 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
1796 other study(ies) available for erlotinib hydrochloride and quinazolines
| Article | Year |
|---|---|
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 1999 |
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.
Topics: Amino Acid Motifs; Animals; Catalytic Domain; Cell Line; Crystallography; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Models, Molecular; Molecular Structure; Quinazolines; Spodoptera | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Patient Selection; Quinazolines | 2003 |
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Topics: Administration, Oral; Antineoplastic Agents; Clinical Trials as Topic; Costs and Cost Analysis; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Neoplasms; Quinazolines; Signal Transduction; Skin; Tyrosine; Up-Regulation | 2003 |
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2003 |
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Topics: 3T3 Cells; Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Enzyme Activation; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Quinazolines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2003 |
Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro.
Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Immunohistochemistry; In Vitro Techniques; Pancreatic Neoplasms; Polymerase Chain Reaction; Quinazolines; Time Factors; Tumor Cells, Cultured | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
Topics: Actins; Apoptosis; Cell Division; Cell Line, Tumor; Cell Movement; DNA Primers; DNA, Complementary; ErbB Receptors; Erlotinib Hydrochloride; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Cell Division; Cell Line; Cluster Analysis; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Nucleic Acid Hybridization; Quinazolines; Sesquiterpenes; Tumor Cells, Cultured | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
EGFR inhibitors square off at ASCO.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Industry; Economic Competition; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Biomarkers; Breast Neoplasms; Endpoint Determination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mouth Mucosa; Neoplasm Metastasis; Phosphorylation; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin; Tomography, Emission-Computed | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Congresses as Topic; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Societies, Medical; United States | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Models, Molecular; Molecular Sequence Data; Oncogene Proteins v-erbB; Protein Conformation; Protein Structure, Secondary; Quinazolines; Substrate Specificity | 2004 |
[Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Topics: Biomarkers, Tumor; Bronchi; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclin D1; DNA; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Exons; G1 Phase; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Kinetics; Luciferases; Necrosis; Neoplasms; Quinazolines; Sequence Analysis, DNA; Time Factors; Transcriptional Activation | 2004 |
Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2004 |
Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Molecular Sequence Data; Predictive Value of Tests; Protein Kinase Inhibitors; Proteome; Quinazolines; Receptor, ErbB-2; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Trastuzumab | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
Topics: Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Humans; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2004 |
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Chromatography, Affinity; Chromatography, Liquid; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoblotting; Isotopes; Mass Spectrometry; Models, Biological; Peptide Mapping; Phosphorylation; Phosphotyrosine; Proteins; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; src-Family Kinases | 2005 |
Erlotinib hydrochloride.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Expert Testimony; Humans; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Treatment Outcome | 2005 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
FDA Oncology Committee debates Iressa's status following negative trial results.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Ligands; Models, Biological; Neoplasm Proteins; Neoplasms; Paracrine Communication; Quinazolines; Skin; Transforming Growth Factor alpha; Treatment Outcome | 2005 |
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Cetuximab; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection | 2005 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
Will lung cancer targeting hit its mark?
Topics: Antineoplastic Agents; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Interferon-alpha; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Up-Regulation | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Targeting EGFR in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Doxorubicin; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Quinazolines | 2005 |
New studies look beyond EGFR mutations for clues to sensitivity to erlotinib.
Topics: Animals; Canada; Cell Cycle Proteins; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Multicenter Studies as Topic; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2005 |
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Approval; Drug Combinations; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide; Middle Aged; Mutation; National Institutes of Health (U.S.); Polymorphism, Genetic; Quinazolines; Risk Factors; Socioeconomic Factors; Treatment Outcome; United States; Uracil; White People | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Neuroscience. Cancer drugs may help injured nerve cells regrow their axons.
Topics: Animals; Antineoplastic Agents; Axons; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Mice; Nerve Crush; Nerve Regeneration; Neurons; Optic Nerve Injuries; Quinazolines; Rats; Signal Transduction; Spinal Cord Injuries | 2005 |
EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans.
Topics: Animals; Axons; Calcium; Cells, Cultured; Chondroitin Sulfate Proteoglycans; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; GPI-Linked Proteins; Humans; Mice; Myelin Proteins; Nerve Crush; Nerve Regeneration; Neurites; Nogo Proteins; Nogo Receptor 1; Optic Nerve; Optic Nerve Injuries; Phosphorylation; Quinazolines; Receptors, Cell Surface; Retinal Ganglion Cells; Signal Transduction; Tyrphostins | 2005 |
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2006 |
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cetuximab; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Quinazolines; Tyrphostins | 2005 |
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Placebos; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Epidermal growth factor receptor inhibitors: a moving target?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Clinical trials referral resource. Current clinical trials of erlotinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines | 2005 |
New approaches in the management of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Quinazolines | 2005 |
Glioblastoma multiforme and the epidermal growth factor receptor.
Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2005 |
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction | 2005 |
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Re: Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Magnesium; Magnesium Deficiency; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2006 |
Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelium; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Genes, Neoplasm; Humans; Immunohistochemistry; Lung Neoplasms; Mesoderm; Mutation; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vimentin | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Electrophoretic Mobility Shift Assay; ErbB Receptors; Erlotinib Hydrochloride; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Pyrazoles; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2005 |
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Topics: Biotransformation; ErbB Receptors; Erlotinib Hydrochloride; Feces; Humans; Male; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2006 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
Bevacizumab and erlotinib show promise for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Years of research come to fruition with launch of oral cancer prevention trial.
Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Proteins; Mouth Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor Cross-Talk; Signal Transduction; Sulfonamides | 2006 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Vinblastine | 2005 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
An acneiform eruption due to erlotinib: prognostic implications and management.
Topics: Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2006 |
Response of glioblastomas to EGFR kinase inhibitors.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2006 |
Assessing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paraffin Embedding; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Survival Analysis | 2006 |
[Molecular therapy for HCC?].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Clinical Trials as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
[Acneiform eruption from epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2005 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Humans; Lung Neoplasms; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
[A new medication for lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2005 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Topics: Adult; Aged; Animals; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Glioblastoma; Humans; Male; Mice; Mice, Nude; Middle Aged; Quinazolines; Survival Rate; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Topics: Antibiotics, Antineoplastic; Brain Neoplasms; DNA Repair; DNA-Binding Proteins; Doxorubicin; Endonucleases; Erlotinib Hydrochloride; Gene Silencing; Genes, erbB-1; Genome, Human; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Xeroderma Pigmentosum Group D Protein | 2005 |
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; ADAM Proteins; ADAM17 Protein; Amphiregulin; Antineoplastic Agents; Cell Line; CSK Tyrosine-Protein Kinase; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Gastrin-Releasing Peptide; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Recombinant Fusion Proteins; Signal Transduction; src-Family Kinases; Tumor Necrosis Factor-alpha | 2006 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Thiophenes | 2006 |
Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
Topics: Animals; Benzamides; Cattle; Cyclic AMP-Dependent Protein Kinases; Erlotinib Hydrochloride; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Models, Molecular; Mutagenesis, Site-Directed; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; rho-Associated Kinases; Structure-Activity Relationship; Substrate Specificity | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
Erlotinib: optimizing therapy with predictors of response?
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Gene Amplification; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Quinazolines; Trastuzumab | 2006 |
Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2006 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
Contrasts, conflicts, and change: A case in cultural oncology.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Attitude to Health; Carboplatin; Cultural Characteristics; Erlotinib Hydrochloride; Family Relations; Female; Humans; Middle Aged; Paclitaxel; Physician-Patient Relations; Quinazolines; Thoracic Neoplasms | 2006 |
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-3; Lung Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2 | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Cancer research. Fake data, but could the idea still be right?
Topics: Aneuploidy; Antineoplastic Agents; Controlled Clinical Trials as Topic; Erlotinib Hydrochloride; Genetic Markers; Humans; Loss of Heterozygosity; Mouth Diseases; Mouth Neoplasms; Quinazolines; Risk Factors; Scientific Misconduct | 2006 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2006 |
Pulmonary fibrosis in a patient treated with erlotinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
Topics: Aged; Antineoplastic Agents; Dermatomycoses; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Malassezia; Male; Quinazolines; Rosacea | 2006 |
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Topics: Actins; Anticarcinogenic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2006 |
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2006 |
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transfection | 2006 |
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Topics: Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Cloning, Molecular; ErbB Receptors; Erlotinib Hydrochloride; Genetic Vectors; Humans; Kinetics; Mutagenesis; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2006 |
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Size; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Floxuridine; Humans; Male; Prostatic Neoplasms; Quinazolines; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous | 2007 |
Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Complementary; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Poly A; Protein Kinase Inhibitors; Quinazolines | 2006 |
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2005 |
[Pancreatic cancer: Roche versus the European Agency of Drugs].
Topics: Drug Approval; Drug Industry; Erlotinib Hydrochloride; European Union; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Epidermal Growth Factor; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Ribosomal Protein S6; Signal Transduction; Sirolimus; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2006 |
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptors, Somatomedin; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
Erlotinib-induced breast cancer regression.
Topics: Adult; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Radiography; Remission Induction | 2006 |
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Discriminant Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Tumor Cells, Cultured | 2006 |
The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Erlotinib Hydrochloride; Humans; Molecular Structure; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Should every lung cancer patient be tested for EGFR mutation?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Pharmacogenetics; Quinazolines | 2006 |
Erlotinib-associated skin reactions - case report and proposal for classification.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2006 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
[Epidermal growth factor receptor family and targeted anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasms; Quinazolines; Trastuzumab | 2006 |
Paired drugs give advanced lung cancer a double punch.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Sulfonamides | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Topics: Animals; Astrocytes; Binding Sites; Cell Line, Tumor; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Models, Molecular; Mutation, Missense; Neoplasms, Experimental; NIH 3T3 Cells; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2006 |
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine | 2007 |
[New medications; erlotinib].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Repression of cyclin D1 as a target for germ cell tumors.
Topics: Antineoplastic Agents; Cell Differentiation; Cyclin D1; DNA Fragmentation; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Germ Cell and Embryonal; Quinazolines; Receptors, Retinoic Acid; RNA, Heterogeneous Nuclear; RNA, Small Interfering; Time Factors; Tretinoin | 2007 |
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Acute drug induced hepatitis due to erlotinib.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
Topics: Animals; Cell Line; Cell Line, Tumor; Cells, Cultured; Chlorocebus aethiops; ErbB Receptors; Erlotinib Hydrochloride; Genetic Therapy; Humans; Immunoblotting; In Situ Hybridization; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Nerve Sheath Neoplasms; Oligonucleotide Array Sequence Analysis; Oncolytic Virotherapy; Protein Kinase Inhibitors; Quinazolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Simplexvirus; Vero Cells; Xenograft Model Antitumor Assays | 2007 |
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-2; Genes, ras; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Respiratory Mucosa | 2007 |
[Clinical results observed with tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Associations of tyrosine kinase inhibitors with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Use of tyrosine kinase inhibitors in particular situations].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Perspectives and future developments of epidermal growth factor receptors inhibitors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dermatitis, Phototoxic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Inhibition of epidermal growth factor receptor by erlotinib: wound healing of experimental tympanic membrane perforations.
Topics: Animals; Chronic Disease; ErbB Receptors; Erlotinib Hydrochloride; Protein Kinase Inhibitors; Quinazolines; Rats; Tympanic Membrane Perforation; Wound Healing | 2007 |
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cetuximab; DNA, Complementary; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
New blood cancer therapies under study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Topics: Adenocarcinoma; Animals; Biopsy, Fine-Needle; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Xenograft Model Antitumor Assays | 2007 |
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.
Topics: Biomarkers, Tumor; Cadherins; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Mesoderm; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis; Vimentin | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines; Skin | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Topics: ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2007 |
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Topics: Analysis of Variance; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Interferon-alpha; Mutation; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2007 |
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome | 2007 |
When you look matters: the effect of assessment schedule on progression-free survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Neoplasms; Population Surveillance; Quinazolines; Research Design; Statistics, Nonparametric; Time Factors | 2007 |
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CA-125 Antigen; Cell Growth Processes; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ovarian Neoplasms; Quinazolines; Radioimmunoassay | 2007 |
Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Renal Cell; Cell Cycle; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Kidney Neoplasms; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2007 |
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking | 2007 |
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay | 2007 |
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Introns; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Genetic; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2007 |
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Topics: Active Transport, Cell Nucleus; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; S Phase; Up-Regulation | 2007 |
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Topics: Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; RNA, Small Interfering | 2007 |
Erlotinib-associated acute pneumonitis: report of two cases.
Topics: Acute Disease; Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Glucocorticoids; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Shock, Septic | 2007 |
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Topics: Alleles; Amino Acid Substitution; Animals; Cell Survival; Cells, Cultured; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Peptide Fragments; Phosphorylation; Point Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retroviridae; Sequence Deletion | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea | 2007 |
Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry.
Topics: Animals; Autoradiography; Biotransformation; Calibration; Erlotinib Hydrochloride; Indicators and Reagents; Protein Kinase Inhibitors; Quinazolines; Rats; Reference Standards; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2007 |
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Polymerase Chain Reaction; Quality of Life; Quinazolines | 2007 |
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2007 |
Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2007 |
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Topics: Aged; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2007 |
Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Agents; Brachiocephalic Veins; Carcinoma, Non-Small-Cell Lung; Cyanosis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Superior Vena Cava Syndrome; Syncope; Tomography, X-Ray Computed; Venous Thrombosis | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, Liquid; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gene Dosage; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Mass Spectrometry; Molecular Sequence Data; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Transfection; Up-Regulation | 2007 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mice, SCID; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2007 |
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Topics: Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Gefitinib; Humans; Microsomes, Liver; Midazolam; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
Fulminant hepatic failure secondary to erlotinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Failure, Acute; Liver Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2007 |
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Genes, Dominant; Humans; Phosphorylation; Phosphotyrosine; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Transfection | 2007 |
Erlotinib-responsive actinic keratoses.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Keratosis; Male; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Skin Neoplasms; Sunlight | 2007 |
[Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Optimizing targeted therapy in patients with lung cancer with a performance status of 2.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed | 2007 |
[Erlotinib (Tarceva) induced severe exanthema].
Topics: Biopsy; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin; Time Factors | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
Topics: Blotting, Western; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; STAT3 Transcription Factor; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2007 |
Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Crystallography, X-Ray; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; In Vitro Techniques; MAP Kinase Kinase Kinases; Microsomes, Liver; Models, Molecular; Protein Structure, Tertiary; Proto-Oncogene Proteins; Quinazolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2007 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Humans; Leg; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Fatal Outcome; Hematoma, Subdural; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2008 |
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Glioma; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer.
Topics: Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic | 2007 |
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Signal Transduction; Sulfonamides | 2007 |
Pulmonary toxicity associated with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Dipeptides; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Silencing; Heparin-binding EGF-like Growth Factor; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Matrix Metalloproteinases; Pancreatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2007 |
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.
Topics: Bacterial Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Luminescent Proteins; Lung Neoplasms; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Point Mutation; Polymorphism, Genetic; Quinazolines; Sequence Deletion | 2007 |
Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Research Design; Vascular Endothelial Growth Factor A | 2007 |
EGFR inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2007 |
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; United States | 2007 |
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Intestinal Polyps; Intestine, Small; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Prostaglandins; Pyrazoles; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hungary; Immunohistochemistry; Lung Neoplasms; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2007 |
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Reference Values | 2008 |
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-Associated Death Protein; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mice; Mutation; Quinazolines; Sensitivity and Specificity | 2007 |
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Genes, myc; Humans; Ligands; Mutation; Phosphorylation; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Signal Transduction; STAT5 Transcription Factor; Tumor Cells, Cultured | 2008 |
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Topics: Animals; Area Under Curve; Erlotinib Hydrochloride; Injections, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Quinazolines | 2008 |
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase; Humans; Immunoblotting; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2007 |
Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.
Topics: Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Magnetic Resonance Spectroscopy; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2006 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.
Topics: Aged; Anti-Bacterial Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Eruptions; Emollients; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Minocycline; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2008 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
Colloidal oatmeal lotion is an effective treatment for pruritus caused by erlotinib.
Topics: Avena; Colloids; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Phytotherapy; Plant Preparations; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2008 |
Acneiform reaction to erlotinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sex Factors | 2008 |
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment | 2008 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Small Interfering; Signal Transduction | 2007 |
Erlotinib in pancreatic cancer: are tumor cells the (only) target?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Erlotinib-associated alopecia in a lung cancer patient.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2007 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
[TRUST study: general practice relevant data on erlotinib in NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extracts; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Folic Acid Antagonists; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Morpholines; Pemetrexed; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2008 |
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.
Topics: Animals; Calcitriol; Carcinoma, Squamous Cell; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Renal Insufficiency, Chronic; Transforming Growth Factor alpha | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
Topics: Breast Neoplasms; Cluster Analysis; Erlotinib Hydrochloride; Female; Humans; Intracellular Signaling Peptides and Proteins; Lasers; Liver Neoplasms; Microdissection; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Interleukins; Lung Neoplasms; MAP Kinase Signaling System; Mutant Proteins; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Quinazolines; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2008 |
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors | 2008 |
Of mice and (wo)men: is this any way to test a new drug?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ki-67 Antigen; Mice; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2008 |
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Topics: Bacteremia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin; Staphylococcal Infections | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Dideoxynucleosides; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Topics: Crystallography, X-Ray; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2008 |
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Topics: Adult; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2008 |
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2008 |
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2008 |
Erlotinib-induced episcleritis in a patient with pancreatic cancer.
Topics: Carcinoma; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Scleritis | 2008 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |
Images in clinical medicine. Erlotinib-induced hair alterations.
Topics: Erlotinib Hydrochloride; Hair Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Gene Dosage; Genes, ras; HCT116 Cells; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Quinazolines; ras Proteins; Resting Phase, Cell Cycle; RNA, Messenger | 2008 |
Epidermal growth factor receptor inhibitors and hair.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines | 2008 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Painful pustular eruption in the groin and the scrotum induced by erlotinib.
Topics: Aged; Drug Eruptions; Erlotinib Hydrochloride; Genital Diseases, Male; Groin; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Scrotum; Skin Diseases, Vesiculobullous | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Mesoderm; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; STAT3 Transcription Factor; Vimentin | 2008 |
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Transplantation, Heterologous | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Taxoids | 2008 |
[Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Quinazolines; Signal Transduction | 2008 |
[Efficacy of erlotinib on advanced non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2008 |
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Bronchoalveolar Lavage Fluid; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Mice; Pulmonary Fibrosis; Quinazolines; RNA, Messenger; Transforming Growth Factor alpha | 2008 |
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Acneiforme rash in woman with pulmonary adenocarcinoma].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Erlotinib Hydrochloride; Esters; Female; Mice; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Spiro Compounds | 2008 |
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Nerve Sheath Neoplasms; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation | 2008 |
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Lung; Lung Neoplasms; Mice; Nicotinic Acids; Oleanolic Acid; Protein Kinase Inhibitors; Quinazolines; Tetrahydronaphthalenes | 2008 |
Bilateral eardrum perforation after long-term treatment with erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tympanic Membrane Perforation | 2008 |
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Topics: Aged; Budgets; Deoxycytidine; Drug Costs; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; United States | 2008 |
The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib: the first biologic in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2008 |
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Cerebrospinal Fluid; Diagnosis, Differential; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2008 |
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Topics: Amino Acid Substitution; Apoptosis; Arginine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leucine; Lung Neoplasms; Mitochondria; Mutation; Oxidative Phosphorylation; Protein Structure, Quaternary; Protein Transport; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2008 |
Response of malignant thymoma to erlotinib.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma | 2008 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous | 2008 |
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases | 2008 |
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Drug Combinations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Immunoblotting; Immunoprecipitation; Interleukin-3; Lapatinib; Mice; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure | 2008 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis | 2008 |
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Codon, Nonsense; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Genes, erbB; Magnetic Resonance Imaging; Mice; Mice, Nude; Neuroma, Acoustic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2008 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.
Topics: Acitretin; Administration, Oral; Diagnosis, Differential; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratolytic Agents; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Genes, p16; Genes, p53; Humans; Immunohistochemistry; Nerve Sheath Neoplasms; Polymorphism, Single-Stranded Conformational; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Trastuzumab | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Cell Line, Tumor; Cell Proliferation; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesoderm; Microfilament Proteins; Middle Aged; Pancreatic Neoplasms; Phenotype; Quinazolines | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Trichomegaly induced by erlotinib.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Erlotinib Hydrochloride; Female; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Protein Kinase Inhibitors; Quinazolines | 2008 |
Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2008 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
[Targeted therapies. New hopes, new challenges].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2008 |
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Arrestins; beta-Arrestins; Carbazoles; Carvedilol; Cell Line, Transformed; Dose-Response Relationship, Drug; Enzyme Activation; Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Heart; Humans; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Propanolamines; Quinazolines; Signal Transduction; Transcriptional Activation | 2008 |
Non-small cell lung cancer-smokers or non-smokers, does it matter?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Newer opportunities in systemic therapy of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.
Topics: Cells, Cultured; Chemistry, Pharmaceutical; Drug Carriers; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Kinetics; Muramidase; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2008 |
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Quinazolines; Substrate Specificity; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiotherapy; Treatment Outcome | 2008 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Rosaceiform eruption induced by erlotinib.
Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; Imidazoles; Insulin Receptor Substrate Proteins; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Chronic Disease; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Female; HIV; HIV Infections; Humans; Lung Diseases, Interstitial; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"].
Topics: Adult; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Male; Multiple Pulmonary Nodules; Pericardial Effusion; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Oncogene Protein v-akt; Quinazolines; Time Factors; Tumor Cells, Cultured | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatorenal Syndrome; Humans; Liver Failure; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Quinazolines | 2008 |
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2008 |
How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?
Topics: Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Quinazolines; Serratia Infections; Serratia marcescens; Suppuration | 2008 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromosome Breakage; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Genes, BRCA1; Histones; Humans; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; Recombination, Genetic | 2008 |
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Topics: Amino Acid Substitution; AMP-Activated Protein Kinase Kinases; Animals; Chlorocebus aethiops; COS Cells; ErbB Receptors; Erlotinib Hydrochloride; Focal Adhesion Kinase 1; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Growth Factor; Sulfonamides | 2009 |
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation | 2008 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
[Hand-foot syndrome: A new side effect of erlotinib].
Topics: Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Erythema; Foot Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Syndrome | 2008 |
Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disseminated Intravascular Coagulation; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thrombocytopenia | 2009 |
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dideoxynucleosides; Down-Regulation; Early Detection of Cancer; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Lung Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2009 |
Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhalation Exposure; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2009 |
[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Utilization; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden | 2009 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Erlotinib for the treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2009 |
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Risk Assessment | 2009 |
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Caspase 12; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transcription Factor CHOP; Tunicamycin | 2009 |
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines | 2008 |
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines | 2008 |
Unusual hair changes with prolonged erlotinib exposure.
Topics: Adult; Erlotinib Hydrochloride; Female; Hair; Hair Color; Humans; Quinazolines | 2008 |
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Topics: Aged; Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Tensins; Time Factors; Tumor Cells, Cultured | 2009 |
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; delta-Crystallins; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Mesoderm; Phenotype; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Humans; Mitoxantrone; Neoplasm Proteins; Quinazolines; Tyrphostins | 2009 |
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous | 2009 |
Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Humans; Liver Cirrhosis, Alcoholic; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Ultrasonography | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
Arsenic activates EGFR pathway signaling in the lung.
Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds | 2009 |
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome | 2009 |
[Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2008 |
[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction; Treatment Failure; Young Adult | 2008 |
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quinazolines; Radiotherapy Dosage | 2009 |
Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway.
Topics: Animals; Antineoplastic Agents; Biological Assay; Catalytic Domain; Computer Simulation; Drosophila melanogaster; ErbB Receptors; Erlotinib Hydrochloride; Eye; Gefitinib; Gene Expression Regulation; Models, Molecular; Protein Conformation; Protein Structure, Tertiary; Quinazolines; ras Proteins; Wings, Animal | 2008 |
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Depsipeptides; Drug Synergism; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
Avastin-Tarceva combination fails in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2009 |
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Erlotinib-induced pustular eruption.
Topics: Acneiform Eruptions; Administration, Cutaneous; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythromycin; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Topics: Animals; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Immunoprecipitation; Indoles; Luciferases; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; RNA, Small Interfering; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Carrier Proteins; Collagen; Disease Models, Animal; Disease Progression; Doxycycline; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Lung; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Quinazolines; Respiratory Mechanics; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha; Uteroglobin | 2009 |
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib-induced dermatologic side-effects.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Chickenpox; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Herpesvirus 3, Human; Humans; Protein Kinase Inhibitors; Quinazolines; Virus Activation | 2009 |
Targeting the future in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Topics: Aged; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed | 2009 |
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Folic Acid; Gefitinib; Genotype; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression; Genome-Wide Association Study; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Survival; Depsipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Cluster Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Gene Expression; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2009 |
Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Predictive Value of Tests; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Smoking | 2008 |
Akt demoted in glioblastoma.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Maleimides; Models, Biological; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases | 2009 |
Selecting promising treatments in randomized Phase II cancer trials with an active control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2009 |
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2009 |
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Topics: Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Metabolome; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2009 |
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, SCID; Multigene Family; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiourea | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Analysis of ErbB receptors in pulmonary carcinoid tumors.
Topics: Adult; Aged; Base Sequence; Carcinoid Tumor; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymorphism, Single Nucleotide; Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2009 |
Erlotinib and bevacizumab have synergistic activity against melanoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, SCID; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Docetaxel; Drug Costs; Erlotinib Hydrochloride; Germany; Glutamates; Guanine; Humans; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer.
Topics: Bacteremia; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin; Staphylococcal Infections; Staphylococcus aureus | 2009 |
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factor RelA; Tumor Suppressor Protein p53 | 2009 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tumor Cells, Cultured; Vincristine | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Proteins; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
American Association for Cancer Research 100th Annual Meeting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Male; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research; Societies, Medical; United States; Vorinostat | 2009 |
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biliary Tract Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Persistent corneal epithelial defect associated with erlotinib treatment.
Topics: Aged; Cataract Extraction; Corneal Diseases; Epithelium, Corneal; Erlotinib Hydrochloride; Female; Humans; Keratitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections; Staphylococcus epidermidis | 2009 |
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
Topics: Amino Acid Sequence; Cell Line; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Molecular Sequence Data; Mutant Proteins; Phosphopeptides; Phosphorylation; Phosphotyrosine; Quinazolines; Time Factors | 2009 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Lung Neoplasms; Middle Aged; Quinazolines | 2009 |
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2009 |
Assessment of erlotinib in chemoresponse assay.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2009 |
Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Proteins; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris.
Topics: Acantholysis; Animals; Apoptosis; Betacellulin; Carrier Proteins; Disease Models, Animal; Enzyme Activation; Epidermal Growth Factor; Epidermis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulin G; Intercellular Signaling Peptides and Proteins; Intradermal Tests; Isoenzymes; Mice; Mice, Inbred C57BL; Pemphigus; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Sirolimus; src-Family Kinases; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Topics: Biological Availability; Brain Neoplasms; Child; Combined Modality Therapy; Cystic Fibrosis; Erlotinib Hydrochloride; Exocrine Pancreatic Insufficiency; Female; Glioma; Humans; Malabsorption Syndromes; Pancrelipase; Protein Kinase Inhibitors; Quinazolines | 2009 |
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
Topics: Apoptosis; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction | 2009 |
Erlotinib for the treatment of relapsed non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Hepatocyte Growth Factor; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Quantitative prediction of fold resistance for inhibitors of EGFR.
Topics: Animals; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Models, Molecular; Quinazolines | 2009 |
Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Injections, Intraocular; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vitreous Body | 2009 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasms, Experimental; Oxygen; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production.
Topics: Acrolein; Animals; Enzyme Activation; Epithelial Cells; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Lung; Matrix Metalloproteinase 14; Mice; Mucins; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Respiratory Mucosa | 2009 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Lung cancer trials probe effects of maintenance therapy, targeted agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Respiration; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mitochondria; NADPH Oxidase 2; NADPH Oxidases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k.
Topics: Drug Eruptions; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United Kingdom | 2009 |
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines.
Topics: Antigens, Surface; Antineoplastic Agents; Benzoquinones; Biomarkers, Tumor; Blotting, Western; Calmodulin-Binding Proteins; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Lactams, Macrocyclic; Mass Spectrometry; Membrane Proteins; Protein Binding; Protein Interaction Mapping; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Screening for epidermal growth factor receptor mutations in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sex Distribution; Survival Analysis; Young Adult | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line; Drug Resistance, Multiple; Erlotinib Hydrochloride; Humans; Lapatinib; Multidrug Resistance-Associated Proteins; Quinazolines | 2010 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Response to erlotinib in a patient with treatment refractory chordoma.
Topics: Antineoplastic Agents; Chordoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sacrococcygeal Region | 2009 |
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides | 2009 |
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Topics: Adolescent; Blotting, Western; Cell Proliferation; Child; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Prognosis; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Tumor Cells, Cultured | 2009 |
Three cases of severe hepatic impairment caused by erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Failure; Liver Function Tests; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib: potentially fatal in cases of liver failure: a contraindication.
Topics: Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Failure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Topics: Afatinib; Amphiregulin; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Transplantation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cisplatin; Commiphora; Drug Synergism; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasm Transplantation; Phytotherapy; Plant Preparations; Pregnenediones; Quinazolines; STAT3 Transcription Factor | 2009 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Insurance, Health, Reimbursement; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2010 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Lung Neoplasms; Male; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction | 2009 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Topics: Adolescent; Adult; Aged; Area Under Curve; Bilirubin; Binding, Competitive; Biocatalysis; Cell Line; Child; Drug Interactions; Erlotinib Hydrochloride; Female; Gefitinib; Glucuronic Acid; Glucuronosyltransferase; Humans; Hymecromone; Imipramine; Indinavir; Isoenzymes; Kinetics; Male; Microsomes, Liver; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Young Adult | 2010 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Topics: Analytic Sample Preparation Methods; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Microchemistry; Piperazines; Pyrimidines; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor, Notch3; Receptors, Notch; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2010 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Genes, ras; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Thymidylate Synthase; Trifluridine | 2010 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; Community Health Services; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors | 2009 |
Clinical significance of the KRAS mutation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2009 |
Radiation recall dermatitis induced by erlotinib.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2009 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
Topics: Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Female; Humans; Hypertrichosis; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Erlotinib-induced skin manifestations.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Topics: Budgets; Carcinoma, Non-Small-Cell Lung; Cost Control; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Protein Synthesis Inhibitors; Quinazolines | 2010 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical | 2009 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Multicomponent crystals of erlotinib.
Topics: Crystallography, X-Ray; Erlotinib Hydrochloride; Fumarates; Hydrogen Bonding; Models, Molecular; Oxalates; Quinazolines | 2010 |
Treatment of lung cancer.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Trichomegaly secondary to erlotinib.
Topics: Adenocarcinoma; Aged; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Humans; Hypertrichosis; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Erlotinib Hydrochloride; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recombinant Proteins; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2010 |
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Situs Inversus; Treatment Outcome | 2011 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Gastroenteritis; Gastrointestinal Tract; Glucagon-Like Peptide 2; Mice; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines | 2010 |
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Mutation; Quinazolines; Treatment Outcome | 2010 |
[The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].
Topics: Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2009 |
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Duplexed on-microbead binding assay for competitive inhibitor of epidermal growth factor receptor by quantitative flow cytometry.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Competitive Bidding; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Microspheres; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2010 |
Economics and the new generation of targeted therapies for non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; United States | 2010 |
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Hospitalization; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
[Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Humans; IgA Vasculitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
The influence of inhibition of the epidermal growth factor receptor on tympanic membrane wound healing in rats.
Topics: Administration, Topical; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred Lew; Tympanic Membrane; Tympanic Membrane Perforation; Wound Healing | 2010 |
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Interstitial infusion of erlotinib in the rodent brain.
Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude | 2009 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat.
Topics: Animals; Dose-Response Relationship, Drug; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Lactic Acid; Materials Testing; Nanocapsules; Nanomedicine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Rats; Rats, Wistar | 2009 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phosphorylation; Proto-Oncogene Proteins c-cbl; Quinazolines; Ubiquitin | 2010 |
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Interleukins; Melanoma; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction | 2011 |
Treatment of multiple keratoacanthomas with erlotinib.
Topics: Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Keratoacanthoma; Male; Neoplasms, Multiple Primary; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms; Treatment Outcome | 2010 |
Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Keratoacanthoma; Protein Kinase Inhibitors; Quinazolines; Scalp; Skin Neoplasms; Treatment Outcome | 2010 |
[Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Topics: Acneiform Eruptions; Antineoplastic Agents; Arm; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neck Dissection; Neoplasm Proteins; Organ Specificity; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin; Thorax | 2010 |
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2009 |
Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Topics: Algorithms; Animals; Antimalarials; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Dantrolene; Erlotinib Hydrochloride; Flavonoids; Kinetics; Male; Mice; Mice, Knockout; Mitoxantrone; Muscle Relaxants, Central; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinidine; Testis; Tissue Distribution; Xenobiotics | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured | 2010 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Network meta-analysis: importance of appropriate trial selection.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Confidence Intervals; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meta-Analysis as Topic; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Taxoids | 2010 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Cancer: drug-tolerant insurgents.
Topics: Biological Evolution; Cell Line, Tumor; Cisplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Tolerance; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Quinazolines; Retinoblastoma-Binding Protein 2; Selection, Genetic | 2010 |
Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.
Topics: Animals; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glutathione; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; Microsomes; Quinazolines; Time Factors; Tissue Distribution | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lignans; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Serious hematologic complications following erlotinib treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure | 2010 |
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk | 2010 |
Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seasons; Vaccination | 2010 |
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A | 2010 |
Folliculitis decalvans associated with erlotinib.
Topics: Alopecia; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Folliculitis; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcus aureus | 2010 |
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2010 |
Targeted therapy in inflammatory breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Quinazolines | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.
Topics: Adult; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Hemangioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; von Hippel-Lindau Disease | 2011 |
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochromes b5; Cytoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Membrane Proteins; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptors, Progesterone; RNA Interference | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Knockout; Morpholines; Neoplasm Transplantation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Drug Combinations; Erlotinib Hydrochloride; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2010 |
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erlotinib and gastrointestinal ulcer.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Humans; Male; Peptic Ulcer; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Markov Chains; Neoplasm Staging; Pemetrexed; Placebos; Quinazolines; Remission Induction; Survival Rate; Treatment Outcome | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling.
Topics: Animals; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Mice; Mice, Inbred C57BL; Quinazolines; TRPM Cation Channels | 2010 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bronchi; Cell Line, Tumor; Cetuximab; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Quinazolines; RNA, Small Interfering; Signal Transduction | 2010 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Face; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma.
Topics: Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Protein Kinase Inhibitors; Quinazolines | 2010 |
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Topics: Animals; Carcinoma; Cell Cycle; Cell Growth Processes; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred C3H; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Receptors, Growth Factor; Triazoles; Xenograft Model Antitumor Assays | 2010 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Aprepitant for erlotinib-induced pruritus.
Topics: Adult; Aged; Aprepitant; Erlotinib Hydrochloride; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2010 |
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Topics: Aged; Animals; Blotting, Western; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Serum concentrations of Erlotinib at a dose of 25 mg daily.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; Retrospective Studies; Young Adult | 2010 |
ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Bilateral anterior uveitis secondary to erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Uveitis | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins | 2010 |
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.
Topics: Animals; Bleomycin; Dogs; Erlotinib Hydrochloride; Humans; Hydroxyproline; Injections; Lung; Lung Injury; Neutrophils; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Rats; Trachea | 2010 |
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Proliferation; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Protein Binding; Quinazolines; Ribonuclease, Pancreatic; Sulfhydryl Compounds; Tumor Cells, Cultured | 2010 |
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Methylation; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Ubiquitin-Protein Ligases | 2011 |
Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Coagulase; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections | 2010 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equipment Design; Equipment Failure Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hydrogels; Lung Neoplasms; Peptides; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |
EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tyrphostins | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Hepatorenal Syndrome; Humans; Liver Failure; Male; Pancreatic Neoplasms; Quinazolines | 2010 |
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Repressor Proteins; RNA Interference; Signal Transduction; Sirolimus; Survival Analysis; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Small tumors, intermediate models, big hopes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gemcitabine; Gene Expression; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin | 2010 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase IV as Topic; Compassionate Use Trials; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Topics: DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesothelioma; Mutation; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Aprepitant for erlotinib-induced pruritus.
Topics: Antineoplastic Agents; Aprepitant; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2010 |
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mutation; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2010 |
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Capillary Permeability; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Metabolic Clearance Rate; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2012 |
Kinase inhibitors in the treatment of chronic hepatitis C virus.
Topics: Adult; Antiviral Agents; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Topics: Antineoplastic Agents; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Piperidines; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Silencing; Genes, erbB-1; Humans; Mice; Mice, Nude; Phosphorylation; Protein Binding; Protein Kinases; Quinazolines; RNA, Small Interfering; Serine; Stathmin; Xenograft Model Antitumor Assays | 2010 |
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Topics: Alternative Splicing; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Lung Neoplasms; Mutation; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Serine-Arginine Splicing Factors; Signal Transduction | 2010 |
[TARCEVA Clinical Registry].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Registries | 2010 |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Array Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase.
Topics: Animals; Arterioles; Cells, Cultured; Coronary Vessels; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; GRB2 Adaptor Protein; Janus Kinases; Mice; Mice, Inbred C57BL; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Nitroprusside; Phosphorylation; Potassium Chloride; Pressure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Son of Sevenless Proteins; STAT Transcription Factors; STAT3 Transcription Factor; Tyrphostins; Vasoconstriction; Vasodilation | 2011 |
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2010 |
Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Topics: Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Transforming Growth Factor alpha | 2010 |
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Peptide Fragments; Peptide Mapping; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
Topics: Animals; ATP-Binding Cassette Transporters; Carrier Proteins; Cell Line; Central Nervous System; Erlotinib Hydrochloride; Extracellular Fluid; Female; Humans; Mice; Mice, Knockout; Quinazolines; Solubility; Tissue Distribution | 2011 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-lasting drop in perfusion of a non-small cell lung cancer induced by monotherapy with the epithelial growth factor receptor inhibitor erlotinib persisting despite tumor progression at remote sites.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cells, Cultured; Cytokines; Enzyme Activation; Erlotinib Hydrochloride; Gefitinib; Gene Knockout Techniques; HEK293 Cells; HT29 Cells; Humans; Mice; Nod2 Signaling Adaptor Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2010 |
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Mutation, Missense; Quinazolines; Sequence Deletion | 2011 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Signal Transduction; Silybin; Silymarin; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
Topics: 4-Nitroquinoline-1-oxide; Animal Feed; Animals; Carcinogens; Carcinoma, Squamous Cell; Commiphora; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Immunoenzyme Techniques; Mice; Mice, Inbred CBA; Mouth Neoplasms; Plant Extracts; Plant Gums; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Mutation; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Translocation, Genetic | 2011 |
Erlotinib and pantoprazole: a relevant interaction or not?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Quinazolines | 2010 |
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Oncogene Protein v-akt; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinazolines; T-Lymphocyte Subsets | 2011 |
Effects of erlotinib on pulmonary function and airway remodeling after sensitization and repeated allergen challenge in Brown-Norway rats.
Topics: Airway Remodeling; Allergens; Animals; Bronchial Hyperreactivity; Erlotinib Hydrochloride; Immunohistochemistry; Ovalbumin; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred BN; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Genes, BRCA1; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Treatment Outcome | 2011 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kidney; Mice; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor | 2011 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P | 2011 |
Is FISH floating or still swimming in the lung cancer ocean?
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mite Infestations; Mites; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Rosacea; Skin | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
[A case of lung cancer with skin metastases responding to erlotinib].
Topics: Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2011 |
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Erlotinib Hydrochloride; Humans; Microsomes, Liver; Protein Kinase Inhibitors; Quinazolines | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Inbred ICR; Mice, SCID; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Xenograft Model Antitumor Assays | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; BRCA1 Protein; Breast; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, BRCA1; Genes, p53; Humans; Isoenzymes; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Retinal Dehydrogenase; RNA Interference | 2011 |
Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms | 2011 |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2011 |
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; fas Receptor; Genes, erbB-1; Humans; I-kappa B Proteins; Lung Neoplasms; Models, Biological; Mutant Proteins; Mutation; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays | 2011 |
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2011 |
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome | 2011 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |
Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Topics: Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Lung Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcription Factor AP-2 | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Topics: Bronchi; Butadienes; Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hyperplasia; Luciferases; Lung Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Nitriles; Organ Culture Techniques; Quinazolines; RNA, Small Interfering | 2011 |
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Caspases; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; HeLa Cells; Humans; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Signal Transduction | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Topics: Animals; Antigens, CD; Antiviral Agents; Base Sequence; Cell Line; Claudin-1; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Ligands; Membrane Proteins; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, EphA2; RNA Interference; RNA, Small Interfering; Tetraspanin 28; Virus Internalization | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
Topics: Animals; Biomarkers, Pharmacological; Carcinoma; Cyclin D1; Cyclin D3; Cyclin E; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Quinazolines | 2011 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; France; Germany; Glutamates; Guanine; Italy; Pemetrexed; Quinazolines; Spain | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders.
Topics: Base Sequence; Cell Line; Chromatography, Liquid; Erlotinib Hydrochloride; Humans; Jurkat Cells; Lymphocytes; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; RNA, Small Interfering; Skin Diseases; Tandem Mass Spectrometry | 2011 |
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2011 |
Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
Topics: Antineoplastic Agents; Capsules; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Linking Reagents; Drug Compounding; Drug Stability; Drug Storage; Erlotinib Hydrochloride; Fiber Optic Technology; Gelatin; Quinazolines; Solubility; Solutions; Spectrophotometry, Ultraviolet; Tablets | 2011 |
Salvage with erlotinib plus bevacizumab: not in NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Topics: Alternative Splicing; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Erlotinib Hydrochloride; HeLa Cells; Humans; Introns; Lung Diseases; Nuclear Proteins; Paclitaxel; Quinazolines; RNA Precursors; RNA Splice Sites; RNA-Binding Proteins; RNA, Antisense; RNA, Small Interfering; Serine-Arginine Splicing Factors | 2011 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome | 2011 |
Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Intestinal Fistula; Intestinal Perforation; Protein Kinase Inhibitors; Quinazolines; Radiography; Sigmoid Diseases | 2011 |
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outpatients; Protein Kinase Inhibitors; Quinazolines | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome | 2011 |
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Computational Biology; Cyclin D1; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1 | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Markov Chains; Medical Oncology; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sensitivity and Specificity | 2012 |
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Logistic Models; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Tumor Microenvironment | 2011 |
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
[Erlotinib in non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.
Topics: Axilla; Biopsy, Needle; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Shoulder; Skin Neoplasms; Treatment Outcome | 2011 |
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Neoplasm Invasiveness; Osteoblasts; Osteolysis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
Topics: Adult; Aged; Aged, 80 and over; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Incidence; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; United States | 2011 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
The use of erlotinib in daily practice: a study on adherence and patients' experiences.
Topics: Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Culture; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Informed Consent; Lung Neoplasms; Medication Adherence; Multicenter Studies as Topic; Patient Selection; Patients; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design | 2011 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2011 |
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic | 2011 |
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2012 |
In vitro photo-controlled drug release system based on amphiphilic linear-dendritic diblock copolymers; self-assembly behavior and application as nanocarrier.
Topics: Azo Compounds; Biological Availability; Chromatography, Gel; Delayed-Action Preparations; Drug Carriers; Erlotinib Hydrochloride; Isomerism; Light; Magnetic Resonance Spectroscopy; Micelles; Microscopy, Electron; Particle Size; Photochemical Processes; Polyethylene Glycols; Polymers; Protein Kinase Inhibitors; Pyrenes; Quinazolines; Scattering, Radiation; Siloxanes; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Surface-Active Agents; Ultraviolet Rays | 2011 |
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Evolution, Molecular; Female; Gefitinib; Genes, erbB-1; Humans; Mice; Mice, Nude; Models, Theoretical; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2011 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Immunohistochemistry; Mice; Mice, SCID; Neuregulin-1; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transplantation, Heterologous | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat | 2011 |
Drug-induced effects on erlotinib metabolism.
Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2011 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.
Topics: Crystallography, X-Ray; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Linear Models; Principal Component Analysis; Protein-Tyrosine Kinases; Quantitative Structure-Activity Relationship; Quinazolines | 2011 |
Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Quinazolines; Sarcoma; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mutation; Quinazolines; Radionuclide Imaging | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Cetuximab; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2011 |
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment | 2011 |
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
EGFR mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines | 2012 |
Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
Topics: Amphiregulin; Animals; Breast Neoplasms; Cell Growth Processes; Cell Line; Cell Movement; Cell Transformation, Neoplastic; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Mammary Glands, Human; MAP Kinase Signaling System; Mice; Mice, Transgenic; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1 | 2011 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colonic Neoplasms; Drug Delivery Systems; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; HCT116 Cells; HT29 Cells; Humans; Quinazolines; Radiation-Sensitizing Agents; Recombinant Fusion Proteins; Signal Transduction | 2012 |
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration | 2012 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases | 2011 |
Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3.
Topics: Amides; Amination; Aniline Compounds; Anticholesteremic Agents; Azabicyclo Compounds; Benzamides; Catalysis; Chemistry, Pharmaceutical; Erlotinib Hydrochloride; Eszopiclone; Fluorobenzenes; Heterocyclic Compounds; Humans; Hydrogen-Ion Concentration; Hypnotics and Sedatives; Hypoglycemic Agents; Imatinib Mesylate; Molecular Structure; Phosphorus Compounds; Piperazines; Prescription Drugs; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones; Urea | 2011 |
The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Cetuximab; Cisplatin; DNA Damage; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult | 2011 |
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Topics: Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors | 2011 |
The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Growth Processes; Cetuximab; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Keratinocytes; Mice; Mice, Inbred ICR; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Reactive Oxygen Species; Skin; Vitamin K 3 | 2011 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |
Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.
Topics: Aged; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2011 |
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United Kingdom | 2011 |
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Biomarkers; Blood-Brain Barrier; Brain; Dogs; Erlotinib Hydrochloride; Female; Humans; Male; Mice; Mice, Knockout; Neoplasm Proteins; Protein Binding; Quinazolines; Quinidine; Rats | 2011 |
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Protein Stability; Quinazolines; RNA Interference; RNA Stability; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Quinazolines; Vulvar Neoplasms | 2011 |
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Topics: Blotting, Western; Chromatin Immunoprecipitation; Colonic Neoplasms; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; GPI-Linked Proteins; Humans; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2012 |
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation | 2012 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2011 |
Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Computer Simulation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Lymphoma; Mice; Mice, Transgenic; Models, Theoretical; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Cells, Cultured | 2011 |
A systems biology approach to model neural stem cell regulation by notch, shh, wnt, and EGF signaling pathways.
Topics: Basic Helix-Loop-Helix Transcription Factors; Computer Simulation; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation; Hedgehog Proteins; Homeodomain Proteins; Humans; Models, Biological; Neural Stem Cells; Protein Interaction Mapping; Protein Kinase Inhibitors; Quinazolines; Receptors, Notch; Signal Transduction; Systems Biology; Transcription Factor HES-1; Wnt Proteins | 2011 |
Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.
Topics: Apoptosis; Cell Transformation, Viral; Cervix Uteri; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Viral; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Repressor Proteins; Signal Transduction; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glycosylation; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mucins; N-Acetylgalactosaminyltransferases; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polypeptide N-acetylgalactosaminyltransferase; Quinazolines; RNA, Messenger | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.
Topics: Carcinoma, Non-Small-Cell Lung; Decision Making; Decision Support Techniques; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Middle Aged; Pharmacopoeias as Topic; Protein Kinase Inhibitors; Quinazolines; State Medicine; Tape Recording; United Kingdom | 2011 |
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morphine; Quinazolines; Receptors, Opioid, mu | 2011 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Rearrangement; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2011 |
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome | 2011 |
Epidermal growth factor receptor-induced hirsutism and trichomegaly.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hirsutism; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Quinazolines | 2012 |
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Granuloma, Pyogenic; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tracheal Diseases | 2011 |
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; British Columbia; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Taxoids | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2011 |
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin | 2012 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
[New 'targeted therapy' for lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Treatment Outcome | 2011 |
Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma.
Topics: Adult; Carcinoma, Mucoepidermoid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Splenic Neoplasms | 2011 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
Reactive perforating collagenosis during erlotinib therapy.
Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2012 |
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2012 |
Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Laboratory Techniques; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Office Visits; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Taxoids; United States | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2011 |
Pneumocystis jiroveci Pneumonia in an Atypical Host.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Erlotinib Hydrochloride; Female; France; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Spain | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2011 |
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Insulin-Like Growth Factor II; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Quinazolines | 2010 |
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand | 2012 |
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Eruptions; Drug Interactions; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Hematoma; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Neoplasm Staging; Quinazolines; Severity of Illness Index; Venous Thrombosis | 2012 |
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.
Topics: Animals; Cell Line; Cell Proliferation; Colitis; Colon; Colonic Neoplasms; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid | 2011 |
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].
Topics: Adult; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Recurrence; Thymoma; Thymus Neoplasms | 2011 |
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells.
Topics: Cell Line, Tumor; Erlotinib Hydrochloride; Fluorescence; Humans; Intracellular Signaling Peptides and Proteins; Protein Array Analysis; Proteomics; Quinazolines; Signal Transduction | 2012 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Recurrent congenital fibrosarcoma with heart metastases.
Topics: Erlotinib Hydrochloride; Female; Fibrosarcoma; Heart Neoplasms; Humans; Infant; Oncogene Proteins, Fusion; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2012 |
Treatment of vestibular schwannoma cells with ErbB inhibitors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Ear Neoplasms; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lapatinib; Neuroma, Acoustic; Oncogene Proteins v-erbB; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Vestibular Nerve | 2012 |
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.
Topics: Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Transfection | 2012 |
The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Optimising therapy for EGFR-addicted NSCLC: just the start.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Vimentin; Young Adult | 2012 |
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Subacute transient encephalopathy induced by erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence | 2011 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Naphthyridines; Neoplasms; Phenazines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Becaplermin; Cell Division; Cyclooxygenase 2; Cytokines; Drug Evaluation, Preclinical; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred DBA; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Quinazolines; Synovial Membrane | 2012 |
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis | 2012 |
A study of electrochemical biosensor for analysis of three-dimensional (3D) cell culture.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Collagen; Drug Combinations; Electrochemical Techniques; Erlotinib Hydrochloride; Gels; Humans; Laminin; Lung Neoplasms; Proteoglycans; Quinazolines; Spheroids, Cellular | 2012 |
Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1.
Topics: Acetylation; Acute-Phase Proteins; Animals; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Lipocalin-2; Lipocalins; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Nude; Models, Biological; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptors, Progesterone; Transcription Factor RelA; Transcription, Genetic; Transplantation, Heterologous; Tyrphostins | 2012 |
Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury.
Topics: Acute Kidney Injury; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Kidney Tubules, Proximal; Mice; Mice, Inbred BALB C; Mice, Knockout; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recovery of Function; Reperfusion Injury; Time Factors | 2012 |
Retrospective study of erlotinib in patients with advanced squamous lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
Topics: Antigens, CD; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines; Tumor Stem Cell Assay | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Separation and determination of process-related impurities of erlotinib using reverse-phase HPLC with a photo-diode array detector.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Erlotinib Hydrochloride; Light; Linear Models; Quinazolines; Time Factors | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiation Tolerance; Radiotherapy, Conformal; Treatment Outcome | 2012 |
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro].
Topics: Cell Differentiation; Cell Proliferation; Cells, Cultured; Erlotinib Hydrochloride; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Polycythemia Vera; Quinazolines | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Crizotinib; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Amplification; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, SCID; Mutation, Missense; Oncogene Proteins, Fusion; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib | 2012 |
Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.
Topics: beta Catenin; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Chi-Square Distribution; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Phenotype; Quinazolines; Snail Family Transcription Factors; Transcription Factors; Wound Healing | 2012 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence | 2012 |
A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Comorbidity; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
Topics: Adult; Biopsy; Bronchoscopy; Cell Transformation, Neoplastic; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Quinazolines | 2012 |
Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis.
Topics: Aged; Antitubercular Agents; Dermatomyositis; Diagnosis, Differential; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2012 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Topics: Animals; Breast Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tumor Cells, Cultured | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Purpuric drug eruption and alopecia induced by erlotinib.
Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptors, Tumor Necrosis Factor; Signal Transduction; Tumor Cells, Cultured; TWEAK Receptor | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.
Topics: Acyltransferases; Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, Reporter; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Luciferases, Renilla; Mice; NIH 3T3 Cells; Peptide Fragments; Phosphoproteins; Protein Binding; Protein Interaction Domains and Motifs; Protein Interaction Mapping; Protein Tyrosine Phosphatases, Non-Receptor; Quinazolines; RNA, Small Interfering; Survivin; Transcription Factors; Transcriptional Activation; YAP-Signaling Proteins | 2013 |
[A case of a corneal disorder after lung cancer treatment with erlotinib].
Topics: Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Erlotinib-related bilateral anterior uveitis.
Topics: Aged; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Uveitis, Anterior | 2011 |
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome | 2013 |
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors | 2012 |
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival Rate | 2012 |
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Erlotinib Hydrochloride; Humans; Micelles; Nanoparticles; Protein Kinase Inhibitors; Quinazolines; Surface-Active Agents; Triglycerides | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Topics: Adult; Aged; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.
Topics: Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Carcinoma, Squamous Cell; Carrier Proteins; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Topics: Alleles; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single-Stranded Conformational; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2012 |
Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytarabine; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Meningeal Neoplasms; Methotrexate; Mutation; Pemetrexed; Quinazolines; Radiation Dosage | 2012 |
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Tumor Burden | 2012 |
Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
Topics: Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokine CCL5; Chromones; Collagenases; Diphenylamine; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor I; Lymphokines; MCF-7 Cells; Morpholines; Phosphorylation; Platelet-Derived Growth Factor; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Estrogen; RNA, Small Interfering; Transforming Growth Factor beta | 2012 |
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors | 2012 |
KRAS wild-type lung cancer: a moving target in an era of genotype migration.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Erlotinib Hydrochloride; Humans; Quinazolines; Spectrometry, Fluorescence; Time Factors | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Humans; Mammary Glands, Human; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Structure, Tertiary; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptome | 2012 |
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 2012 |
Follow-up of erlotinib related uveitis.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Uveitis; Visual Acuity | 2012 |
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography; Treatment Outcome | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2012 |
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Cell Culture Techniques; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Young Adult | 2013 |
Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
Erlotinib-associated dermatological toxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines | 2013 |
Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation.
Topics: Animals; Aorta; Capillary Permeability; Cells, Cultured; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Inositol Polyphosphate 5-Phosphatases; Kidney; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA Interference; Systemic Inflammatory Response Syndrome; Transfection; Vascular Cell Adhesion Molecule-1 | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Quinazolines; Receptors, CXCR; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2012 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Skin; Skin Neoplasms | 2012 |
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cells, Cultured; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2012 |
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.
Topics: Cell Line, Tumor; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Phosphatase 2; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2012 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Theoretical; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution; Tumor Cells, Cultured | 2012 |
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dioxanes; Dioxins; Drug Design; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Thermodynamics | 2012 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotretinoin; Male; Quinazolines | 2012 |
Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lung Neoplasms; Quinazolines; Taxoids; Tubulin | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss.
Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Blotting, Western; Chlorocebus aethiops; COS Cells; Drosophila; Drosophila Proteins; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Maze Learning; Memantine; Memory; Memory Disorders; Mice; Mice, Transgenic; Molecular Structure; Peptide Fragments; Protein Kinase Inhibitors; Quinazolines | 2012 |
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2012 |
14th World Congress on Gastrointestinal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Fluorouracil; Genotype; Humans; Molecular Targeted Therapy; Pharmacogenetics; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2012 |
Erlotinib in patients with advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
[Personalised treatment of lung cancer].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Positron-Emission Tomography; Precision Medicine; Quinazolines | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Topics: Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Investigation on the site-selective binding of bovine serum albumin by erlotinib hydrochloride.
Topics: Binding Sites; Circular Dichroism; Erlotinib Hydrochloride; Molecular Conformation; Molecular Docking Simulation; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Quinazolines; Serum Albumin, Bovine; Spectrometry, Fluorescence; Thermodynamics | 2013 |
Who should receive EGFR tyrosine-kinase inhibitors?
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines | 2012 |
Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
Topics: Animals; Cell Line; Crystallography, X-Ray; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insecta; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mitogen-Activated Protein Kinases; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplastic Stem Cells; Quinazolines; Veratrum Alkaloids | 2012 |
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Furans; Gene Expression; Glioblastoma; Humans; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
Topics: 3' Untranslated Regions; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Signal Transduction | 2012 |
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Catalase; Cell Line, Tumor; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Necrosis; Oxidation-Reduction; Oxidative Stress; Peroxiredoxins; Quinazolines; RNA, Small Interfering; Thioredoxin-Disulfide Reductase; Thioredoxins; Xenograft Model Antitumor Assays | 2012 |
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; RNA Interference; TOR Serine-Threonine Kinases; Ubiquitin-Conjugating Enzymes | 2012 |
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Quinazolines; Survival Analysis | 2013 |
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Neoplasms; Qualitative Research; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Models, Statistical; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Topics: Adult; Base Sequence; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed | 2013 |
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Next-generation cDNA screening for oncogene and resistance phenotypes.
Topics: Animals; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Library; Genes, erbB-2; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Mice; Oncogenes; Phenotype; Protein Isoforms; Quinazolines | 2012 |
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies | 2013 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |
Indian drug maker cuts price of three cancer drugs by between 50% and 63%.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Fluorouracil; Humans; India; Quinazolines; Taxoids | 2012 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Topics: Calibration; Chromatography, High Pressure Liquid; Edetic Acid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
First-line erlotinib inferior to chemo in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering | 2013 |
Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Replication; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kinetics; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Transcriptional Activation | 2013 |
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2012 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Male; Orbital Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; England; Erlotinib Hydrochloride; Humans; Inappropriate Prescribing; Lung Neoplasms; Polypharmacy; Prevalence; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Stability; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Intravitreal Injections; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Oxygen; Protein Kinase Inhibitors; Quinazolines; Retinal Diseases; Signal Transduction; Tissue Inhibitor of Metalloproteinase-3 | 2013 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2013 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha | 2012 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.
Topics: Adult; Aged; Capsule Opacification; Cell Line; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Middle Aged; Neuroglia; Posterior Capsule of the Lens; Protein Kinase Inhibitors; Quinazolines; Retinal Pigment Epithelium | 2013 |
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2013 |
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles | 2013 |
Imaging of TKI-target interactions for personalized cancer therapy.
Topics: Carbon Radioisotopes; Erlotinib Hydrochloride; Humans; Positron-Emission Tomography; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats.
Topics: Animals; Antibiotics, Antineoplastic; Aquaporin 2; Creatinine; Doxorubicin; Epithelial Sodium Channels; ErbB Receptors; Erlotinib Hydrochloride; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Nephrotic Syndrome; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Rats; Renal Insufficiency; Sodium Chloride Symporters; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1 | 2013 |
Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Inflammation; Quinazolines; Tumor Necrosis Factor-alpha | 2013 |
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Topics: Adult; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Family Health; Fatal Outcome; Female; Germ-Line Mutation; Humans; In Situ Hybridization; Lung; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Squamous Cell; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
Gene expression changes associated with erlotinib response in glioma cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cluster Analysis; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Apoptosis Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survivin; Transcription Factors | 2013 |
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Thoracic Diseases; Treatment Outcome | 2013 |
Epidermal growth factor regulates hematopoietic regeneration after radiation injury.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Hematopoiesis; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries, Experimental; Regeneration; Signal Transduction; Tumor Suppressor Proteins; Whole-Body Irradiation | 2013 |
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2013 |
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2013 |
Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Humans; MCF-7 Cells; Molecular Conformation; Molecular Docking Simulation; Naphthalenes; Protein Structure, Tertiary; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2013 |
Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced non-small cell lung cancer with cancer anorexia-cachexia syndrome.
Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Parenteral Nutrition; Quinazolines; Syndrome | 2013 |
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Sample Size; Software | 2013 |
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Signal Transduction; Tumor Cells, Cultured | 2013 |
[Fatal interstitial lung disease associated with erlotinib use].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Mutation; Pemetrexed; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2013 |
Erlotinib-induced hair repigmentation.
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Hair Color; Humans; Lung Neoplasms; Pigmentation; Protein Kinase Inhibitors; Quinazolines | 2014 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1 | 2013 |
Dose reduction or intermittent administration of erlotinib: which is better for patients suffering from intolerable toxicities?
Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Proteome; Proteomics; Quinazolines; Retrospective Studies | 2013 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Diagnostic Tests, Routine; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms.
Topics: Androsterone; Antiviral Agents; Enzyme Inhibitors; Erlotinib Hydrochloride; Glucuronides; Glucuronosyltransferase; Humans; Indoles; Isoenzymes; Kinetics; Mefenamic Acid; Metabolic Detoxication, Phase II; Microsomes, Liver; Quinazolines; Recombinant Proteins; Tandem Mass Spectrometry; UDP-Glucuronosyltransferase 1A9; Uridine Diphosphate Glucuronic Acid | 2013 |
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2013 |
Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Mutation; Neutropenia; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Pancreatic carcinoma].
Topics: Erlotinib Hydrochloride; Everolimus; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2012 |
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Liver Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Blotting, Western; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Mammary Neoplasms, Animal; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Survival Rate; Tissue Distribution | 2013 |
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2013 |
[Erlotinib-induced acneiform eruption].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Erlotinib Hydrochloride; Fluoroquinolones; Humans; Lung Neoplasms; Male; Methylprednisolone; Quinazolines; Quinolizines; Treatment Outcome | 2013 |
Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2013 |
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Topics: Animals; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
[Report from a small registry-permetrexed, tarceva and yondelis].
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Mesothelioma; Pancreatic Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Sarcoma | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Biomarkers; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Longevity; Mice; Mice, Transgenic; Microglia; Motor Neurons; Neuromuscular Junction; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Spinal Cord; Staining and Labeling; Superoxide Dismutase; Superoxide Dismutase-1; Survival Analysis; Synapses; Time Factors | 2013 |
RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Female; HT29 Cells; Humans; Male; Membrane Potential, Mitochondrial; Mice; Microsomes, Liver; Mutation; Phosphorylation; Piperazine; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Pemetrexed; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2013 |
Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quinazolines; Signal Transduction; Tyrphostins | 2013 |
Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Hand-Foot Syndrome; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
A swollen knee in a 77-year-old lung cancer patient receiving antimicrobial therapy for pneumonia.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Humans; Knee; Knee Injuries; Lung Neoplasms; Male; Pneumonia; Quinazolines | 2013 |
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib | 2013 |
Recurrent respiratory papillomatosis with lung involvement and malignant transformation.
Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Signal Transduction; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer.
Topics: Endoscopic Ultrasound-Guided Fine Needle Aspiration; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reproducibility of Results | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Topics: Animals; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 1; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Integrin beta1; Lung Neoplasms; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2013 |
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Topics: Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotope Labeling; Neoplasm Proteins; Phosphopeptides; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tandem Mass Spectrometry; Tyrosine | 2013 |
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-4F; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; RNA Caps; Signal Transduction; Tumor Cells, Cultured | 2013 |
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2013 |
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Topics: Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mutation; Niclosamide; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines | 2013 |
Erlotinib in the treatment of advanced squamous cell NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Topics: Autophagy; Carcinoma, Squamous Cell; Cytoprotection; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; HEK293 Cells; Humans; NADPH Oxidase 4; NADPH Oxidases; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Transcriptome | 2013 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.
Topics: Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Lineage; Cetuximab; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; Neoplasm Invasiveness; Quinazolines; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Erlotinib Hydrochloride; Humans; I-kappa B Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference | 2014 |
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses | 2013 |
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Silybin; Silymarin; Treatment Outcome | 2013 |
Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Topics: Animals; Antineoplastic Agents; Chemokines; Cytokines; Dermatitis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Hair Follicle; Humans; Inflammation Mediators; Interleukin-1; Keratinocytes; Langerhans Cells; Lymphocytes; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms; Quinazolines; Skin; Translational Research, Biomedical | 2013 |
EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.
Topics: Antigens, CD34; CD11b Antigen; Cell Cycle Checkpoints; Cell Differentiation; Cholecalciferol; ErbB Receptors; Erlotinib Hydrochloride; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tretinoin; Tumor Cells, Cultured | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Exons; Genes, erbB-1; Humans; Quinazolines; Receptor, IGF Type 1; Sequence Deletion; Treatment Outcome | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Luciferases; Multienzyme Complexes; Neuregulin-1; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2013 |
A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib.
Topics: Antineoplastic Agents; Drug Delivery Systems; Erlotinib Hydrochloride; Ethylene Glycol; Hep G2 Cells; Humans; Indoles; Isoindoles; Neoplasms; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Quinazolines; Zinc Compounds | 2013 |
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Niclosamide; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor | 2013 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Triazoles | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Cells, Cultured; Cytokine TWEAK; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Silencing; Heparin-binding EGF-like Growth Factor; Humans; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Kidney Tubules; Ligands; Mice; Mice, Inbred C57BL; Nephritis; NF-kappa B; Phosphorylation; Quinazolines; Receptors, Tumor Necrosis Factor; Signal Transduction; Transcriptional Activation; Transforming Growth Factor alpha; Tumor Necrosis Factors; TWEAK Receptor | 2013 |
Modulation of PPIX synthesis and accumulation in various normal and glioma cell lines by modification of the cellular signaling and temperature.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cytoplasm; Erlotinib Hydrochloride; Glioblastoma; Humans; Hypothermia, Induced; Mitochondria; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Protoporphyrins; Quinazolines; Rats; Signal Transduction | 2013 |
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Topics: Acetylation; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mice; Mice, Nude; Propidium; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smad4 Protein; Treatment Outcome | 2013 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Transforming Growth Factor beta | 2014 |
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Inbred BALB C; Models, Biological; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Dermal toxicity of erlotinib].
Topics: Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome | 2014 |
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin B1; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Microtubules; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Quinazolines; Quinolines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection | 2014 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cytokines; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Topics: Animals; Apoptosis; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oncolytic Virotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Simplexvirus; Survival Rate; Tumor Cells, Cultured; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Mutation; Quinazolines | 2014 |
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Roche v. Cipla litigation.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Drugs, Generic; Erlotinib Hydrochloride; India; Legislation, Drug; Patents as Topic; Quinazolines | 2013 |
Erlotinib-induced folliculitis decalvans.
Topics: Aged; Anti-Infective Agents; Drug Therapy, Combination; Erlotinib Hydrochloride; Folliculitis; Glucocorticoids; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Down-Regulation; Erlotinib Hydrochloride; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Neural Conduction; Neuregulin-1; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sural Nerve | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
Erlotinib inhibits growth of a patient-derived chordoma xenograft.
Topics: Animals; Cell Line, Transformed; Cell Proliferation; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Genome-Wide Association Study; Heterografts; Humans; Mice; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
Topics: Animals; Animals, Newborn; Cells, Cultured; Desmoglein 1; Desmoglein 3; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratinocytes; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Nonlinear Dynamics; Pemphigus; Quinazolines | 2014 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Prognosis; Proteomics; Quinazolines; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2014 |
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Single-Cell Analysis; Tumor Cells, Cultured; Withholding Treatment | 2014 |
Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Retrospective Studies; Stem Cells | 2013 |
Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2013 |
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells | 2014 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Models, Economic; Multicenter Studies as Topic; Quality-Adjusted Life Years; Quinazolines | 2014 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; Docetaxel; Drug Dosage Calculations; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2014 |
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Skin; Survival Analysis; Treatment Outcome | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines | 2013 |
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Community Networks; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Pemetrexed; Practice Patterns, Physicians'; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines | 2014 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.
Topics: Animals; Carbon Radioisotopes; Catalytic Domain; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Mutation, Missense; Neoplasm Transplantation; Phosphorylation; Positron-Emission Tomography; Protein Binding; Protein Processing, Post-Translational; Quinazolines; Radiopharmaceuticals | 2013 |
Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, Lethal; Humans; MAP Kinase Signaling System; Mice; Pancreatic Neoplasms; Quinazolines; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Small Interfering | 2013 |
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclization; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Molecular Structure; Oxazepines; Oxazines; Phosphotransferases; Protein Binding; Quinazolines; Receptor, ErbB-2 | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.
Topics: Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; Humans; Microscopy, Confocal; Quinazolines; Spectrum Analysis, Raman | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
Oral erlotinib, but not rapamycin, causes modest acceleration of bladder and hindlimb recovery from spinal cord injury in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Erlotinib Hydrochloride; Female; Hindlimb; Immunosuppressive Agents; Locomotion; Protein Kinase Inhibitors; Quinazolines; Rats, Sprague-Dawley; Recovery of Function; Sirolimus; Spinal Cord Injuries; Urinary Bladder | 2014 |
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2013 |
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tamoxifen; Thymidine Phosphorylase; Time Factors | 2014 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Durable stabilization of three chordoma cases by bevacizumab and erlotinib.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Chordoma; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Sacrum; Skull Neoplasms; Treatment Outcome | 2014 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Receptor, IGF Type 1; RNA, Small Interfering | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Luteolin; Male; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Frequency; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Simultaneous determination of erlotinib and metabolites in human urine using capillary electrophoresis.
Topics: Calibration; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Limit of Detection; Quinazolines; Reproducibility of Results | 2014 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Random Allocation; Survivin; Xenograft Model Antitumor Assays | 2013 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinazolines; Sulfonamides; Transplantation, Heterologous | 2014 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
In-depth analysis shows synergy between erlotinib and miR-34a.
Topics: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Quinazolines | 2014 |
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Heterografts; Humans; Mice, Inbred BALB C; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 2; STAT3 Transcription Factor; Tyrphostins | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2014 |
EGFR-blockade with erlotinib reduces EGF and TGF-β2 expression and the actin-cytoskeleton which influences different aspects of cellular migration in lens epithelial cells.
Topics: Actin Cytoskeleton; Cell Movement; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lens, Crystalline; Microscopy, Fluorescence; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Time-Lapse Imaging; Transforming Growth Factor beta2 | 2014 |
Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phenotype; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2014 |
Erlotinib induced target-like purpura.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines | 2014 |
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms | 2014 |
Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.
Topics: Apoptosis; Betacellulin; Cell Count; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cycloheximide; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lipopolysaccharides; Lung Neoplasms; Models, Biological; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Necrosis Factor-alpha | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines; Radiography; Treatment Outcome | 2014 |
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Topics: Animals; Apoptosis; Aurora Kinase B; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Chromatin; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase C-alpha; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation Tolerance; ras Proteins; Xenograft Model Antitumor Assays | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.
Topics: Animals; Bile Ducts; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Diethylnitrosamine; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Phosphorylation; Prognosis; Quinazolines; Rats; Rats, Wistar; Transcriptome | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy; Taxoids | 2014 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing | 2014 |
Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Blood Glucose; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Immunohistochemistry; Kidney; Mice; Mice, Inbred NOD; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Erlotinib Hydrochloride; Female; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Topics: Adult; Aged; Budgets; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; Erlotinib Hydrochloride; Female; For-Profit Insurance Plans; Humans; Male; Managed Care Programs; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; SEER Program; United States | 2014 |
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines | 2014 |
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice, Nude; Microtubules; Mitosis; Niacinamide; Paclitaxel; Phosphorylation; Polymerization; Quinazolines; STAT3 Transcription Factor; Sulfonamides; Tubulin; Tumor Suppressor Protein p53; Vincristine | 2014 |
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR.
Topics: Aged; Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Survival Rate; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice, Transgenic; Mutation; Neoplasms, Experimental; Quinazolines; SOXB1 Transcription Factors | 2014 |
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Integrin alphaVbeta3; Integrin beta3; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Proto-Oncogene Proteins p21(ras); Quinazolines; ral GTP-Binding Proteins; Randomized Controlled Trials as Topic; ras Proteins; RNA Interference; Signal Transduction; Spheroids, Cellular; Time Factors; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
The TAILOR study: to agree or to disagree?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Research Design; Salvage Therapy; Taxoids | 2014 |
Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Cell Line; Diarrhea; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Erlotinib Hydrochloride; Humans; Inflammation Mediators; Interleukin-17; Interleukin-6; Interleukins; Intestinal Absorption; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Permeability; Protein Kinase Inhibitors; Quinazolines; Rats; RNA Interference; RNA, Messenger; Time Factors; Transcription Factor CHOP; Transfection | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Adsorption and desorption of tyrosine kinase inhibitor erlotinib on gold nanoparticles.
Topics: Adsorption; Erlotinib Hydrochloride; Gold; Metal Nanoparticles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Spectrum Analysis, Raman | 2014 |
Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Case of erlotinib-induced photosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines | 2014 |
The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
Topics: Aldehyde Dehydrogenase; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Crizotinib; Disulfiram; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Oxidative Stress; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Animals; Camptothecin; Erlotinib Hydrochloride; In Vitro Techniques; Irinotecan; Liver; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Animal; Molecular Structure; Pyridones; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Carriers; Erlotinib Hydrochloride; Female; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Quinazolines | 2014 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiography; Severity of Illness Index | 2014 |
Small-cell lung cancers in patients who never smoked cigarettes.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Chromogranins; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Rearrangement; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Retinoblastoma Protein; Retrospective Studies; Small Cell Lung Carcinoma; Smoking; Survival Rate; Telomerase; Tumor Suppressor Protein p53 | 2014 |
Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis.
Topics: beta-Defensins; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Host-Pathogen Interactions; Humans; Immunity, Innate; Keratinocytes; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Staphylococcus aureus; Staphylococcus epidermidis; Time Factors | 2014 |
VeriStrat validated in patients with non-small-cell lung cancer.
Topics: Blood Proteins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Paclitaxel; Quinazolines | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2014 |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2014 |
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolome; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2014 |
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases | 2014 |
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Derivation and experimental comparison of cell-division probability densities.
Topics: Antineoplastic Agents; Cell Count; Cell Cycle; Cell Division; Cell Proliferation; Cycloheximide; Dimethyl Sulfoxide; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Probability; Quinazolines; Stochastic Processes | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcription, Genetic | 2014 |
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.
Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines | 2014 |
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Systems Biology; Time Factors | 2014 |
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1 | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Topics: Adenocarcinoma; Anti-Infective Agents; Atovaquone; Chorioretinitis; ErbB Receptors; Erlotinib Hydrochloride; Female; Food Parasitology; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Toxoplasma; Toxoplasmosis, Ocular | 2014 |
Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2014 |
EGFR inhibitors may induce tumor stemness.
Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Integrin beta3; Neoplastic Stem Cells; Pyrazines; Quinazolines | 2014 |
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome | 2014 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Network-based modeling and intelligent data mining of social media for improving care.
Topics: Antineoplastic Agents; Artificial Intelligence; Computer Simulation; Data Mining; Erlotinib Hydrochloride; Health Literacy; Humans; Lung Neoplasms; Meaningful Use; Models, Statistical; Natural Language Processing; Needs Assessment; Patient Education as Topic; Patient Satisfaction; Quality Improvement; Quinazolines; Social Media; Treatment Outcome; Vocabulary, Controlled | 2015 |
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed | 2014 |
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Topics: Adult; Breast Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2014 |
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Radiopharmaceuticals; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Metastasis; Quinazolines | 2014 |
"Companion diagnostics": has their time come and gone?
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Proto-Oncogene Proteins c-met; Quinazolines | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
Topics: Breast; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOS1 Protein; Up-Regulation | 2014 |
Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury.
Topics: Animals; Aorta; Chronic Disease; Epidermal Growth Factor; Erlotinib Hydrochloride; Graft Rejection; Immunohistochemistry; Kidney; Kidney Transplantation; Male; Quinazolines; Rats; Rats, Wistar; Transplantation, Homologous | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Hepatocellular; Cell Line, Tumor; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Acquired trichomegaly: trichomegaly secondary to erlotinib.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2014 |
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Monitoring cancer through the blood.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines | 2014 |
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Topics: Biomarkers, Tumor; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.
Topics: Animals; Carcinogenesis; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Kaplan-Meier Estimate; Mice; NF-kappa B; Paracrine Communication; Protein Kinase C; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha | 2014 |
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplastic Stem Cells; Quinazolines; Receptor, Notch3; Receptors, Notch; Signal Transduction; Transcription, Genetic | 2014 |
AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; CDC2 Protein Kinase; Cisplatin; Cyclin-Dependent Kinases; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; HeLa Cells; Humans; Mesoderm; Mice, Nude; Mitosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Taxoids; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2014 |
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Phleomycins; Quinazolines; Signal Transduction | 2014 |
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
What new therapeutic targets exist for EGFR-mutant NSCLC?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Quinoxalines | 2015 |
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines | 2014 |
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2014 |
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oncogene Proteins, Viral; Oropharyngeal Neoplasms; Papillomavirus E7 Proteins; Predictive Value of Tests; Prognosis; Quinazolines; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Translocation, Genetic | 2015 |
Pulmonary embolism with haemorrhagic pericardial effusion and tamponade: a clinical dilemma.
Topics: Anticoagulants; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Diagnosis, Differential; Drainage; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Pericardial Effusion; Protein Kinase Inhibitors; Pulmonary Embolism; Quinazolines; Treatment Outcome; Vena Cava Filters | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome | 2014 |
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glycosides; Humans; Marsdenia; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pregnanes; Quinazolines | 2014 |
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Green Fluorescent Proteins; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Plasmids; Quinazolines; ras Proteins; Recombinant Proteins | 2014 |
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
[Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumour].
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Pancoast Syndrome; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2014 |
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2014 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2015 |
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous | 2014 |
Erlotinib-induced skin inflammation is IL-1 mediated in KC-Tie2 mice and human skin organ culture.
Topics: Animals; Biopsy; Dermatitis; Disease Models, Animal; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Hyperplasia; In Vitro Techniques; Interleukin-1; Mice; Mice, Transgenic; Organ Culture Techniques; Phenotype; Quinazolines; Receptor, TIE-2; Skin | 2015 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.
Topics: Animals; Cell Culture Techniques; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Myristoylated Alanine-Rich C Kinase Substrate; Phosphatidylinositol 3-Kinase; Phosphatidylinositol Phosphates; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Molecular-target-based anticancer photosensitizer: synthesis and in vitro photodynamic activity of erlotinib-zinc(II) phthalocyanine conjugates.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Indoles; Isoindoles; Light; Liver Neoplasms; Microscopy, Confocal; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Quinazolines; Structure-Activity Relationship; Zinc Compounds | 2015 |
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
Topics: Animals; Aprepitant; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Ventricular Function, Left | 2015 |
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2015 |
Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiosurgery | 2014 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Metformin and erlotinib synergize to inhibit basal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Metformin; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
EGF promotes mammalian cell growth by suppressing cellular senescence.
Topics: Animals; Cell Line; Cell Proliferation; Cells, Cultured; Cellular Senescence; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines | 2015 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Adducts; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Organoplatinum Compounds; Phosphorylation; Quinazolines; Signal Transduction | 2014 |
Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Line; Chemical and Drug Induced Liver Injury; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Tubules, Proximal; Liver; Macrophages; Male; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Topics: Antigens, CD; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Vimentin | 2014 |
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2015 |
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Imidazoles; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolines; ras Proteins; TOR Serine-Threonine Kinases | 2014 |
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2014 |
[Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction].
Topics: Antineoplastic Agents; Biochemistry; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Structure-Activity Relationship | 2014 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Chromones; Cytoplasm; Diketopiperazines; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Morpholines; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; CpG Islands; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Phenotype; Prognosis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2014 |
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Connective Tissue Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hippo Signaling Pathway; Humans; Lapatinib; Mechanotransduction, Cellular; Neuregulin-1; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-4; Transcription Factors | 2014 |
Pilot study of erlotinib in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Protein Kinase Inhibitors; Quinazolines | 2015 |
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiography; Thymidine Phosphorylase; Withholding Treatment | 2014 |
Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sodium; Treatment Outcome | 2014 |
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2015 |
Epidermal growth factor receptor inhibitor protects against abdominal aortic aneurysm in a mouse model.
Topics: Aminopropionitrile; Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Cells, Cultured; Cytoprotection; Disease Models, Animal; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats, Sprague-Dawley; Time Factors | 2015 |
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HLA-A2 Antigen; Humans; Immunotherapy; Mutation; Peptides; Quinazolines | 2015 |
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2014 |
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People | 2015 |
Synthesis, characterization and in vitro anti-tumoral evaluation of Erlotinib-PCEC nanoparticles.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Ethylene Oxide; Humans; In Vitro Techniques; Lactones; Nanoparticles; Protein Kinase Inhibitors; Proton Magnetic Resonance Spectroscopy; Quinazolines; Spectroscopy, Fourier Transform Infrared | 2014 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Receptor, Notch1; Tumor Suppressor Protein p53 | 2014 |
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor | 2015 |
Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2015 |
A kinase-independent role for EGF receptor in autophagy initiation.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Cell Line, Tumor; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines; Vesicular Transport Proteins | 2015 |
A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Topics: Calibration; Chromatography, Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Microsomes, Liver; Plasma; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2015 |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2015 |
A case of new onset keratosis pilaris after discontinuation of erlotinib.
Topics: Abnormalities, Multiple; Antineoplastic Agents; Darier Disease; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
Topics: Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Metastasis; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Tumor Suppressor Proteins | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Topics: Blotting, Western; Cell Line; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Luciferases; Microscopy, Fluorescence; Plasmids; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sunitinib; Virus Internalization | 2015 |
mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Transcription Factors; Humans; Morpholines; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy.
Topics: Adenocarcinoma; Antineoplastic Agents; Endoscopy, Digestive System; Erlotinib Hydrochloride; Esophagus; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Necrosis; Quinazolines | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glycosylation; Humans; Metabolic Engineering; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; STAT Transcription Factors | 2015 |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Knockout; Mice, Nude; Myeloid Differentiation Factor 88; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Cells, Cultured | 2015 |
Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2015 |
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2015 |
A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.
Topics: Animals; Anti-Arrhythmia Agents; Blotting, Western; Carcinoma, Pancreatic Ductal; Cation Transport Proteins; Cell Line; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Guanidines; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sulfones | 2015 |
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Circadian Rhythm; ErbB Receptors; Erlotinib Hydrochloride; Female; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines | 2015 |
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
[Erlotinib, sunitinib, and everolimus].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.
Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Endothelium, Vascular; ErbB Receptors; Erlotinib Hydrochloride; Hypertension; Hypertrophy; Mice; Muscle, Smooth, Vascular; Phenylbutyrates; Quinazolines; Random Allocation; Role; Sensitivity and Specificity; Signal Transduction; Vascular Remodeling | 2015 |
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Topics: Adult; Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Quinazolines; Skin Diseases, Papulosquamous; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.
Topics: Adult; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Conscious Sedation; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Frameshift Mutation; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Pain Management; Pain, Intractable; Palliative Care; Quinazolines; Radiography | 2015 |
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Cell Line, Tumor; DNA Damage; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; Lapatinib; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Transfection | 2015 |
Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Photochemotherapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.
Topics: Afatinib; Carcinoma, Large Cell; Cell Differentiation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
Topics: Animals; Cell Line; Cytokines; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Humans; Lipopolysaccharides; MAP Kinase Kinase Kinases; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Phosphorylation; Protective Agents; Proto-Oncogene Mas; Quinazolines; Signal Transduction; src-Family Kinases; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.
Topics: Antineoplastic Agents; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2015 |
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2015 |
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Mice; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States | 2015 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia.
Topics: Animals; Endotoxemia; ErbB Receptors; Erlotinib Hydrochloride; Heart Failure; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2015 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.
Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
Topics: Animals; Carrier Proteins; Cell Line; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Glucose; Glucose Transporter Type 1; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Oncogene Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Response Elements; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?
Topics: Beverages; Drug Interactions; Erlotinib Hydrochloride; Humans; Proton Pump Inhibitors; Quinazolines | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
Topics: Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Lapatinib; Ligands; Mutagenesis, Site-Directed; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Spectrometry, Fluorescence | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.
Topics: A549 Cells; Antineoplastic Agents; Azurin; Bacterial Proteins; Cell Adhesion; Cell Membrane; Cell Movement; Cell Proliferation; Drug Synergism; Elastic Modulus; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gefitinib; Gene Expression; Humans; Integrin beta1; Microscopy, Atomic Force; Quinazolines; Surface Properties | 2016 |
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2016 |
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.
Topics: Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Least-Squares Analysis; Linear Models; MAP Kinase Signaling System; Quinazolines; Receptor, ErbB-2 | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lapatinib; Quinazolines; Suspensions | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Propensity Score; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2016 |
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape | 2016 |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Topics: Algorithms; Animals; Antineoplastic Agents; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Plexin A1 signaling confers malignant phenotypes in lung cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucose; Mice; Nerve Tissue Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Cell Surface; RNA, Small Interfering; Semaphorin-3A; Signal Transduction | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Topics: Afatinib; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Transfection | 2017 |
A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma.
Topics: Acetonitriles; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Lapatinib; Plasma; Quinazolines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2016 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Topics: Anti-HIV Agents; Antineoplastic Agents; Computer Simulation; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; HIV Infections; Humans; Models, Biological; Quinazolines | 2017 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2017 |
Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Choline Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hep G2 Cells; Humans; Immunoblotting; Immunohistochemistry; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases; Wound Healing; Xenograft Model Antitumor Assays | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Heterogeneity; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Herb-Drug Interactions; Lapatinib; Limit of Detection; Linear Models; Plant Extracts; Quinazolines; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tea | 2017 |
Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Topics: Antineoplastic Agents; Computer-Aided Design; Databases, Pharmaceutical; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydroxamic Acids; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; Small Molecule Libraries | 2017 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Editing; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Biotransformation; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Gemcitabine; Male; Plant Extracts; Plants, Medicinal; Protective Agents; Quinazolines; Rats; Rats, Sprague-Dawley | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pneumonectomy; Point Mutation; Postoperative Period; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
A method of high-throughput functional evaluation of
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; HEK293 Cells; Humans; Mice; Mutation; Quinazolines | 2017 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Spain; Treatment Outcome | 2018 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MEF2 Transcription Factors; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2018 |
EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Quinazolines; Telomerase; Tyrphostins | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines; Vinorelbine | 2018 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neuraminidase; Protein Kinase Inhibitors; Quinazolines | 2019 |
The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors.
Topics: Biomarkers, Pharmacological; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Mouth Neoplasms; Phosphorylation; Plakins; Polymorphism, Single Nucleotide; Quinazolines; Signal Transduction | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2019 |
Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2.
Topics: A549 Cells; Aminoquinolines; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Conformation; Quinazolines; Quinolines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.
Topics: Apoptosis; Binding Sites; Catalysis; Catalytic Domain; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Palladium; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship | 2019 |
Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Mutation; Neoplasm Invasiveness; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2020 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment.
Topics: Cornea; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Sjogren's Syndrome | 2022 |
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Renal Insufficiency | 2021 |
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides | 2021 |
Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification.
Topics: Chromatography, Liquid; Erlotinib Hydrochloride; Isomerism; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2021 |
[Establishment of animal models of epidermal growth factor receptor inhibitor-related rashes].
Topics: Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Lung Neoplasms; Mice; Mice, SCID; Models, Animal; Quinazolines; Rats | 2021 |
Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Humans; Hydrazones; Lung Neoplasms; Models, Molecular; Mycobacterium tuberculosis; Quinazolines; Structure-Activity Relationship; Tuberculosis | 2021 |
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
Topics: Afatinib; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines | 2021 |
Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
Topics: Aniline Compounds; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2023 |